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Abstract
Abstract
A mature Plasmodium falciparum parasite inside a human red blood cell consumes 
large amounts of glucose. This work investigates the mechanisms by which the 
parasites obtain the glucose required for their survival. Two different approaches are 
employed: a molecular biological approach and a kinetic analysis. Using molecular 
biological techniques, especially PCR, an attempt was made to obtain the malarial 
glucose transporter sequence. Although unsuccessful, this produced many novel DNA 
sequences from Plasmodia and confirmed the sequence of a portion of malarial 
enolase. The kinetic approach showed that glucose enters the parasite by passive 
diffusion, that the red blood cell transporter is not rate-limiting and that the malaria 
induced pore does not play a significant role in D-glucose transport. The kinetic 
approach also indicated that L-glucose and D-glucose enter infected cells by different 





Malaria has an immense impact on humans. It is the biggest killer in the history of man 
(Philips, 1983), presently killing more people than any other single cause. It is no 
coincidence that countries with a high prevalence of malaria are the poorest in the 
world. There are between 250 and 500 million new cases of malaria each year and 
malaria currently kills 1-2.5 million people annually (Cox, 1991). Recently, research 
into new treatments for malaria has become even more important because in certain 
regions of the world the traditional antimalarial drugs (like quinine and chloroquine) 
are no longer effective.
1.1.1. Th e  Ca u se  o f  M a l a r ia
Malaria is caused by a single-celled eukaryote protozoan. There are many species of 
Plasmodium, four of which (P. falciparum, P. vivax, P. malariae, and P. ovale) infect 
humans. Almost all the deaths from malaria are attributed to Plasmodium falciparum. 
Although common, Plasmodium vivax produces a milder form of the disease with 
frequent relapses. The other two human malarias are rare and not life threatening. In 
mice there are at least four common species of malaria P. yoelii, P. knowlesi, P. 
vinckei and P. chabaudi.
1.1.2. T he  L ife  Cy c l e  o f  M a l a r ia
All species of Plasmodium share a complex life cycle, which is described for 
Plasmodium falciparum in figure 1. The Plasmodium in its sporozoite form (11pm 
long, 1pm thick) is released from the salivary gland of the insect into the host's blood 
stream when the mosquito takes a blood meal. The sporozoites are carried in the 
blood to the liver where they invade the hepatocyte. The parasite, which is surrounded 
by a vacuolar membrane, grows and divides mitotically to become a pre-erythrocytic 
schizont cell. Each nucleus buds off with part of the cytoplasm to form a merozoite. 
Rupture of the liver cell releases thousands of merozoites into the bloodstream and 
ends the incubation period of the parasite (Philips, 1983).
2
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Figure 1. The life cycle of Plasmodium falciparum, the malarial parasite. Redrawn 
from R. S. Philips, Malaria.
The merozoites must now survive for a short time free in the bloodstream where they 
are exposed to the full wrath o f the host's immune system. The merozoites rapidly 
bind to an erythrocyte and cause the host cell to invaginate. The merozoites probably 
bind to glycophorins in the red blood cell membrane (Pasvol and Jungery, 1983). The 
invasion process takes less than a minute (Philips, 1983) after which the parasite is 
almost completely enclosed inside the erythrocyte.
1.1.2.1. The Erythrocytic Stage
In the red blood cell the merozoite rapidly transforms into a ring-stage parasite. The 
parasite continues to grow and a food vacuole develops. After 24 hours the parasite 
has grown in size, takes up Giemsa stain more readily and is known as a trophozoite. 
The host's erythrocyte cytoplasm is rapidly ingested by the trophozoite and partially 
digested. The haemoglobin is degraded to the waste product haemozoin and the 
amino acids that are released are incorporated into the parasite's proteins (Goldberg 
and Slater, 1992). The trophozoite further enlarges and then divides mitotically 
forming schizont stage parasites. As in the liver, the nuclei bud off with cytoplasm to
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form a segmented schizont. The host's erythrocyte bursts open releasing merozoites 
into the blood stream. The released merozoites can then infect further erythrocytes. 
This describes the asexual cycle that takes about 48 hours to complete for Plasmodium 
falciparum.
Within the red blood cell some ring stage parasites do not develop into trophozoites 
and undergo mitotic division. Instead they transform into micro- or 
macrogametocytes, starting the sexual cycle of reproduction. There is no genetic 
reorganisation within the gametocytes. Plasmodium is haploid throughout all the 
stages of development in the human (Philips, 1983).
1.1.2.2. The Mosquito Stages
When the mosquito takes a blood meal from a malaria infected person, merozoites and 
gametocytes in erythrocytes are taken into the insect's gut. In the midgut the gametes 
lose their red cell membranes. Microgametes divide mitotically three times to give 8 
nuclei that go on to form 8 flagella (Philips, 1983). These swim through the blood 
meal. The macrogametocyte becomes primed for fertilisation and then fertilisation 
occurs within minutes. Over the next 12-18 hours the oocyte develops into an 
ookinete. Within 24 hours the ookinete crosses the epithelium of the gut-wall where it 
enlarges and develops into an oocyst. Development into the oocyst takes 10-12 days. 
Although the exact timing of meiosis is uncertain it is believed to be during this stage 
of the life cycle (Philips, 1983). The oocyst enlarges further and goes on to form 
sporozoites. Each oocyst produces thousands of sporozoites and each mosquito may 
have hundreds of developing oocysts in its midgut. The sporozoites enter into the 
haemocoel and are carried to the lumen of the salivary gland. The next time the 
mosquito takes a blood meal the sporozoites are released into the bloodstream of 
another person.
1.1.3. Th e  H ist o r y  of  M a l a r ia
Although today cases of malaria are rare in Britain, it has not always been this way. 
The marshy lowlands in Britain were prime breeding sites for the mosquitoes and 
during the 16th and 17th centuries 'swamp fever' was rife in Britain (Dobson, 1989).
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Probably the earliest known drug against malaria was quinine. In Peru, during the 17th 
century people with malaria were given the bark of a local tree (a natural source of 
quinine). In 1629, this treatment was administered to the wife of the Viceroy of Peru, 
the Countess of Chinchon, with successful results. It was not until the 19th century 
that quinine was extracted from this "Cinchona bark" and found to be the active 
component.
The causative agent of malaria and its mode of infection were not fully understood 
until the middle of this century. Early work was performed by Meckel in 1847 who 
noticed black granules in the spleens of patients who had died of malaria. These black 
deposits are now known to be haemozoin a degradation product of the parasite's 
metabolism of haemoglobin (Goldberg and Slater, 1992). Thirty years later Kelsch 
noted that these black deposits in the blood, were most noticeable just before the 
patient became feverish. In 1878 Lavaran, working in Algeria, saw clear cells, the free 
forms of the parasite, in the blood of infected patients (Philips, 1983).
The insect vector for the malaria parasite was not known to be the female Anopheles 
mosquito (A. gambia) until the 1890's. It had been noticed for a long time that 
mosquitoes flourished together with malaria. In 1895 Ross discovered the 
purplish/black haemozoin pigment in the mosquito. The link was made conclusively by 
Manson at the end of the 19th century who used live mosquitoes, which had been 
allowed to suck blood from malaria patients, in Italy. These mosquitoes were then 
allowed to bite healthy volunteers in London. The experiment was 'successful' and the 
volunteers contracted malaria (Thomson, 1958). It was not until 1947 that Gamham 
discovered that the parasite first infected human liver cells before infecting the 
erythrocytes (Philips, 1983).
Although nowadays cases of malaria in the United States, Israel, Cyprus and most of 
Western Europe are very rare, malaria is still a major killer especially in tropical Africa, 
Asia and Central and South America. The disease has proven hard to eradicate mainly 
because both the parasite and its mosquito host have become resistant to all the drugs 
so far used to kill them. For example in 1956 the World Health Organisation (WHO)
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tried to rid the world of malaria by attempting to eliminate the insect vector using 
DTT. After early success the mosquitoes became resistant and have now returned to 
their original levels.
Over the last decade approximately 1800 cases of malaria have been reported in Britain 
each year. In the vast majority of cases the person acquired the disease abroad and 
returned to Britain before becoming ill. Small numbers are acquired congenitally 
(transplacentally) from their infected but often asymptomatic mothers (1-2 cases 
annually), by blood transfusion (although this has now virtually been eradicated by 
taking a travel history of donors and by testing donors serologically), or from infected 
mosquitoes that have successfully stowed away on aeroplanes. Two such cases have 
been reported in Britain in the last twenty years (Dobson, 1989).
1.1.4. Th e  Pa t h o l o g y  a n d  D ia g n o sis  of M a l a r ia
The incubation period (i.e. the time between infection and any symptoms being seen) 
for malaria is 8-14 days. The first symptoms are usually gastrointestinal upset and 
headaches followed by fever when the erythrocytes burst and the merozoites are 
released. The fevers occur cyclically every 48 hours and each lasts for about 12 hours.
One of the long term effects of malaria on the host is anaemia. The red blood cells are 
lysed directly by the parasite, and both infected and uninfected erythrocytes are 
destroyed by phagocytes in the liver and spleen. Another long term danger is from 
blocked capillaries in the brain and other tissues. This is caused by the parasites, at the 
trophozoite stage, adhering to the walls of the capillary. Together with the destruction 
of red blood cells this can limit the oxygen supply to the brain, leading to convulsions 
and other nervous disorders. The spleen and liver of malarial patients are often 
enlarged.
1.1.5. P l a s m o d iu m  U l t r a s t r u c t u r e
The ultrastructure of Plasmodium falciparum has been studied in detail (Langreth et 
al, 1978). Figure 2 shows a mature Plasmodium falciparum trophozoite within a 
human red blood cell. Knobs (K) are found on the surface of erythrocytes infected by 
many strains of Plasmodium falciparum. These structures are produced by a malarial
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protein that is transported to the erythrocyte membrane (section 1.1.6.). The knob 
protein is believed to be involved in the adhesion on malaria infected erythrocytes to 
epithelial cells (Smith et al, 1992; Chishti et al, 1992). The Maurer's clefts (M) are 
lipid based structures produced by the malarial parasite. It is thought that these 
vesicles are probably involved in the transport of proteins from the malarial parasite to 
the erythrocyte membrane (section 1.1.6.).
The malarial parasite is bounded almost completely by two membranes: the 
parasitophorous plasma membrane (PVM) and the parasite's plasma membrane (PM). 
The outer of the two membranes, the PVM, is derived from the erythrocyte. It has 
been suggested that the parasite is completely enclosed in these membranes and that 
any nutrients required by the parasite must cross all three membranes (Izumo et al, 
1989). Recently, however, this has been called into question. A parasitophorous duct 
(Pouvelle et al, 1991) which joins the erythrocyte plasma membrane and the PVM has 
been reported (section 4.1.1.3.), and it has also been suggested by many workers that 
at certain regions the PVM and the PM fuse into a single lipid bilayer (Gormley et al, 
1992; Elmendorf and Haidar, 1993).
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Figure 2. A transmission electron micrograph of a human red blood cell infected with 
a P. falciparum trophozoite. The print is a magnification of 25200X (1mm on the 
figure is equivalent to 27 nanometers). Many of the common features of the malaria 
infected cell are highlighted. K: Knobs, M: Maurer's cleft, PVM: Parasite Vacuolar 
Membrane, PM: Parasite's plasma membrane, F: Feeding vacuole, H: Haemozoin 
Pigment, EC: Erythrocyte cytoplasm N: Nucleus, V: Vacuoles. This electron 
micrograph was kindly donated by T. Schneider and T. F. Taraschi, Thomas Jefferson 
University, Philadelphia.
The parasite has a typical eukaryotic nucleus (N) and other organelles that are 




I.I.5.I. The feeding vacuole and haemozoin
The parasite ingests portions of the erythrocyte cytoplasm (EC) and carries it to the 
feeding vacuole (FV). Inside the feeding vacuole the haemoglobin is degraded with 
the help of a highly specific aspartic protease. This enzyme, haemoglobinase, cleaves 
the haemoglobin at a specific site in the hinge region opening the structure to further 
proteolytic attack (Goldberg and Slater, 1992). When ferrous haem is released from 
globin it oxidises to a toxic ferric form. To prevent damage from haem the parasite 
converts the compound to haemozoin (H). Haemozoin can be synthesised by heating 
haemoglobin to 80°C under highly acidic conditions (Goldberg and Slater, 1992). It is 
believed that it is comprised of a polymer of haems linked by an unusual iron- 
carboxylate bond (Goldberg and Slater, 1992). The parasite achieves this conversion 
by using an enzyme known as haem polymerase, and chloroquine and quinine inhibit 
the polymerisation process (Slater, 1993). Although parasite proteins associate with 
haemozoin, their removal does not alter the properties of the pigment, which 
accumulates in the host's spleen. It has been suggested that human macrophages 
become unresponsive following digestion of haemozoin (Goldberg and Slater, 1992; 
Aresee/a/, 1993).
1.1.6. T r a f f ic k in g  in  M a l a r ia  In fe c te d  Er y t h r o c y t e s
During its development within the red blood cell, the malarial parasite alters the 
erythrocyte in many ways. The parasite changes the lipid composition (Hsiao et al,
1991) and inserts some of its proteins (Gormley et al, 1992; Elmendorf and Haidar, 
1993) into the erythrocyte membrane. It is thought that there are several mechanisms 
to transport specific malaria proteins to the surface of the infected cell (Gormley et al,
1992). Three different membranous structures have been described in parasitised cells. 
These structures have been described as long slender unit membrane clefts (Maurer's 
clefts - figure 2), circular unit membranes with electron dense contents, and vesicles 
with multiple membranous whorls (Gormley et al, 1992).
It is believed that the PVM does not simply surround the parasite. Protrusions are 
seen appearing from the PVM and these often bud-off forming vesicles (Elford and 
Ferguson, 1993). The term 'tubovesicular membrane system' (TVM) has been used to
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describe these structures and it has been proposed that they have similarities to the 
Golgi apparatus (Elmendorf and Haidar, 1993). The TVM contains proteins with 
significant homology to Golgi house-keeping proteins namely BiP, ERD2 and thiamine 
pyrophosphatase.
The export of a number of parasite proteins has been be tracked using specific 
antibodies and confocal immunofluorescence (Gormley et al, 1992). The 300kd 
protein MESA (also known as PfEMP2) has been shown to be associated with 
electron dense vesicles that bud off the PVM. A histidine-rich protein (known as 
PfHRPl) has been shown to be associated with the knobs on the erythrocyte 
membrane. During the export of this protein it has been localised in the electron dense 
vesicles and membranous whorls found in the red blood cell cytoplasm. Another 
histidine-rich protein (known as PfHRP2) is excreted into the bloodstream from 
malaria infected erythrocytes. This protein appears to cross the erythrocyte as an 
aggregate that does not contain lipid (Gormley et al, 1992).
Elmendorf and Haidar (1993) suggested that the malarial parasite secretes proteins, 
like MESA, into the vacuolar space surrounding the parasite and that a second round 
of secretion occurs through the tubovesicular system. It has also been suggested that 
in certain positions the PVM and the PM fuse to form a single lipid bilayer (Gormley et 
al, 1992). In this model PfHRPl would be secreted from the parasite at a region 
where these two regions have fused and carried in membranous vesicles to the 
erythrocyte membrane.
1.1.7. C a r b o h y d r a t e  M e t a b o l i s m  in  P l a s m o d iu m  f a l c ip a r u m  I n f e c t e d  
E r y t h r o c y t e s
Plasmodium does not contain stores of carbohydrate and is totally dependent on blood 
glucose for its energy supply (Sherman, 1979). Virtually all the glucose utilised by 
Plasmodium is converted to lactate by glycolysis. All the glycolytic enzymes have 
been shown to increase in activity in infected erythrocytes (Roth et al, 1988) and 
glycolytic rates 30-50 times that of the uninfected cell have been reported 
(Shakespeare et al, 1979). Many of the glycolytic enzymes have been cloned from 
malarial parasites including lactate dehydrogenase (Bzik and Fox, 1993), 3-phospho-
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glycerate kinase (Hicks et al, 1991), aldolase (Knapp et al, 1990), triose phosphate 
isomerase (Ranie et al, 1992) and enolase (Read et al, 1993 and figure 17).
There has been some debate about whether Plasmodium falciparum possesses an 
active pentose phosphate pathway. On theoretical grounds, it seemed probable that 
the malaria parasite would have an absolute requirement for the pentose phosphate 
pathway if only to supply pentoses for DNA synthesis. Human erythrocytes are 
resistant to Plasmodium falciparum when they are deficient in glucose-6-phosphate 
dehydrogenase (G6PDH), the first enzyme of the pentose phosphate pathway, 
suggesting that they require the host's enzyme for survival. For many years it was not 
thought that Plasmodium falciparum had endogenous G6PDH activity but this has 
now been detected (Ling and Wilson, 1988) and it has been cloned and sequenced 
(O 'Brien^ al, 1993).
Although Plasmodium falciparum contains a mitochondrion it is acristate and is not 
thought to possess an active citric acid cycle (Sherman, 1979).
1.1.8. T h e  G e n e t ic s  o f  P l a s m o d iu m  f a l c ip a r u m
Plasmodium falciparum has 14 chromosomes as determined by pulse field gel 
electrophoresis (PFGE) and by electron microscopy (Carle and Olson, 1984; Schwartz 
and Cantor, 1984; Chu et al, 1986). The largest chromosome is 3.4Mb and the 
smallest 640kb (Foote and Kemp, 1989). Structurally the chromosomes are typical of 
lower eukaryotes. Malarial parasites do not contain a sex chromosome as the asexual 
parasites can develop into either a microgametocyte or a macrogametocyte. The sizes 
of the chromosomes vary between different P. falciparum isolates sometimes by 
several hundred kilobases. The size differences are seen both in fresh and cultured 
strains indicating that variations arise during mitosis as well as meiosis. The variation 
is almost entirely in the sub-telomeric regions and occurs in wild populations taken 
directly from a patient, suggesting that they have little effect on the parasite. The size 
variation is thought to be due to several factors (Foote and Kemp, 1989). These 
include:
i) Chromosomal breakage and healing in sub-telomeric regions.
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ii) Frequent crossover events during meiosis. The highly repetitive nature of 
these regions facilitates the transfer of DNA from one chromosome to another 
by recombination during meiosis.
iii) Amplification and suppression of regions of the genome under selective 
pressure. Many of the most antigenic proteins in Plasmodium falciparum are 
encoded in regions near the ends of the chromosomes. These proteins contain 
many repeats making them highly antigenic. It is possible that their location in 
highly labile areas of the genome allows them to change quickly and evade the 
host's immune system. In some cases these proteins can be deleted altogether. 
For example the gene encoding the knob-associated histidine-rich protein is 
completely missing from the DIO isolate and partially deleted in other isolates 
(Foote and Kemp, 1989).
The major problems in the study of Plasmodium falciparum genetics are:
i) Recombination is difficult. To obtain a genetic cross the two strains must be 
cloned, induced to produce gametes in vitro, fed to mosquitoes, passaged 
through a chimpanzee and cloned and cultured again. With recent advances in 
culturing of mosquito stages in vitro (Trager et al, 1992) the ability to produce 
genetic crosses may be improved, but are still troublesome.
ii) The chromosomes are not visible by light microscopy which makes in situ 
hybridisation impossible. This is because of the comparatively small genomic 
size, 3xl07 bases, of Plasmodium falciparum and because the chromosomes do 
not condense in the same way that human chromosomes do during DNA 
replication.
iii) The genome is AT-rich (82%) which makes fragments of malarial DNA 
unstable in Escherichia coli. Cosmid libraries of P. falciparum DNA grown in 
E. coli are unstable undergoing spontaneous deletions and rearrangements.
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Despite these problems much progress in mapping the malarial genome has been made 
in the past few years. The success of this technique has mainly been due to the use of 
yeast artificial chromosomes (YAC) (Burke et al, 1987) and PFGE (Schwartz and 
Cantor, 1984) that can separate chromosome sized pieces of DNA on a 1.5% agarose 
gel. Large pieces of DNA can be made to behave like a yeast chromosome by 
attaching a centromere, and a telomere to each end. This DNA can then be 
propagated in Saccharomyces cerevisiae. It has been shown that large pieces of 
malarial DNA (~200kb) are stable in YACs, probably due to yeast also being AT-rich 
(Triglia and Kemp, 1991). A potential problem with YACs is that only one copy of 
the cloned DNA is present per yeast cell. This has recently been overcome by a 
method that amplifies YAC chromosomes so that there are up to 20 copies per cell 
(S m iths al, 1990).
Traditionally small genomes are mapped using a 'bottom up approach'. Overlapping 
cosmids (30-45kb) are screened with genetic markers and pieced together to obtain a 
map of each chromosome. As malarial DNA is not stable in E. coli this approach is 
impractical for Plasmodium DNA but the genome is now being mapped using YACs. 
Another advantage of the YAC system is that the ends of YACs can be cloned (as a 2- 
5kb fragment in E. coli) and used for rescreening to find overlapping YACs (Riley et 
al, 1990).
There are many reasons why a high density map of Plasmodium falciparum would be 
advantageous (Triglia et al, 1992), including the identification of specific genes 
involved in various processes like drug resistance and cytoadherence.
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1.2. The Facilitative Sugar Transporters
Glucose is an essential energy source for most cells. For this reason, and because the 
lipid bilayer is impermeable to sugars, most cells require a specific glucose transport 
protein. Sugar transport proteins have recently been cloned from a variety of 
organisms, ranging from mammals through to protozoa, algae, yeasts and prokaryotes. 
Most of these proteins are believed to have a common structure because of their low, 
but significant, sequence similarity to the mammalian erythrocyte glucose transporter 
known as HepG2 or GLUT1 (Mueckler et al, 1985). Table 1 lists the members of the 
facilitative sugar transporter superfamily. These are discussed in more detail in section
1.2.3.
Members of the superfamily transport a range of hexoses including glucose, fructose, 
lactose and galactose. Two members of the family transport quinate, a six-membered 
ring compound (figure 3) (Hawkins et al, 1988; Geever et al, 1989; Lamb et al, 1990) 
and some transport the pentoses xylose and arabinose. The mechanism of transport 
also differs across the superfamily. For example some, including the mammalian 
transporters, allow passive diffusion, whilst others, including three transporters from E. 
coli, actively transport the sugar across the membrane in conjunction with a proton. 
This may be an essential adaptation. The red blood cell finds itself permanently bathed 
in approximately 5mM glucose and so does not need to transport glucose against a 
concentration gradient. Organisms such as E. coli find the external glucose 
concentration highly variable and need to accumulate sugar when the external 
concentration is low.
OH




GLUT1 Human, rat, mouse, rabbit, chicken, pig, D-glucose
(HEPG2) cow
GLUT2 Human, rat, mouse D-glucose
GLUT3 Human, mouse, chicken D-glucose
GLUT4 Human, rat, mouse D-glucose
GLUT 5 Human, rat Fructose
GLUT7 Rat D-glucose
SNF3 Saccharomyces cerevisiae D-glucose
HXT1 Saccharomyces cerevisiae D-glucose
HXT2 Saccharomyces cerevisiae D-glucose
HXT3 Saccharomyces cerevisiae D-glucose
HXT4 Saccharomyces cerevisiae D-glucose
MAL6T Saccharomyces cerevisiae Maltose
GAL2 Saccharomyces cerevisiae D-galactose
RAG1 Kluyveromyces lactis D-glucose
LACP Kluyveromyces lactis Lactose
Synechocystis PCC6803 D-glucose/H+
AraE Escherichia coli L-Arabinose/H+
XylE Escherichia coli D-Xylose/H+
GalP Escherichia coli D-galactose/H+ & D-glucose/H
Zymomonas mohilis D-glucose
STP1 Arahidopsis thaliana D-glucose/H+
Chlorella kessleri D-glucose/H+
THT1 Trypanosoma brucei hrucei D-glucose, Fructose
THT2 Trypanosoma hrucei brucei D-glucose
SGTP1 Schistosome Glucose ??
SGTP2 Schistosome Glucose ??
SGTP4 Schistosome Glucose ??
Prol Leishmania enriettii D-glucose/H+
Prol-cpl Leishmania enriettii D-glucose/H+
D1 Leishmania donovani D-glucose/H+
D2 Leishmania donovani D-glucose/H+
qa-y Neurospora crassa Quinate
QUTD Aspergillus nidulans Quinate
Table 1. Members of the facilitative sugar transporter superfamily. These are
discussed in more detail in section 1.2.3.
1.2.1. T h e  A sy m m e t r ic  K in e t ic s  of t h e  Er y t h r o c y t e  T r a n spo r t e r
The human erythrocyte transporter is believed to exist in two mutually exclusive 
forms: an inward (Tj) and an outward facing conformation (Tc). This is known as the 
















Figure 4. The two state carrier model for the human erythrocyte glucose transporter. 
Glucose can bind to either the inward or outward conformations.
The following experimental data on the kinetics of red blood cell glucose transport 
support the two state model:
i) Sugar influx and efflux can have different kinetic constants
The erythrocyte protein is regulated by phosphorylation (Carruthers, 1986). The 
unphosphorylated carrier is symmetric, while the phosphorylated transporter has a Km 
for influx of approximately 2mM and a Km for efflux of approximately 25mM 
(Widdas, 1980). In the two carrier model the internal and external binding sites would 
be expected to be constructed of two different regions of protein and similar affinities 
would be purely coincidental.
ii) Sugar exchange is faster than sugar flux
The rate of glucose/glucose exchange is faster than the maximal uptake or efflux rates 
(Widdas, 1980). For a two-state carrier model this would imply that the transporter
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can change between the inward and outward facing conformations faster when the 
sugar is bound and that the transition in the absence of sugar is rate limiting.
iii) Differential inhibition of influx and efllux.
Experiments using 4,6-O-ethylidene-a-D-glucopyranose (ethylidene glucose) showed 
that the glucose analogue entered red blood cells by direct diffusion through the 
membrane and did not enter through the glucose transporter (Baker and Widdas, 
1973b). However, ethylidene glucose on the outside of the cell is a potent non­
competitive inhibitor of glucose efflux (Baker and Widdas, 1973 a). The two-state 
carrier model accounts for this by suggesting that ethylidene glucose binds to the 
outward facing binding site, locking the transporter into the outward-facing 
conformation. When the cells were preloaded with ethylidene glucose it was found to 
be a poor inhibitor of uptake and did not cause the transient accumulation of glucose 
(Baker and Widdas, 1973a). These results are consistent with ethylidene glucose 
binding with a high affinity to the outward-facing binding site and a low affinity to the 
inward-facing site.
The effects of alkyl sugar derivatives on glucose influx and efflux have also been 
studied (Barnett etal, 1973a). Like ethylidene glucose, these compounds enter the red 
blood cell by simple diffusion through the lipid bilayer and are not transported by the 
facilitative carrier. When the sugar was derivitised in the Cl position (e.g. n-Propyl-P- 
D-glucopyranose) the analogue inhibited on the inside of the cells but was a poor 
inhibitor on the periplasmic face. By contrast, sugars derivitised in the C6 position 
(e.g. 6-O-propyl-D-galactose, 6-O-pentyl-D-galactose, 6-O-benzyl-D-galactose, 6-0- 
methyl-D-glucose, 6-0-propyl-D-glucose and 6-0-pentyl-D-glucose) were found to 
behave like ethylidene glucose. They were good inhibitors at the external site and poor 
inhibitors at the internal site (Barnett etal, 1973a, 1975).
From the experiments with glucose derivatives it has been suggested that glucose 
binding on the inside and outside of the cell involves different regions of the glucose 
molecule (Barnett et al, 1975). The glucose molecule approaches the outside binding 
site with the Cl end facing the transporter. The protein undergoes a conformational
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change to the internal conformation by closing around the C4/C6 end and opening 
around the Cl end (figure 4). On leaving the cell the glucose molecule approaches 
with the C4/C6 end leading (Barnett et al, 1975).
Cytochalasin B is a specific inhibitor of the internal binding site (Tavema and Langdon, 
1973; Lin and Spudich, 1974) and maintains the transporter in the inward-facing 
conformation. Kinetic analysis suggests that cytochalasin B is a competitive inhibitor 
of substrate efflux and a non-competitive inhibitor of substrate influx. By contrast the 
photolabel bis-mannose compound ATB-BMPA irreversibly labels the protein and 
locks it in the outward facing conformation (Holman and Rees, 1987).
iv) Inactivation of transporter with FDNB increases in the presence of its 
substrate.
Further evidence that the transport protein undergoes a conformational change when 
the sugar binds is provided by work using the modifying agent l-fluoro-2,4- 
dinitrobenzene (FDNB). The inactivation of sugar transport in red blood cells by 
FDNB is faster in the presence of substrates of the protein such as D-glucose, 2- 
deoxy-D-glucose or mannose (Krupka, 1971). Maltose is not transported and protects 
the transporter from labelling (Krupka, 1971). The inhibitor phloretin similarly 
protects the transporter from labelling but its glucoside analogue phlorizin exposes the 
transporter to faster modification (Krupka, 1971). The C l, C2 and C3 alkyl 
substitutes of glucose enhance FDNB labelling whereas the C4 and C6 alkyl substitutes 
protect or have little effect on the rate of transporter labelling (Barnett et al, 1975). 
This suggests that FDNB labels a form of the transporter that binds sugars on the 
inside of the cell and is further evidence for the two-state carrier model.
1.2.2. St r u c t u r e  of  Su g a r  T r a n spo r t e r s
All the members of the facilitative sugar transporter superfamily are believed to have a 
common structure. Most are about 500 amino acids in length and have a molecular 
weight of between 45-55kD. Many however, migrate at around 40kD on SDS 
polyacrylamide gels. The proteins often appear as a diffuse band on such gels due to 
the glycosylation variations on the protein.
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An unusual feature of this family of membrane proteins is their lack of an N-terminal 
signal sequence to direct the protein to the membrane. Instead of being inserted into 
the membrane cotranslationally, like most mammalian membrane proteins, they are 
inserted post-translationally into microsomes. This property has meant that it has been 
possible to insert the human erythrocyte transporters into the membrane of 
Escherichia coli and to obtain a functional protein (Sarkar et al, 1988).
A 2-dimensional model of the human erythrocyte transporter is depicted in figure 5. 
All the superfamily members are believed to span the lipid bilayer twelve times. The N 
and C termini of the protein are positioned in the cytoplasm. A large and highly 
hydrophilic region between TM6 and TM7, is predicted to contain a large proportion 
of a-helix and to be cytoplasmic (Henderson, 1991). Models suggest that about 80% 
of the protein is a-helical, with most of the amino acids residing within the lipid bilayer 
(Baldwin and Henderson, 1989). Despite this 80% of the residues are accessible to 
deuterium exchange suggesting that most of the protein molecule is accessible to water 
(Gould and Bell, 1990). This is consistent with the hypothesis that the transmembrane 
regions form a pore through which glucose can travel.
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Figure 5. Schematic view of the human GLUT1 glucose transporter showing the twelve 
predicted transmembrane regions. Residues that are conserved within the facilitative 
sugar transporter superfamily are shown.
The N  terminus varies in length greatly between members o f the superfamily; from 10 
residues in the human liver transporter to over 90 in the yeast SNF3 transporter. The 
region connecting transmembranes 1 and 2 is also o f a highly variable length ranging 
from 19-66 residues. Except for the region between TM1 and TM2, and the region 
between TM6 and TM7, all the transmembrane regions are usually joined by short 
loops between 7 and 15 residues long.
Some regions o f the protein are conserved throughout the superfamily. Variations in 
the amino acids in these regions are rare, and changes that occur are conservative 
substitutions. The regions o f conservation are shown in figure 5.
There is a conserved region that begins in transmembrane 4 and stretches through to
the start o f transmembrane 5. The sequence is G VPMY-GE—P—RG and its
importance is at present unknown.
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It has been suggested that another conserved motif PESPRFL, which is located just 
after TM6, may serve a role in the recognition of substrates (Henderson, 1990)
In transmembrane 7 is the sequence motif QQ--GIN—FYY, which is highly conserved 
in all members of the superfamily. If the first glutamate molecule is mutated to a 
leucine in the erythrocyte transporter it loses the ability to bind the externally binding, 
impermeant, photolabel ATB-BMPA and the rate of glucose transport is reduced by 
half (Hashiramoto et al, 1992). It is believed that this region is part of the substrate's 
external binding site. The amphipathic nature of this membrane spanning region has 
led to the proposal that this highly conserved region may form part of the channel 
across the membrane.
The structural motif R-GRR, which is found in two places between TM2-3 and 
between TM8-9 is also very well conserved. This motif is strongly predicted to form a 
p-tum and is also found in other transporters that have 12 membrane spans. For 
example the motif is found twice in similar positions in the otherwise non-homologous 
citrate/H+ symporter, lactose/H+ and glucuronide transporters from Escherichia coli 
(Maiden et al, 1987; Henderson, 1991). It has been suggested (Henderson, 1990) that 
the protein is composed of two structurally independent domains: the C terminal and 
the N terminal halves. The 6 transmembrane regions in each half would fold together 
to produce a bilobal protein. The presence of this sequence in the same position in 
both halves of the protein supports this hypothesis. The presence of this feature in 
mammalian, yeast and bacteria sequences means that this duplication must have 
occurred very early in the evolution of the gene (Szkutnicka et al, 1989). When the 
Escherichia coli lactose/H+ transporter (Lac Permease) is expressed in two separate 
halves, TM1-6 and TM7-12, the two proteins combine to produce a functional protein 
whereas neither half is active on its own (Kaback et al, 1990). Similar results have 
been obtained when the two halves of the human erythrocyte transporter were 
expressed in Baculovirus. When expressed independently the C-terminal and the N- 
terminal halves failed to bind the glucose transporter specific photolabel ATB-BMPA; 
when expressed together labelling was detected (Cope, 1993).
21
Chapter 1. Introduction
In transmembrane 10 of the mammalian transporters is the triple proline motif, 
GPGPIP, which confers considerable flexibility to this transmembrane spanning domain 
and is believed to have a role in changing the protein between its two forms the 
internal and external binding types (Gould and Bell, 1990). It is also believed that the 
internal facing, competitive inhibitor cytochalasin B binds near this region (Holman and 
Rees, 1987) in the human erythrocyte transporter. This suggests that this region may 
form part of the internal substrate binding site.
At the end of the protein, just after transmembrane 12 is found the motif KVPETKG, 
which is found in a similar position in many transmembrane superfamilies including 
both the muscarinic and nicotinic acetylcholine receptors, the calcium transporting 
ATPase from endoplasmic and sarcoplasmic reticulum, and the arsenical pump from 
Escherichia coli.
In rat GLUT1 mutants where the C-terminal 37 amino acids are deleted the transporter 
appears to be locked into the inward facing form that can bind cytochalasin B but not 
ATB-BMPA. It has therefore been suggested that the C-terminus may be involved in 
switching the protein between its two conformations (Oka et al, 1990)
1.2.3. Su p e r f a m il y  M e m b e r s
1.2.3.1. The Mammalian Transporters
In humans there are at least 6 functionally different facilitative sugar transporters and 
one pseudogene. All the transporters are expressed in highly controlled ways, with 
very specific tissue distribution. Each transporter has different properties and fills a 
particular niche.
1.2.3.1.1. Mammalian GLUT1
The human GLUT1 transporter is the best studied member of this superfamily. It is 
located in red blood cells, the brain, blood barrier tissues (e.g. blood/brain, placenta, 
retina) and in insulin sensitive muscle and fat cells. Human erythrocytes are an 
extremely rich source of this protein (5% of membrane protein is GLUT1). Human 
GLUT1 is the only member of this superfamily to have been purified (Baldwin et al,
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1982; Baldwin and Lienhard, 1989). The purification led to an N-terminal sequence, 
and to the cloning of the protein (Mueckler et al, 1985). The sequence revealed a site, 
between TM1 and TM2, for the attachment of an asparagine linked oligosaccharide. 
Since then the analogous rat, mouse, rabbit, chicken and pig sequences have been 
determined. All these proteins are highly homologous to the human sequence. For 
example the rat protein has 98% identity to the human GLUT1 at the amino acid level. 
This suggests that all the regions of the protein have a function so that none can 
diverge significantly.
As mentioned earlier this transporter shows asymmetric kinetics. The Kminflux is ten 
times lower than Kmefflux, cytochalasin B binds to the internal binding site, ATB- 
BMPA binds to the external site, and many deoxy and fluoro analogues of glucose 
have differing specificities for the internal and external binding sites (Barnett et al, 
1973b). The discrepancy in Km values means the transporter acts as a unidirectional 
transporter when the extracellular concentration is low and the intracellular demand for 
glucose is high. This may explain the increased expression of GLUT1 in cultured cells 
where the external glucose concentration is often low (Gould and Holman, 1993).
The specificity of the transporter has been investigated. It is 2-deoxy-D-glucose > 6- 
deoxy-D-glucose ~ D-glucose > D-mannose > D-galactose ~ 2-deoxy-D-galactose > 
D-xylose > L-arabinose > D-fiicose »  L-fucose > L-rhamnose »  L-glucose (Baldwin 
and Henderson, 1989).
1.2.3.1.2. Mammalian GLUT2
The low levels of GLUT1 mRNA in liver cells and the different properties of glucose 
transport in liver suggested that another protein was responsible for glucose transport 
into liver cells. The liver transporter, known as GLUT2 was cloned (Fukumoto et al,
1988) and shown to be highly homologous to the erythrocyte transporter. The 
transporter has also been localised in the pancreatic P-cells suggesting that it has a role 
in the glucose stimulated release of insulin from these tissues. It is also localised in the 
kidney and intestine where it is believed to act in conjunction with the Na+/glucose 
symport protein in the unidirectional transport of glucose in these tissues.
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Kinetically GLUT2 has a high Km ~42mM for 3-0-methyl-glucose and a high Kd for 
cytochalasin B ~106M when compared to the erythrocyte transporter (Gould and Bell, 
1990). The high Km means that at physiological concentrations the glucose flux is 
proportional to the concentration of glucose and hence transporter saturation does not 
occur and is not rate limiting. Along with the transporter's high transport capacity this 
makes this transporter ideal for the rapid glucose efflux from the liver following 
gluconeogenesis or the degradation of glycogen.
The equivalent rat (Thorens et al, 1988) and mouse (Asano et al, 1989; Suzue et al,
1989) sequences have been determined. The rat protein has 82% identity to the human 
sequence.
1.2.3.1.3. Mammalian GLUT3
Mammalian GLUT3 protein is localised in tissues that have a high demand for glucose 
namely the brain, nerves and the heart. This isoform may act in conjunction with 
GLUT1 in these tissues to help these tissues meet their high energy demands. The 
comparatively low km for 3-O-MG (lOmM) makes this isoform essential in times of 
hypoglycaemia or high glucose demand when blood glucose levels are low (Gould et 
al, 1991). Tissues expressing this isoform will receive glucose in preference to tissues 
expressing other isoforms with higher Km's (e.g. the liver) when glucose is scarce.
The GLUT3 protein has been cloned from human (Kayano et al, 1988), mouse 
(Nagamatsu et al, 1991) and chicken (White et al, 1991) sources. All show very high 
degrees of homology to each other.
1.2.3.1.4. Mammalian GLUT4
The GLUT4 protein is the main glucose transporter found in the brown and white fat 
cells and cardiac and skeletal muscle. This isoform is the insulin regulatable glucose 
transporter. Stimulation of these cells with insulin produces a 30 fold increase in the 
rate of glucose transport. Labelling studies with the impermeant photolabel ATB- 
BMPA show that there is a 20 fold increase in GLUT4 at the cell surface after insulin
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stimulation (Holman et al, 1990). The stimulation is achieved by the movement of 
GLUT4 protein to the plasma membrane from stores sequestered in light microsomes 
(Cushman and Wardzala, 1980; Suzuki and Kono, 1980). It is believed that insulin 
increases the rate of exocytosis and fusion of the microsome fraction with the plasma 
membrane releasing these transporters into the membrane.
The human (Fukumoto et al, 1989), rat (James et al, 1989) and mouse (Kaestner et al,
1989) genes have been cloned and sequenced. All three proteins are highly 
homologous. For example, the rat and human sequences are 95% identical at the 
amino acid level.
1.2.3.1.5. Mammalian GLUT5
Mammalian GLUT5 has been found to be a high affinity fructose transporter (Burant 
et al, 1992). The cloned protein was expressed in Xenopus laevis oocytes and found 
to have a Km of 6mM for fructose. This isoform appears to be insensitive to 
cytochalasin B (Burant etal, 1992).
Normally, GLUT5 is located in the small intestine where it clears fructose from the 
gut, and in testes, spermatozoa, muscle, brain and adipose tissue where its function is 
to supply fructose (Burant et al, 1992). The human (Kayano et al, 1990) and rat 
(Rand et al, 1993) sequences have been determined. The human protein consists of 
501 amino acids and has significant homology to the mammalian glucose transporters.
1.2.3.1.6. Mammalian GLUT6
GLUT6 is a pseudogene, found in humans, whose mRNA is found in most tissues 
(Kayano et al, 1990). The sequence has 80% identity to the human GLUT3 sequence 
but does not contain introns. It probably resulted from the reinsertion of a GLUT3 
mRNA transcript into the genome by a viral reverse transcription event during 
evolution (Kayano etal, 1990). Due to the lack of evolutionary pressure to maintain a 
functional protein, the sequence has mutated extensively and now contains several stop 
codons and frame shifts. It is very unlikely to produce a full length or functional 




It is believed that GLUT7 is responsible for the transport of glucose across the ER 
membrane into the cytosol (Waddel et al, 1992). When the body needs glucose the 
liver produces it either by the degradation of glycogen or by synthesis from pyruvate 
(gluconeogenesis). The final step in both these processes, the removal of the P 0 4 
from glucose-6-phosphate, is accomplished by the multi-component enzyme glucose-6- 
phosphatase. This enzyme resides in the endoplasmic reticulum and the synthesised 
glucose is made in the lumen of the ER.
The rat GLUT7 gene has been cloned and found to consist of 528 amino acids 
(Waddel etal, 1992). GLUT7 is 68% identical to GLUT2 at the amino acid level with 
very high identity in transmembrane regions 1,2,3,4,9,10. Lack of base drift in the 3rd 
position suggests its origin is from GLUT2.
One difference between GLUT2 and GLUT7 is that the sequence motif KKMKND is 
appended to the end of the C terminus of GLUT7. This sequence is believed to mark 
the transporter for retention in the endoplasmic reticulum (Waddel et al, 1992).
I.2.3.2. The Yeast Members of the Superfamily
A series of glucose transporters from yeast have been identified. Five genes (HXT1, 
HXT2, HXT3, HXT4 and SNF3) have been shown to transport glucose in 
Saccharomyces cerevisiae. Four other genes in the facilitative sugar transporter 
superfamily have also been isolated from yeast: the maltose permease from 
Saccharomyces carlsbergensis, a galactose transporter from Saccharomyces 
cerevisiae, a lactose permease from Kluyveromyces lactis and a glucose/galactose 
permease from Kluyveromyces lactis.
1.2.3.2.1. The Saccharomyces cerevisiae SNF3 Gene
Mutants lacking the SNF3 gene are unable to use sucrose (SNF = Sucrose Non- 
Fermenting) as a carbon source. Normally sucrose is hydrolysed to glucose and 
fructose in the periplasmic space and then the monosaccharides transported by the
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SNF3 gene. The protein has a high affinity (Km ~ ImM) for glucose and can also 
transport fructose (Bisson and Fraenkel, 1983). The low Km for glucose allows 
Saccharomyces to grow on low levels of glucose (Bisson and Fraenkel, 1983).
The protein has been cloned (Celenza et al, 1988) and has been localised to the left 
arm of chromosome IV (Marshall-Carlson et al, 1990). This protein is much longer 
than the other members of the superfamily. It consists of 884 amino acids and has a 
molecular weight of 97kDaltons. It contains an additional 85 amino acids at the N- 
terminus and an additional 303 amino acids at the C-terminus. Mutations where the C 
terminal 246 amino acids were removed have a greatly impaired ability to transport 
glucose (Marshall-Carlson et al, 1990). It is believed that this region is important in 
the protein's interaction with hexose kinases (Bisson and Fraenkel, 1983).
I.2.3.2.2. The HXT Family of Glucose Transporters from Saccharomyces 
cerevisiae
The four HXT genes so far identified as glucose transporters in Saccharomyces are 
differentially expressed. For example HXT1 appears to be expressed during 
exponential growth whereas HXT3 appears to be maximally expressed after entry into 
stationary phase. All the glucose transporters from Saccharomyces are very similar in 
structure. For example, the inferred amino acid sequence of HXT3 is 87% identical to 
HXT1, 64% identical to HXT2 and 32% identical to SNF3 (Ko et al, 1993). 
Expression of any one of these genes allows the yeast to grow on >1% glucose (w/v). 
Overexpression of HXT3 in Asnf3 mutants allows the cells to grow on low glucose 
medium (Ko e ta l, 1993).
HXT2 was first identified by its ability to restore growth to mutants that were deficient 
in the SNF3 gene. It has been cloned (Kruckeberg and Bisson, 1990) and found to 
consist of 541 amino acids. Genetic and biochemical analysis has revealed that both 
this gene and SNF3 are required for wild-type levels of high-affinity glucose transport 
to occur (Kruckeberg and Bisson, 1990).
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None of the HXT genes are essential for growth even in SNF3- mutants. Mutants 
lacking all five genes are unable to grow on high concentrations of glucose (5% w/v) 
but mutants containing one functional gene are viable on high glucose medium. The 
mutants lacking all five genes are able to grow on low concentrations of glucose (0.5% 
w/v) suggesting a 6th glucose transporter that is itself glucose repressible (Ko et al, 
1993).
1.2.3.2.3. The Saccharomyces carlshergensis Maltose/H+ Symporter Gene MAL6T
The presence of any one of five unlinked MAL loci (MALI, MAL2, MAL3, MAL4 and 
MAL6) confers the ability of the cells to grow on maltose. Each locus codes for three 
genes: a maltase protein (MAL6S) which is an a-glucosidase, a maltose permease gene 
(MAL6T) and a protein (MALR) whose function is to regulate the expression oiMALS 
and MALT (Hong and Marmur, 1986). The maltose permease protein is in the 
superfamily of hexose transporting proteins.
1.2.3.2.4. The Saccharomyces cerevisiae Gal2 Gene
The primary sequence of the gal2 gene from Saccharomyces cerevisiae has been 
determined (Szkutnicka et al, 1989). The protein consists of 574 amino acids and has 
a molecular weight of 63,789. The HXT2 gene has 65% identity at the amino acid 
level. Like other members of the superfamily this protein lacks a signal sequence for 
directing the protein to the plasma-membrane. The protein has a substrate site for 
cyclic AMP-dependent protein kinase that appears to be a way of inactivating the 
transporter (Szkutnicka et al, 1989).
1.2.3.2.5. The RAG1 Glucose Transporter from Kluyveromyces lactis
The RAG1 gene has been sequenced and encodes a protein containing 567 amino acids 
(Goffrini et al, 1990). This protein has 73% identity to the S. cerevisiae GAL2 protein 
over a 500bp stretch (Goffrini et al, 1990) and only 29% identity with S. cerevisiae 
SNF3 (Goffrini et al, 1990). Despite this, RAG1 does not appear to be a galactose 
transporter. The protein cannot complement a gal2 mutation in S. cerevisiae and A
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ragJ mutants assimilate galactose normally. RAG1 can complement a snfS mutation 
indicating that this protein is likely to be a glucose transporter (Goffrini et al, 1990).
I.2.3.2.6. The Lactose Permease of Kluyveromyces lactis
The Kluyveromyces lactis lactose permease gene is located on a 4.7kbase mRNA that 
codes for two genes (Chang and Dickson, 1988). The first open reading frame 
encodes a 587aa protein that has been shown to be lactose permease. It is not believed 
that the second open reading frame is involved in lactose transport (Chang and 
Dickson, 1988).
As with other members of the superfamily the Kluyveromyces lactis lactose permease 
does not contain an N-terminal signal sequence and does not show significant 
homology to lactose permease from Escherichia coli (Chang and Dickson, 1988).
I.2.3.3. Prokaryotic Members of the Superfamily
Currently five genes homologous to the mammalian and yeast facilitative transporters 
have been isolated from prokaryotes. These include the glucose transporters from the 
Gram negative bacteria Zymomonas mobilis and the cyanobacteria Synechocystis and 
the xylose, arabinose and galactose/glucose transporters from Escherichia coli.
I.2.3.3.I. The Synechocystis Glucose Transporter
A glucose transporter has been isolated from the cyanobacterium Synechocystis strain 
PCC 6803. It was cloned by complementation in mutants that could not transport 
glucose and was found to be homologous to the mammalian transporters (Schmetterer, 
1990). When the gene was interrupted the mutants again lost their ability to transport 
glucose.
Fructose is toxic to Synechocystis and it has been noted that mutants that lack the 
ability to transport glucose (and lack a functional glucose transporter) are resistant to 
fructose. This very strongly suggests that the transporter also transports fructose 
albeit with reduced affinity (Flores and Schmetterer, 1986).
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1.2.3.3.2. The Escherichia coli araE Gene
The pentose L-arabinose is transported into E. coli by two mechanisms, one of which 
is a proton symporter. The protein encoding the symport protein has been cloned 
(Maiden et al, 1988), consists of 472 residues, has a molecular weight of 51,683, is 
commonly known as araE and is a member of this superfamily.
The proton symporter has the following specificity 6-deoxy-D-galactose ~ L-arabinose 
> 6-deoxy-D-glucose > D-xylose »  D-galactose ~ D-glucose (Baldwin and 
Henderson, 1989). The uptake of sugar is inhibited by cytochalasin B (Kd ~ 10'6M) 
and can be photolabelled under appropriate conditions. The sugar substrates protect 
the protein from cytochalasin B labelling (Baldwin and Henderson, 1989).
1.2.3.3.3. The Escherichia coliXylE  Gene
Escherichia coli possess a xylose-proton symporter protein known as xylE. This 
protein has been cloned (Davis and Henderson, 1987), and was found to consist of 491 
residues and to have a molecular weight of 53, 607.
Kinetically it has been found that cytochalasin B is not able to inhibit xylose transport 
by this protein. The xylE protein is believed to be a proton symporter because it is 
uncoupler sensitive and xylose transport is accompanied by an intracellular pH change 
(Davis and Henderson, 1987).
1.2.3.3.4. The GalP Gene of Escherichia coli
The galP locus in Escherichia coli has traditionally been associated with the ability of 
the bacteria to utilise galactose. Despite this, the specificity of the galP protein is 
similar to mammalian GLUT1. The specificity is D-glucose > 2-deoxy-D-glucose > D- 
galactose > 6-deoxy-D-glucose > D-talose > 2-deoxy-D-galactose > D-mannose > D- 
fiicose > D-xylose »  L-glucose * L-arabinose (Baldwin and Henderson, 1989). 
Cytochalasin B inhibits transport with a Kd of ~10'6M and cytochalasin B binding is 
inhibited by D-glucose, D-galactose and 2-deoxy-D-glucose (Cairns, et al, 1991). The
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protein migrates at 38,000kD on an SDS polyacrylamide gel and has homology to the 
Escherichia coli arabinose and xylose symporters (Baldwin and Henderson, 1989).
I.2.3.3.5. The Zymomonas mobilis Facilitative Glucose Transporter
Zymomonas mobilis is a Gram negative bacterium that, during evolution, has become 
highly specialised for growth in plant saps with a high sugar content. The glucose 
transporter from Z  mobilis is located in an operon with the first three enzymes of the 
pentose phosphate pathway glucokinase, glucose-6-phosphate dehydrogenase and 6- 
phosphogluconate dehydratase (Bamell et al, 1990). The pentose phosphate enzymes 
were cloned by complementation in E. coli and the glucose transporter sequence 
determined purely by its proximity to these enzymes on the operon (Bamell et al,
1990). The Z  mobilis glucose transporter is 473 amino acids long and kinetically it 
has been confirmed that it is a facilitative transporter with a Km of ~10mM (DiMarco 
and Romano, 1985).
I.2.3.4. Other Members of the Superfamily
1.2.3.4.1. The Arabidopsis thaliana D-gIucose/H+ Symporter
A glucose transporting protein that has homology to the mammalian transporters has 
been cloned from the higher plant Arabidopsis thaliana (Sauer et al, 1990b). It is 
interrupted by three introns, consists of 522 amino acids and has a M.W. of 57,581 
Daltons. When expressed in Schizosaccharomyces pombe, the protein caused the 
accumulation of 3-O-methyl-glucose, D-glucose and galactose (Sauer et al, 1990b). 
This suggests that the transport of glucose may be an active process in Arabidopsis.
1.2.3.4.2. The Chlorella kessleri D-Glucose/H+ Symporter
The transport of D-glucose into Chlorella kessleri has been conclusively shown to be 
linked to the transport of a proton (Komor and Tanner, 1974). Addition of sugars 
caused a transient proton uptake under both respiratory and photosynthetic conditions. 
The non-metabolisable glucose analogue 6-deoxy-D-glucose was also used and it was 
found that its uptake was associated with proton flux (Komor and Tanner, 1974). 
Transport of sugars was found to be reduced considerably under anaerobic conditions,
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in the dark, and in the presence of uncouplers. For example 50pM carbonylcyamide-p- 
trifluoromethyloxyphenyl-hydrazone totally destroyed transport. Sodium and 
potassium ions were unable to substitute for H+ in the transport system (Komor and 
Tanner, 1974).
The transporter has been characterised kinetically. The Km values for D-glucose, 6- 
deoxy-D-glucose and 3-O-methyl-glucose are 1.5xlO*5M, 2.7xlO-4M and 1.0xl0‘3M 
respectively (Sauer et al, 1990a).
The gene responsible for D-glucose/H+ transport in Chlorella has been isolated and 
sequenced (Sauer and Tanner, 1989). The isolated gene has been expressed in 
Schizosaccharomyces pombe (Sauer et al, 1990a). The transformed cells accumulated 
3-O-methyl-D-glucose up to 10 fold whereas wild-type S. pombe only equilibrate the 
sugar (Sauer et al, 1990a).
I.2.3.4.3. The D-Glucose Transporter from Trypanosoma brucei brucei
In trypanosomes two tandemly arranged multigene families of glucose transporters 
have been isolated (Bringaud and Baltz, 1993). The first, known as THT1, has been 
expressed in Xenopus oocytes and found to have properties identical to those found in 
the bloodstream form of the parasite. The second, THT2, is expressed differentially in 
the procyclic form of the parasite (Bringaud and Baltz, 1993). Both THT1 and THT2 
have homology to the mammalian facilitative transporters and both sequences are 
virtually identical over the second half of the protein (Bringaud and Baltz, 1992, 
1993).
In the human host, trypanosomes are totally dependent on glucose for their energy 
supply and they have developed a unique organelle (the glycosome) to help it to 
maintain a fast turnover of glucose. In the bloodstream form THT1 is insensitive to the 
inhibitors cytochalasin B and phloretin (Eisenthal et al, 1989). It is, however, inhibited 
by phlorizin that is traditionally considered an inhibitor of the mammalian glucose/Na+ 
symporter (Koepsell and Madrala, 1987) and ineffective against this superfamily of
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transporters. THT1 appears to be kinetically symmetrical with a Km of ~4mM for 6- 
deoxy-D-glucose (Eisenthal etal, 1989).
The metabolism of glucose in trypanosomes appears to be poorly regulated. It appears 
that both glucose transport and glycolysis are unregulated and are working at full 
capacity (Ter Kuile, 1993). The transport of glucose across the plasma membrane 
appears to be rate-limiting. The bloodstream form of T. brucei transports glucose by 
way of a facilitative carrier (Eisenthal et al, 1989).
Both 1-deoxy-D-glucose and 1 -fluoro-P-D-glucose exist exclusively in pyranose ring 
forms and both interact efficiently with THT1. This suggests that the transporter 
accepts glucose in a pyranose form (Eisenthal et al, 1989). Interestingly it appears as 
though the same transporter transports fructose, with a high affinity (Km ~ 2.5mM), in 
the furanose ring form (Fry et al, 1993).
I.2.3.4.4. The Leishmania D-glucose Transporters
Although both are kinetoplastids, Leishmania and Trypanosoma encounter widely 
differing conditions in their respective hosts. Trypanosoma brucei inhabits the midgut 
of the tsetse fly and the mammalian bloodstream; Leishmania the gut of the sandfly 
and the lysosomal vesicle of the human macrophage. Trypanosomes, in the human 
blood stream, are in a well-regulated system where the pH, temperature and glucose 
concentration are constant allowing the parasite to have a glucose metabolism that is 
uncontrolled (Ter Kuile, 1993). The lysosome of the human macrophage, by contrast, 
is acidic (pH4.0) and a much more hostile environment than the bloodstream. For this 
reason Leishmania must control metabolism carefully. Leishmania controls the 
internal pH and the electrochemical gradient across its plasma membrane allowing it to 
withstand large extracellular pH changes (Ter Kuile, 1993).
It has been reported (Zilberstein and Dwyer, 1985) that Leishmania transports glucose 
in conjunction with a proton. The evidence for this included the accumulation of 2- 
deoxy-D-glucose in untreated cells, the uptake of glucose in response to an artificial 
proton gradient and an increased flow of protons, in energy depleted cells, on the
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addition of D-glucose. Recently it has been proposed that these conclusions are 
erroneous and D-glucose enters the parasites through a facilitative transporter (Ter 
Kuile, 1993). The formation of 6-phospho-2-deoxy-D-glucose explains the 
accumulation of the sugar and the stoicheometry of 2-deoxy-D-glucose/H+ uptake was 
found to be about 10:1 once the phosphorylation of the analogue was taken into 
account (Ter Kuile, 1993). It has been suggested that D-glucose is passively 
transported across the plasma membrane and actively transported into an organelle. 
This would explain the D-glucose induced proton flux (Ter Kuile, 1993). Unlike the 
trypanosome protein the transport of glucose into Leishmania is inhibited by 
cytochalasin B and phloretin (Zilberstein and Dwyer, 1985).
Two isoforms, in the facilitative sugar superfamily have been isolated from Leishmania 
enriettii (Cairns, et al, 1989; Stack et al, 1990). These proteins are encoded in a 
tandem repeat of genes. All the genes appear to be virtually identical (known as prol) 
except for the first. The first sequence is identical to the others except for the N- 
terminal cytoplasmic region (Stack et al, 1990), which contains 132 amino acids. 
These amino acids are completely different to the 48 amino acids found at the 
extracellular amino terminus of the other genes in the tandem repeat (Stack et al,
1990). The mRNAs encoding both of these isoforms are found in the promastigote 
(insect) form of the parasite (Stack et al, 1990).
Two other genes in the facilitative sugar superfamily have been isolated from 
Leishmania donovani (Langford et al, 1992). The two genes are known as D1 and 
D2. The three genes Prol, D1 and D2 are located on different chromosomes in 
Leishmania donovani (Langford et al, 1992). The gene, D1 is very similar to the 
other members of the superfamily containing all the conserved regions and having 33% 
homology to the E. coli arabinose transporter araE (Langford et al, 1992). The D1 
gene appears to be expressed equally abundantly in both the promastigote and 
amastigote (macrophage) stages of the life-cycle (Langford et al, 1992). One unusual 
feature of D1 is the very short N-terminus and long C-terminus of this protein. The 
first transmembrane region is predicted to begin with the third amino acid. The D2 
protein is most similar to Prol (44% identity) and both lack some of the conserved
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regions. D2, like Prol, is expressed predominantly in the insect form of the parasite 
(Langford etal, 1992).
1.2.3.4.5. The Sugar Transporters of Schistosome
Recently 3 genes with homology to the other members of this superfamily have been 
isolated from the parasitic worm Schistosome. These three genes SGTP1, SGTP2 and 
SGTP4 were cloned using the polymerase chain reaction and oligonucleotides raised 
against conserved regions in the superfamily primary structure (Skelly, 1993).
1.2.3.4.6. The Neurospora crassa Quinate Transporter
The qa gene cluster consists of five structural and two regulatory genes involved in the 
metabolism of quinate (figure 3) as a carbon source (Geever et al, 1989). The genes 
are co-ordinately induced by quinate and repressed by glucose (Geever et al, 1989). 
One of the genes in this cluster qa-y is the quinate transporter that has significant 
homology to human GLUT1 and other members of the superfamily (Geever et al,
1989).
1.2.3.4.7. The Aspergillus nidulans Quinate Transporter
Like Neurospora, Aspergillus nidulans can use quinate as a sole carbon source and the 
six genes required for quinate metabolism are linked on chromosome VIII (Hawkins et 
al, 1988). On this gene cluster is located the QUTD quinate permease gene that has 
homology to the facilitative sugar transporters.
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2. Materials and Methods
2.1. Plasmodium Manipulation - Materials and Solutions
2.1.1. S o l u t io n s  and  G e n e r a l  La b o r a t o r y  Ch e m ic a l s
All the solutions used were either purchased from Gibco-BRL, Merck-BDH or Sigma 
and prepared using ultra pure water (Milli-Q) and detergent free glass and plastic ware. 
All sterile filtering was performed with a 0.22|nm filter. Unwanted cells were soaked in 
a 10% sodium hypochlorite solution for 12 hours before disposal.
2.1.2. M a l a r ia l  Sp e c ie s  a n d  St r a in s
Plasmodium falciparum strain IT04 was obtained from Dr C. Newbold, John Radcliffe 
Hospital, Oxford. Plasmodium yoelii (strain YM) was obtained from Wellcome 
Research, Beckenham.
2.1.3. Cu l t u r e  M e d ia  and  P l a st ic -W a r e
Gentamicin (lOmg/ml), L-Glutamine (200mM) and IX RPMI-1640 Culture Medium 
(with HEPES, Minus Glutamine) were purchased from Gibco.
Incomplete medium was prepared by adding 1ml of lOmg/ml gentamicin to a 500ml 
bottle of RPMI-1640 medium.
Human A Rhesus+ red blood cells were obtained weekly from the local hospital and 
stored in 25ml aliquots with an equal volume of incomplete medium. The cells were 
washed before use with incomplete medium and the Buffy coat (the upper portion of 
packed cells), which contained the white blood cells, was removed. Human serum (A 
Rhesus+) was obtained from the transfusion service and stored at -20°C until ready to 
use.
Culture medium ('complete' medium) was prepared by adding the following chemicals 
to a 500ml bottle of RPMI-1640 medium: 50ml human serum, 5ml of 12.5}ig/ml 
hypoxanthine\10% glucose solution, 1ml of lOmg/ml gentamicin, and 5ml 200mM L- 
glutamine (Geary et al, 1985). When the complete medium had been made it was
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stored at -20°C until ready to use. Once thawed the medium was used within two 
weeks.
Disposable transfer pipettes, 1ml and 10ml Pasteur pipettes, 15 and 50ml sterile tubes 
and 75cm2 culture flasks were obtained from Falcon.
Percoll® was obtained from Pharmacia.
Giemsa stain was purchased from BDH. It was filtered and diluted 10 fold with 
distilled water before use.
2.2. Culturing and Manipulation of Plasmodium falciparum
Plasmodium falciparum was maintained in continuous culture by an adaptation of the 
'candle jar method' (Haynes et al, 1976; Trager and Jensen, 1976; Jensen and Trager,
1977) and is described below.
2.2.1. M ic r o s c o p ic  E x a m in a t io n  o f  P l a s m o d iu m  f a l c ip a r u m
The culture was removed from the incubator and 0.5ml placed into an Eppendorf tube. 
The 0.5ml aliquot was microfuged for 10 seconds; the rest of the culture was returned 
to the incubator. The supernatant was discarded and the pelletted cells resuspended in 
the small amount of fluid that remained using a disposable plastic pipette. A drop of 
this suspension was placed in the centre of a glass microscope slide and smeared across 
it using a second slide. When the slide was dry, it was rinsed briefly with methanol, to 
fix the cells, and then placed in Giemsa's stain. After 2 minutes (or longer) the slide 
was removed from the stain, rinsed under the tap and blotted dry. The slide was 
examined using oil immersion. The malaria stained purple/blue whereas the red blood 
cells were pink/green. The parasites were counted distinguishing the different stages.
2.2.2. Ch a n c in g  M e d iu m
The culture was removed from the incubator and gently swirled to return the settled 
cells to suspension. The culture was poured into a 50ml sterile tube and centrifuged at 
500g in the bench centrifuge for 5 minutes. The supernatant was decanted and 
replaced with fresh, prewarmed (37°C) culture medium. The cells were resuspended
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and returned to the 75cm2 culture flask. The culture was gassed with 3% C 02, 5% 0 2 
and 92% N2 by inserting a pipette attached to the gas line into the culture flask.
Routinely the cells were maintained in 50ml of culture medium and 0.5ml of blood in 
250ml (75cm2) culture flasks. If there were more than 10% trophozoites and schizonts 
in the culture it was split into two or four and fresh blood added to maintain the 1% 
haematocrit.
2.2.3. C r y o p r e s e r v a t io n  o f  E r y t h r o c y t e s  I n f e c t e d  w i t h  P. f a l c ip a r u m
2.2.3.1. Freezing cells in Sorbitol
The cells were pelleted by centrifugation at 500g for 5 minutes, the medium was 
aspirated and the cells gently resuspended in the small amount of supernatant that was 
remaining. An equal volume of sorbitol freezing solution (3% w/v sorbitol, 0.65% w/v 
NaCl and 28% v/v glycerol) was slowly added using a 1ml syringe and a 25 gauge 
needle. Care was taken to ensure that the freezing solution was prewarmed to 37°C as 
glycerol cannot penetrate the cells at 20°C (Mutetwa and James, 1985). The sample 
was transferred to NUNC freezing tubes and frozen rapidly by plunging into liquid 
nitrogen.
2.2.3.2. Thawing of deep frozen cells.
The vial was removed from the liquid nitrogen and placed at 37°C to thaw quickly. 
Once the cells had thawed, the sample was placed in a 50ml Falcon tube and a 1/5 
volume of 12% NaCl (prewarmed to 37°C) added. The 12% NaCl was added 
dropwise through a 1ml syringe and 25 gauge needle with continuous agitation. The 
sample was allowed to stand for five minutes before adding 10ml of prewarmed (37°C) 
1.6% saline. The solution was added slowly using a 21 gauge needle. The sample was 
then centrifuged at 500g for 5 minutes in the bench centrifuge, the supernatant 
removed, and 10ml of prewarmed 0.9% NaCl/0.2% glucose added dropwise to the 
pellet using a 21 gauge needle. After centrifugation at 1 500rpm for 5 minutes the 
supernatant was removed and the cells washed with incomplete medium. The cells 
were centrifuged and resuspended in 50ml of 37°C culture medium. More red blood 
cells were added to produce a 1% haematocrit. The cells were cultured as 10 x 5ml 
cultures in 25ml culture flasks for between one and five days at 37°C until they started
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to grow with a 48 hour life cycle when the cells were transferred to 75cm2 culture 
flasks (section 2.2.2.).
2.2.4. C o n c e n t r a t io n  o f  Er y t h r o c y t e s  In fe c te d  w it h  M a t u r e  Sta g e  
Pa r a sit e s  b y  G e l a t in e  Fl o t a t io n
In the early part of the project the cells were purified using Plasmagel™ (Laboratoire 
Roger Bellon, 159 Avenue A. Peretti, 92200 Neuilly Sur Seine, France) (Pasvol et al,
1978) but this compound became unavailable and was replaced with a 'home-made' 
substitute that behaved in a way indistinguishable from Plasmagel (Goodyer et al, 
1993). This was an adaptation of a previously described method (Jensen, 1978).
A 6% w/v gelatine stock was made and diluted to produce the Plasmagel substitute. 
The stock solution was made by dissolving 1.5g of 150 bloom bovine gelatine (Sigma) 
in 25ml of warm (37°C) 0.7% NaCl, 0.2% C a C l^ ^ O  and 25mM HEPES. The pH 
was adjusted to 7.4 with NaOH, filtered through Whatman's No. 1 filter paper and 
autoclaved. The stock was diluted to 1% w/v gelatine with incomplete medium. Both 
Plasmagel and our substitute were stored at 4°C until ready to use (Goodyer et al, 
1993).
Whether Plasmagel or our gelatine solution was used the concentration method was 
the same. The cells were removed from the incubator and centrifuged in a 50ml 
Falcon tube for 5 minutes at 500g to pellet the cells. The culture medium was 
removed and the cells gently resuspended in the small amount of supernatant remaining 
(~0.5ml). The gelatine solution was warmed to 37°C and placed in 1ml aliquots in 
15ml polypropylene tubes. The concentrated cell suspension (~lml) was mixed with 
the 1ml of gelatine solution. After incubation at 37°C for 15-30 minutes, the 
uninfected and ring infected erythrocytes settled below a layer of erythrocytes infected 
with mature stage (trophozoite and schizont) parasites. The upper layer was carefully 
removed into a clean tube using a plastic pipette and washed with incomplete medium 
before use. Care was taken not to wait too long before removing the upper layer as 
the infected cells settled into the lower layer with time lowering the yield. A Giemsa 
stained slide of the cells was prepared (section 2.2.1.) to determine parasitaemia. After 
purification, typically, 80-95% of the erythrocytes present contained a mature stage
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parasite (Goodyer et al, 1993). The lower layer, containing mainly uninfected red 
blood cells and ring stage parasites, were often reintroduced into culture after washing 
with incomplete medium.
2.2.5. S y n c h r o n is a t io n  o f  P. f a l c ip a r u m  C u l t u r e s  w i t h  S o r b i t o l
The cells were synchronised using a 5% sorbitol in incomplete medium (Lambros and 
Vanderberg, 1979) that was sterile filtered and stored at 4°C until ready to use. The 
cells were removed from the incubator and centrifuged in the bench centrifuge at 500g 
for 5 minutes. As much of the medium as possible was removed from the cells which 
were then resuspended in 5ml of the 37°C sorbitol solution. The cells were incubated 
at 37°C for 5 minutes and then centrifuged again to pellet the cells. The supernatant 
was removed and the cells again resuspended in 5ml of the sorbitol solution. After a 
further 5 minutes incubation at 37°C, the cells were pelletted by centrifugation at 500g, 
washed with incomplete medium and reintroduced into culture (section 2.2.2.). A 
Giemsa stained slide (section 2.2.1.) of the synchronised cells revealed that the mature 
stage (trophozoite and schizont) parasites had lysed leaving only uninfected red blood 
cells and those containing rings intact.
2.2.6. R e l e a se  o f  P a r a sit e s  Fr o m  th e  E r y t h r o c y t e  P l a sm a  M e m br a n e  
u sin g  Sa p o n in
A solution of 0.15% saponin in pH7.4 PBS was prepared (Stauber and Walker, 1946). 
The cells were pelleted by centrifugation in a bench centrifuge at 500g for 5 minutes, 
the medium was carefully removed, and the cells resuspended in 5ml of the 0.15% 
saponin solution. The red blood cells lysed immediately. After centrifugation at 500g 
for 10 minutes the supernatant was removed and replaced with another 5ml of the 
0.15% saponin solution. After centrifugation at 500g for 10 minutes, the released 
parasites, which were still surrounded by the parasitic vacuolar membrane, were 
washed twice in pH7.4 PBS before use.
2.2.7. R e l e a se  o f  F r ee  Pa r a sit e s  by  N2-C a v it a t io n
The mature P. falciparum parasites were concentrated by gelatine flotation (section
2.2.4.), washed twice in modified PBS (140mM NaCl, 5mM KC1, ImM MgCl2, ImM 
CaCl2, 5mM sodium phosphate and 5mM glucose, pH 7.2) (Mikkelsen et al, 1986)
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and then resuspended to 5% haemocrit in modified PBS. The cells were placed in the 
Parr bomb. Air was flushed from the bomb, and the cells subjected to 30 atmospheres 
of pressure for 30 minutes at room temperature. The cells were not stirred during this 
time as this appeared to lyse the mature parasites and cause excess clumping. The cells 
were then released through the valve at the bottom of the bomb removing the pressure 
rapidly. The cells were released into a siliconised tube (section 2.4.7.) containing a 
1/10th volume of modified PBS containing lOmM EGTA to prevent clumping. The 
cells were centrifuged at 500g for 10 minutes and resuspended in artificial intracellular 
medium (AIM). The AIM was a high potassium artificial intracellular buffer which 
consisted of 120mM KC1, 20mM NaCl, lOmM Pipes, ImM MgCl2, and 5mM glucose 
pH 6.7 (Mikkelsen et al, 1986)
2.2.8. Pu r if ic a t io n  o f  Fr ee  P. f a l c i p a r u m  Pa r a sit e s  o n  a P er c o l l  
Gr a d ie n t
The Percoll® (Pharmacia) was diluted to 90% with 10X AIM (Mikkelsen et al, 1986) 
and then diluted further to 35% with IX AIM. The Percoll® (8ml) was placed in the 
bottom of a 10ml polycarbonate ultracentrifuge tube (Beckman) and centrifuged at 30 
OOOg for 30 minutes in a 70.1Ti rotor. The cells (resuspended in 2ml of AIM) were 
carefully layered on top of the gradient and then centrifuged at 10 OOOg for 10 minutes. 
The free parasites failed to enter the Percoll® gradient whereas the red blood cells 
banded towards the bottom of the tube. The released parasites were carefully removed 
into a Siliconised tube (section 2.4.7.) and washed in AIM twice to remove all traces 
of Percoll®.
2.2.9. F l u o r e sc e n c e  of  Fr ee  Pa r a sit e s  w it h  R h o d a m in e  123
Intact viable malarial parasites maintain a potential across their membrane and hence 
retain the fluorescent dye Rhodamine 123 (Tanabe, 1983). Free parasites in AIM 
buffer, at a protein concentration of 0.1 mg/ml, were equilibrated for 15 minutes at 37° 
C with 1.0|ig/ml Rhodamine 123. After a 10 fold dilution with AIM the cells were 
centrifuged at 500g for 10 minutes, resuspended in AIM and examined immediately 
under a fluorescent microscope (Mikkelsen et al, 1986).
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2.2.10. M a in te n a n c e  o f  P l a s m o d iu m  y o e l ii in  M ic e
Mice (CD1 and BalbC strains) were infected with Plasmodium yoelii malaria parasites 
by inter-peritoneal injection of lOOpl of infected mouse blood. The course of the 
infection was followed by removing a drop of blood from the animals, by tail bleeding, 
followed by examination of Giemsa stained smears (section 2.2.1.). When 
approximately 90% of the animal's erythrocytes were infected it was anaesthetised and 
its blood removed by cardiac puncture. It usually took 4-6 days for the animals to 
contract malaria. Spare infected mouse blood was mixed with 35% v/v glycerol and 
plunged into liquid nitrogen. To infect more mice this blood was thawed quickly by 
placing at 37°C and then injecting lOOfil into uninfected mice.
2.2.11. R e m o v a l  o f  W h ite  B l o o d  C e l l s  f r o m  P. y o e l ii  I n f e c t e d  M o u se  
B l o o d
Many methods are available for the removal and separation of white blood cells from 
red blood cells but the only effective way of separating P. yoelii infected erythrocytes 
from uninfected ones is to use cellulose (Homewood and Neame, 1976). This is 
because mature P. yoelii infected red blood cells have a similar density to white blood 
cells and thus co-purify on Percoll gradients (Baggaley and Atkinson, 1972).
Siliconised glass wool (section 2.4.7.) was placed at the bottom of a PDQ column and 
dry CF12 cellulose fibre (Whatman) placed on top until the column was full. The 
cellulose was then packed by sealing the top of the column (using a thumb) and 
applying suction to the bottom (Williams and Richards, 1973). More cellulose was 
added until the cellulose would not pack any further. The infected mouse blood was 
washed in PBS, resuspended in 50ml of PBS and placed in a 50ml syringe that was 
attached to the top of the column. The cells were slowly pushed through the column; 
the red blood cells came through the column while the white blood cells remained in 
the cellulose (figure 6).
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Mouse blood in PBS
Cellulose CF12
Siliconised glass wool
Figure 6. Cellulose column used to separate white blood cells from malaria infected 
mouse erythrocytes.
Complete removal o f white blood cells was confirmed by examination o f a Giemsa 
stained slide (section 2.2.1.).
2.2.12. P u r i f i c a t i o n  o f  M a t u r e  P. y o e l ii  P a r a s i t e s  u s in g  P e r c o l l ®  
G r a d ie n t s
Plasmodium yoelii infected mouse blood contains all the intraerythrocytic stages o f the 
malarial life cycle at any one time, i.e. it is unsynchronised. To purify red blood cells 
infected with mature stage parasites from uninfected red blood cells and those infected 
with ring stage parasites, a Percoll® gradient was used (Kutner et al, 1985). Percoll® 
was diluted to 90% with 10X PBS containing 50mM D-glucose. Aliquots o f this 
diluted Percoll® was further diluted to 80%, 70% and 60% with IX  PBS containing 
5mM D-glucose. The 90% Percoll® (4ml) was placed in the bottom of a 15ml Corex 
tube and then 3ml o f 80% Percoll® carefully layered on top. On this, 3ml o f 70% and 
2ml o f 60% Percoll® were layered. The cells (in 3ml o f PBS containing 5mM glucose) 
were then carefully layered on the Percoll® and centrifuged in a SS34 rotor at 10 OOOg 
for 20 minutes (Kutner et al, 1985). The cells band throughout the Percoll on the 
basis o f density. The cells infected with mature stage parasites, which were closer to
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the top of the gradient, were carefully removed and washed twice with 30ml of PBS 
containing 5mM glucose and examined under oil immersion (section 2.2.1.).
2.3. Molecular Biology Materials and Solutions
2.3.1. V e c t o r s , E n zy m e s  a n d  G e n e r a l  La b o r a t o r y  Ch e m ic a l s
Restriction endonucleases, DNA modifying enzymes, lambda DNA and pUC18 vector 
were obtained from either Pharmacia LKB or Northumbria Biologicals. General 
laboratory chemicals were obtained either from Merck BDH or Sigma. Radioactive 
nucleotides, [32P]-a-dATP (5000 Ci/mmol), [32P]-y-ATP (3000 Ci/mmol) and [35S]-ot- 
dATP (1000 Ci/mmol), were obtained from NEN Ltd., Stevenage. The "Sequenase®" 
DNA sequencing kit were bought from United States Biochemical Corporation, X-gal 
was obtained from NBL, and IPTG and agarose from Sigma.
2.3.2. E s c h e r i c h i a  c o l i  St r a in s
The following three strains of E. coli were used during the project.
E. coli TGI K12 A (lac, pro) supE, thi, hsdD5lF'traD36, pro AB+,
lacl% /acZAM15
E. coli DH5a F_ (p80d/acZAM15 A(/flrcZYA-ar#F)U169 endAl rec Al
hsdRAlfa, mw+) deoK thi-\ susE4t4 Ar gyrA96 relAl 
E. coli XL 1-Blue supE 44, hsdRll, rec A l, endAl, gyrA46, thi, rel A l lac,
F  \proAR+, lacl% /acZAM15, 7>ilO(fe/R)]
2.3.3. M e d ia
All the solutions were made using distilled and filtered (Milli-Q) water. Escherichia 
coli cultures were manipulated using good microbiological practice. Sterilisation of 
equipment and cell cultures was achieved by treating with 2% Hycolin solution. The 
following broths and agar solutions were used for growth of E. coli.
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LB 1% Bacto-tryptone, 0.5% yeast extract, 0.5% NaCl
LB AMP Plates 1% Bacto-tryptone, 0.5% yeast extract, 0.5% NaCl and
1.5% Bacto-Agar. The solution was autoclaved and
allowed to cool to 55°C before lOOpg/ml ampicillin was 
added and the solution was poured into Petri dishes.
SOB broth 2% Bacto-tryptone, 0.5% yeast extract, 0.05% NaCl
SOC broth 2% Bacto-tryptone, 0.5% yeast extract, lOmM NaCl,
2.5mM KC1, 20mM D-glucose, lOmM MgS0 4 , lOmM 
MgCl,
DYT broth 1.6% Bacto-tryptone, 1% yeast extract, 0.5% NaCl
All the media were prepared with distilled water and sterilised by autoclaving at 20 
lb/in2 for 30 minutes.
2.3.4. B u f f e r s  a n d  So l u tio n s
The following solutions were prepared using Milli-Q filtered water.
TE buffer lOmM Tris-HCl, ImM EDTA, pH7.5
10X TBE 0.89M Tris borate, 20mM EDTA, pH8.0
50X TAE 1M Tris acetate, 50mM EDTA pH8.0
20X SSC 3M NaCl, 0.3M sodium citrate, pH7.0
100X Denhardt's 2% w/v Bovine serum albumin, 2% w/v ficoll™
(type 400, Pharmacia), 2% w/v PVP 
(polyvinylpyrollidone).
Salmon sperm DNA (Sigma lOmg/ml solution in water. Sonication was 
Type III sodium salt) required to get the salmon sperm DNA to
dissolve.
A number of stock solutions were also prepared and used to make the buffers required 
for restriction analysis and other manipulations.
2.3.5. Se q u a c e l ™ A c r y la m id e  St o c k  So l u tio n s
The SequaGel™ (National Diagnostics) solutions were used whenever a 
polyacrylamide gel was made. The kit comes with 3 solutions which are mixed in the 
required proportions to provide the correct percentage gel. The three solutions are:
SequaGel Concentrate 23.75% acrylamide, 1.25% methylene
bisacrylamide, 8.3M urea 
SequaGel Diluent 8.3M urea
SequaGel 1 OX Buffer 8.3M urea, 1.0M Tris-Borate, 20mM EDTA
pH8.3
2.4. General DNA Methods
2.4.1. D e t e r m in a t io n  o f  DNA C o n c e n t r a t io n  a n d  P u r it y
The concentration of nucleic acids was determined by placing the sample (l-50pg) in a 
quartz cuvette and measuring the absorbance at 260nm (A ^ ). For double stranded
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DNA one absorbance unit is equivalent to 50p,g/ml and for single stranded DNA it is 
equivalent to 33}ig/ml of nucleic acid. For single stranded RNA one absorbance unit is 
equivalent to 40fig/ml of nucleic acid.
The purity of the nucleic acid was determined by measuring the A ^ /A ^ q ratio of the 
sample. Proteins absorb maximally at 280nm whereas nucleic acids absorb most at 260 
nanometres. A high A260/A280 ratio indicates a pure nucleic acid sample. A spectrum 
of the sample was also taken between 320nm and 240nm. A pure sample has a profile 
that peaks at 260nm and falls off on each side. If  the spectrum does not do this or if 
the A^/Ajgo ratio is less than 1.6 for single stranded, or 1.8 for double stranded 
nucleic acid, the sample is unlikely to be pure.
2.4.2. A g a r o se  G el  E l e c t r o ph o r e sis
The agarose was dissolved in TBE or TAE by heating to almost boiling in a 
microwave. When cooled to 55°C, ethidium bromide was added, to a final 
concentration of 0.5|ig/ml, and the solution poured into the mould. The cast had been 
sealed with masking tape to prevent the agarose solution from leaking. A comb was 
placed in position so that it was 2mm from the bottom of the gel case and 10mm from 
the edge of the mould and the gel left to set. The concentration of agarose depended 




Type of DNA to separate Size of DNA
0.3% Genomic DNA >20kb
0.7% Large vectors, digested genomic DNA 20kb - 5kb
1% Vectors, PCR products, large fragments 5kb - 50bases
2% Small PCR products, small fragments <500bases
Table 2. The concentration of agarose used for the separation of DNA depends on the 
size of the nucleic acid.
Once the gel had set, the comb and masking tape were removed and the gel placed in a 
gel tank that contained TBE or TAE and 0.5|Lig/ml ethidium bromide. The samples 
were loaded into the wells after the addition of a 1/10* volume of loading dye (50% 
glycerol, 0.05% xylene cyanol, 0.05% bromophenol blue). To size the DNA fragments 
Hindlll or PstI digested X DNA (which produce fragments of known size) was loaded
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alongside the DNA samples. The gels were run at 100-200 volts routinely or at 25V 
for preparative purposes. The DNA migrated towards the anode.
Once the samples had separated the gel was removed from the tank and placed on a 
UV transilluminator. The DNA bands were fluorescent due to the presence of 
ethidium bromide. A record of the gel was then made by photographing using 
Polaroid 660 film.
2.4.3. Iso l a t io n  o f  DNA Fr a g m e n t s  fr o m  A g a r o se  G e ls  by  ’F reeze  
Sq u e e z in g ’
The DNA band, visualised under UV (section 2.4.2.), was excised from the gel using a 
razor blade. Excess agarose was trimmed off and then the slice of agarose was placed 
in a 0.5ml Eppendorf that had a hole in the bottom (made with a 25 gauge needle) and 
which was plugged with siliconised glass wool (section 2.4.7.). The tube was plunged 
into liquid nitrogen to freeze rapidly, placed in a 1.5ml Eppendorf tube and centrifuged 
at 10 OOOg for 10 minutes in a microfuge at room temperature. After centrifugation 
the DNA had passed into the 1.5ml Eppendorf tube; the agarose remained above the 
glass wool in the smaller tube (Tautz and Renz, 1983).
2.4.4. Iso l a t io n  o f  DNA Fr a g m e n t s  fr o m  A g a r o se  G e ls  U sing  th e  
’G e n e C l e a n in c ®II K it ’
The GeneClean protocol was used to purify DNA from agarose gels. The method 
relies on a specially formulated silica matrix called Glassmilk or GeneClean beads. 
These beads bind DNA in high salt and low temperature and release the DNA in low 
salt and higher temperatures. The DNA sample was electrophoresed on an agarose gel 
(section 2.4.2.) using TAE buffer. After the DNA had migrated, it was visualised 
under UV (section 2.4.2.), and the agarose containing the sample excised with a clean 
razor blade. The agarose was weighed and added to three volumes of 6M Nal 
solution. The sample was heated to 55°C for the minimum time required to melt the 
agarose, the sample cooled on ice, and lOfil of the GeneClean beads added. After 30 
minutes on ice, when the DNA had bound to the beads, the sample was pulsed in the 
microfuge and the Nal solution removed. The beads were washed three times with 
lml of NEW wash (supplied) by adding the NEW wash and then vortexing the sample
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until the beads were fully resuspended. The sample was then pulsed in the microfuge 
and the wash buffer removed. After the last wash the remaining NEW wash was 
carefully removed following centrifugation using a small white Gilson tip. The beads 
were dried by rotary evaporation to remove any traces of ethanol, and then 
resuspended in 10-50jll1 of water or TE buffer. After heating to 55°C for 5 minutes the 
sample was microfuged and the liquid containing the DNA removed to a fresh tube. 
The elution was then repeated with a further lOp.1 of water or TE buffer to collect the 
DNA trapped in the bead's bed volume. Typically 50-80% of the DNA was recovered 
by this method and was found to be pure enough to sequence or subclone.
2.4.5. Pr e p a r a t io n  o f  D ia l y sis  Tu bing
The tubing was cut into 20cm strips, boiled for 10 minutes in 2% w/v NajCC^ and 
ImM EDTA, and rinsed with distilled water. The tubing was then boiled with ImM 
EDTA and stored at 4°C in this buffer. Care was taken to ensure that the dialysis 
tubing remained submerged during storage and was only handled with gloves. The 
tubing was rinsed with distilled water before use.
2.4.6. Cu t t in g  DNA w it h  R e st r ic t io n  E n z y m e s
The restriction digestion of DNA was performed in 0.5ml or 1.5ml Eppendorf tubes 
using the buffer conditions given for the particular enzyme. An appropriate amount of 
enzyme was used. One unit of enzyme totally digests 1.0|ig of DNA in 1 hour at the 
enzyme's optimal temperature. The restriction enzymes were stored in buffers that 
contained glycerol. Care was taken to ensure that the concentration of glycerol did not 
become too high as glycerol inhibits enzyme activity. The volume of enzyme stock 
was never greater than 1/10th of the final volume of the reaction.
2.4.7. SlLANATION OF PLASTIC TUBES, TIPS AND GLASS WOOL
Plasticware was siliconised to make the surface hydrophobic and to prevent loss of 
material. This was used especially for free parasites (section 2.2.7.) and for RNA 
samples (section 2.4.31.). Glass plates were treated to prevent acrylamide adhering to 
them during DNA sequencing (section 2.4.26.4.). Dry plasticware and glassware were 
rinsed thoroughly in 2% dimethyl-dichloro-silane in 1,1,1-trichloroethane (BDH) and
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then in ethanol. The plasticware was then washed in distilled water and allowed to dry 
in a 55°C oven. Glass plates were washed with water and dried using a towel.
2.4.8. A u t o r a d io g r a ph y
Radioactive gels and blots were placed against Fuji RX-100 film in a cassette. When 
weak 32P samples were used, the film was pre-flashed, an intensifying screen was used 
and the cassette was stored at -70°C in the chest freezer. After the required time the 
film was developed manually using Kodak Developer LX24 and Kodak Fix FX40.
2.4.9. E q u il ib r a t io n  of  Ph e n o l
Water saturated phenol (glass distilled grade) was equilibrated using pH8.0 lOOmM 
Tris-HCl. The aqueous layer was discarded, and replaced with more lOOmM Tris-HCl 
until the aqueous solution reached pH8.0. Distilled water was then mixed with the 
phenol to remove excess Tris-HCl and then discarded. The phenol was stored at -20° 
C, or at 4°C in the dark for up to a week. If the phenol became discoloured it was 
discarded.
2.4.10. P u r if ic a t io n  o f  N u c l e ic  A c ids  u sin g  Ph e n o l
Phenol equilibrated to pH8.0 was mixed in a 1:1 ratio with the DNA sample. The two 
layers were mixed and then the sample centrifuged at 10 OOOg for 5 minutes. The 
upper layer, which contained the DNA sample, was removed to a fresh tube. Care was 
taken not to remove any of the white precipitate at the interface of the two layers. The 
extraction was then repeated using a mixture of phenol:chloroform:Iso Amyl Alcohol 
in a ratio of 24:24:1. The chloroform helps the two layers to separate completely and 
lower the concentration of phenol in the aqueous phase. The excess phenol was then 
removed by extracting with chloroform:iso amyl alcohol (24:1).
2.4.11. Pr e c ip it a t io n  of  Nu c l e ic  A c ids  u sin g  E th a n o l  or  Iso pr o pa n o l
Routinely, DNA was precipitated from solutions by adding 0.1 volumes of 3M sodium 
acetate (pH5.5) and 2.5 volumes of absolute ethanol that had been cooled to -20°C 
before use. The tubes were left at -20°C for 30 minutes then the nucleic acid 
sedimented by centrifuging at 10 OOOg for 10 minutes. The supernatant was removed 
and the nucleic acid washed with 0.5ml of ice-cold 70% (v/v) ethanol. The sedimented
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nucleic acid was dried by rotary evaporation and dissolved in water or TE buffer as 
required.
Precipitation of nucleic acids with isopropanol was similar to using ethanol. An equal 
volume of isopropanol and 0.1 volumes of 3M NaAc pH5.5 were added to the sample 
which was then incubated at -20°C for 30 minutes before centrifugation at 10 OOOg for 
10 minutes. The sediment was again washed with 70% (v/v) ethanol, dried under 
vacuum and resuspended in water or TE buffer.
2.4.12. P r e p a r a t io n  o f  G25/G50 Se p h a d e x  R e s in
One gram of powdered G25 or G50 was added to 100ml of distilled water and allowed 
to swell for 6-8 hours. The slurry was washed five times with distilled water to 
remove soluble dextrans, and then the water was replaced with 20% v/v ethanol.
2.4.13. P u r if ic a t io n  o f  DNA f r o m  N u c l e o t id e s  u s in c  a  G25/G50 Se p h a d e x ® 
C o l u m n
Siliconised glass wool (section 2.4.7.) was placed at the bottom of a disposable 1ml 
plastic syringe and G25 or G50 Sephadex® was added to fill the syringe. The column 
was placed in a test tube and centrifuged at 500g for 5 minutes in a bench centrifuge. 
If the bed volume of the column was less than 1ml more resin was added and it was 
again centrifuged. Once the bed volume was 1ml the column was washed with 100pl 
of TE pH7.6 by centrifugation at 500g for 5 minutes. The column was washed twice 
more (with TE buffer) to remove residual ethanol from the column and then the DNA 
sample (in TE buffer) placed on the column. An Eppendorf tube, that had its cap 
removed, was placed in the test tube, the column replaced and centrifuged at 500g for 
5 minutes. Free nucleotides and small oligonucleotides were trapped by the resin 
whereas the DNA sample was eluted into the Eppendorf tube. The G25 column 
excluded oligonucleotides larger than twelve bases; G50 oligonucleotides larger than 
sixteen bases.
2.4.14. P u r if ic a t io n  o f  DNA f r o m  Sa l t s  u s in g  CL6-B C o l u m n s
Sepharose CL6-B (Pharmacia Ltd.) was used to purify DNA fragments from salts, 
phenol, OH" ions and pieces of DNA less than 400 bases long. A 25 gauge needle was
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used to puncture the bottom of a 0.5ml Eppendorf tube. The hole was covered to a 
depth of 5mm with glass beads of 0.4mm diameter. The tube was then filled with 
CL6-B Sepharose resin (equilibrated in TE buffer pH7.6) and centrifuged at 500g for 5 
minutes or until the resin was dry. The column was washed three times (with TE 
buffer) to remove residual ethanol from the column and then the sample (in TE buffer) 
placed on the column. The column was placed in a fresh 1.5ml Eppendorf tube and the 
sample, in 20-200pl, loaded. After centrifugation the DNA was eluted into the 1.5ml 
Eppendorf tube while the oligonucleotides, salts and other impurities remained in the 
column matrix.
2.4.15. P u r if ic a t io n  o f  DNA u sing  a  N e n so r b™-20 C o l u m n
NENSORB™ columns (DuPont NEN) were used to purify DNA samples from 
nucleotides, protein, salt and agarose contamination. The NENSORB™ column was 
washed with 2ml of HPLC grade methanol and then with 2ml of solution A (lOOmM 
Tris-HCl pH7.5, ImM EDTA, lOmM triethylamine). The DNA sample (up to 20pg) 
in 1ml of solution A was then passed through the column followed by solution A 
(3ml). After washing the column with 2ml of water the DNA was eluted with 200|l l 1 of 
50% v/v methanol followed by 200pl of 20% v/v isopropanol and dried in a rotary 
evaporator. The DNA was of high purity (suitable for ligating and sequencing) after 
purification.
2.4.16. R a d io a c t iv e  La b e l l in g  of  O l ig o n u c l e o t id e s
The 5' hydroxyl of oligonucleotides was labelled using [32P]-y-ATP and T4 
polynucleotide kinase. The oligonucleotide (lOpmoles) was resuspended in 50mM 
Tris-HCl pH7.6, lOmM MgCl2, 5mM DTT, 100|nM EDTA, lOOpCi [32P]-y-ATP and 
10U of T4 polynucleotide kinase. After incubation at 37°C for 30 minutes unlabelled 
ATP was added (500pM final concentration) to chase the reaction and improve 
incorporation. The sample was incubated for a further two minutes before making up 




2.4.17. L a b e l l in g  DNA b y  R a n d o m  Pr im in g
Nucleic acid fragments larger than 200bp were labelled using Klenow in preference to 
T4 Polynucleotide kinase. This method incorporates many radiolabelled 32P molecules 
per DNA fragment. The purified DNA (lOOng) was denatured by boiling for three 
minutes and then rapidly cooled on ice. The sample was mixed with 50ng of random 
14-mer oligonucleotides and resuspended in 50mM Tris-HCl pH7.6, lOmM MgS04, 
100|nM DTT, 600^iM dGTP, 600ttM dCTP, 600pM dTTP, 100|JiCi of [32P]-a-dATP 
and 5 units of Klenow. The tube was left at room temperature for 3 hours before the 
reaction was stopped by adding four volumes of TE buffer. Unincorporated 
nucleotides were removed using a 1ml G50 column (section 2.4.13.).
2.4.18. R e m o v a l  o f  3 f Te r m in a l  Ph o sp h a t e
The terminal phosphate was removed from DNA samples using Calf Intestinal 
Phosphatase (CIP). The DNA sample was resuspended in 50mM Tris-HCl pH8.3, 
ImM MgCl2, O.lmM ZnCl2, ImM spermidine and 0.1U of calf intestinal phosphatase. 
After 30 minutes incubation at 37°C a further 0.1U of enzyme was added and the 
sample incubated at 56°C for 15 minutes.
2.4.19. L ig a t io n  o f  DNA F r a c m e n t s
For blunt ended ligations, linearised and phosphatase treated (section 2.4.18.) plasmid 
DNA was mixed with the fragment to be cloned in a molar ratio of 1:3, then 
resuspended in 25mM Tris-HCl pH7.5, lOmM EDTA, lOmM DTT, 0.5mM ATP, 
5mM MgCl2, 15% PEG 8000 and 10U of T4 DNA ligase. The ligation was then 
allowed to proceed at 15°C for at least 24 hours.
Vectors and fragments with compatible overhanging ends (produced with the same 
restriction enzyme) were mixed in equal molar concentrations. The DNA mixture was 
then resuspended in 25mM Tris-HCl pH7.5, lOmM MgCl2, lOmM DTT, 400|iM ATP 
and 1U of T4 DNA ligase. The ligation was then allowed to proceed at room 
temperature for 4 hours.
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2.4.20. Sy n t h e s is  o f  O l ig o n u c l e o t id e  Pr o b e s
2.4.20.1. Synthesis of the probe
After deciding the sequence of the probe, the oligonucleotides were prepared on a 
Model 381A Applied Biosystems automatic DNA synthesiser. After synthesis, the 
matrix material, to which the oligonucleotide was bound, was removed and placed in a 
screw cap Eppendorf containing 1ml of concentrated ammonia solution. The sample 
was placed at 55°C overnight to cleave the oligonucleotide from the column and 
remove the protecting groups from the oligonucleotide. The oligonucleotide was dried 
in a rotary evaporator and then dissolved in 1ml of water. The probe was placed in a 
15ml Corex tube and 0.1ml of 3M NaAc pH5.5 and 3ml of absolute ethanol were 
added (section 2.4.11.). The sample was left at -20°C overnight to precipitate the 
oligonucleotide, and then centrifuged at 10 OOOg for 10 minutes in a SS34 rotor using 
a Sorvall centrifuge. The supernatant was discarded and the nucleic acid washed with 
80% ethanol. After drying, the oligonucleotide was resuspended in 1ml of water. The 
concentration and purity of the oligonucleotide was determined by measuring the A260 
and A ^q (Section 2.4.1.) of the sample. The DNA was usually at a concentration of 
about 150pmolar.
2.4.20.2. Checking the Quality of Artificially Synthesised Probes
To check the quality of the oligonucleotide probe, lOpmoles was end-labelled using 
5|uCi [32P]-y-ATP (section 2.4.16.) and electrophoresed on a 20x20cm, 0.2mm thick, 
20%, denaturing polyacrylamide gel (Sequagel - section 2.3.5.). The sample was 
mixed with an equal volume of loading dye (95% formamide, 20mM EDTA, 0.05% 
bromophenol blue, 0.05% xylene cyanol), heated at 75°C for 2 minutes and loaded 
onto the gel. The samples were electrophoresed at 400V (14mA) for 2-3 hours in 
TBE running buffer. The top plate was removed and Saran wrap™ placed over the gel 
and lower plate before exposing to film (section 2.4.8.). After 10 minutes the film was 
developed (section 2.4.8.). Correctly synthesised oligonucleotides (which were all full 




2.4.20.3. Purifying a Poorly Synthesised Probe by Shadowing
If the oligonucleotide was a mixture of products (i.e. laddered) it was electrophoresed 
on a 20% polyacrylamide gel. The sample was dried and resuspended in 100|il of 
sterile water and lOOjil of denaturing loading dye (95% formamide, 20mM EDTA, 
0.05% bromophenol blue, 0.05% xylene cyanol) and heated at 60°C for 5 minutes. 
The sample was loaded on the gel and electrophoresed (using TBE as running buffer) 
at 50mA for 3-4 hours. The gel was examined under UV light (with a fluorescent 
plate as background) and the slowest migrating (largest) band cut out and placed in a 
screw topped universal bottle. The sample was gently shaken with 1ml of 0.3M NaAc 
and ImM EDTA overnight to elute the DNA from the polyacrylamide. The sample 
was centrifuged at 500g to pellet the polyacrylamide. The supernatant was removed 
and the DNA precipitated by the addition of three volumes of absolute ethanol (section 
2.4.11.) and incubation overnight at -20°C. The sample was centrifuged at 10 OOOg 
for 10 minutes in a Sorvall SS34 rotor. The DNA was washed with 80% ethanol, 
dried, and resuspended in 100p.l TE buffer. The A ^q of the sample was determined to 
calculate the concentration of DNA (section 2.4.1.).
2.4.21. P r e p a r a t i o n  o f  C o m p e t e n t  E s c h e r ic h ia  c o l i
A single colony of E. coli (strain XL 1-Blue or TGI) from an LB plate was inoculated 
into 5ml of LB buffer and incubated at 37°C overnight, with continual agitation at 
200rpm. The following morning 0.5ml of the overnight culture was added to 40ml of 
DYT in a 250ml flask, and shaken at 37°C until the culture had an optical density at 
550nm of 0.3 absorbance units. The cells were then plunged into ice cold water and 
centrifuged at 4°C in the bench centrifuge at 500g for 5 minutes. The cells were gently 
resuspended in 20ml of 50mM CaCl2 ensuring that the sample remained at 4°C 
throughout the procedure. After 20min on ice, the cells were again centrifuged at 
500g and gently resuspended in 2ml of ice cold 50mM calcium chloride. The cells 
remained competent for up to 48 hours as long as they were kept on ice.
When highly competent cells were required (~109 transformants/fig of DNA) super 
competent E. coli (strain DH5a) were purchased from Gibco.
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2.4.22. T r a n s f o r m a t i o n  o f  E. c o l i  w i t h  P la s m id  DN A
The competent cells (200|il) were mixed with the DNA (1 - 50ng) and placed on ice 
for 30 minutes. The sample was then placed at 42°C for 90 seconds to heat shock the 
cells before the addition of 1ml SOC broth. The tube was then placed at 37°C for one 
hour and the cells (2|il - 1ml) were spread onto 10cm diameter agar plates containing 
LB + 100p,g/ml ampicillin (section 2.3.3.). For volumes greater than 200|il the cells 
were centrifuged at 500g for 5 minutes, the supernatant discarded and the cells 
resuspended to concentrate. After the plates had dried they were incubated at 37°C 
overnight. If the vector had a colour selectable marker 50jil of 0.1M IPTG and 50pl 
of 2% (w/v) X-gal, in dimethyl formamide, were spread on each plate (LB AMP) and 
allowed to dry before spreading the cells. When the transformation was successful 
colonies were visible on the plate the following morning.
2.4.23. P l a s m id  D N A  ’M in ip r e p s ’
Small scale preparation of DNA was carried out using a modification of the alkaline 
lysis method (Bimboim and Doly, 1979). The method was used mainly to screen large 
numbers of colonies for the presence of the correct insert in the vector following a 
transformation. A single colony of the transformed E. coli (DH5-a, XLl-Blue or 
TGI) was placed in 3ml of LB containing 100p,g/ml ampicillin and shaken at 37°C for 
no less than 6 hours. When grown, 1ml of the culture was placed in an Eppendorf 
tube and centrifuged at 5 OOOg for 5 minutes to pellet the cells. The medium was 
removed and the cells resuspended in 150(il of ice cold GTE (50mM glucose, 25mM 
Tris-HCl pH8.0, lOmM EDTA). Lysozyme was not required to lyse the cells. After 
incubation on ice for 5 minutes, 300pl of freshly prepared 1% SDS, 200mM NaOH 
was added and the cells returned to ice. When the sample became clear and viscous, 
200fil of 3M potassium acetate pH4.5 was added. The sample was mixed, and then 
placed on ice for 15 minutes. The sample was centrifuged at 4°C for 10 minutes at 10 
OOOg in a microfuge to remove the white precipitate. The supernatant, which 
contained the plasmid DNA, was extracted with an equal volume of equilibrated 
phenol pH8.0 (section 2.4.10.). The aqueous layer was removed to a fresh Eppendorf 
tube and 1ml of ethanol was added. The sample was left at room temperature for 10
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minutes before centrifuging at 10 OOOg for 10 minutes. The DNA pellet was washed 
with 1ml of 70% ethanol, dried by rotary evaporation and resuspended in 50(il of 20fi 
g/ml ribonuclease A dissolved in TE buffer. A sample of the DNA (usually 3 pi) was 
digested with appropriate restriction enzymes (section 2.4.6.) and electrophoresed on 
an agarose gel (section 2.4.2.) to check whether the vector contained the correct 
insert.
2.4.24. P l a s m id  DNA ’M a g ic ™  M in ip r e p s ’
Small scale DNA preparations suitable for DNA sequencing were obtained using the 
magic™ miniprep method from Promega. A single colony was picked from a LB AMP 
plate (section 2.3.3.) and inoculated into 5ml of LB containing 100fig/ml ampicillin. 
The culture was incubated at 37°C with constant shaking at 200rpm for at least 6 
hours. The entire culture was centrifuged at 10 OOOg for 5 minutes. The pellet was 
transferred to a microfuge tube and resuspended in 2 0 0 |ll1 of cell suspension buffer 
(50mM Tris-HCl pH7.5, lOmM EDTA and lOOpg/ml RNAseA); 200pl of cell lysis 
solution (0.2M NaOH, 1% SDS) was added immediately afterwards. The tube was 
gently inverted until the cells had lysed and the solution turned clear. After lysis, 200|l i 1 
of 3M potassium acetate pH4.5 was added. The sample was centrifuged at 12 OOOg 
for 5 minutes to pellet the cell debris. The supernatant was transferred to a clean 
Eppendorf tube and 1ml of DNA purification resin added. A magic miniprep 
minicolumn was added to the end of a syringe that had its plunger removed. The 
sample, containing the resin, was placed in the syringe barrel and pushed through the 
column using the plunger. The resin (and the bound plasmid DNA) was washed with 
3ml of ice cold 0.1M NaCl, lOmM Tris-HCl pH7.4, 2.5mM EDTA, 50% v/v ethanol. 
The minicolumn was removed from the syringe barrel, placed on top of a 1.5ml 
Eppendorf tube and centrifuged at 12 OOOg for 20 seconds to dry the column. The 
column was then placed on a fresh Eppendorf tube and 50pl of hot (80°C) water was 
added. After 1 minute the column was again centrifuged at 12 OOOg for 20 seconds to 




2.4.25. P l a s m id  DNA ’M a x ip r e p s ’
The cells (XL 1-Blue or DH5a) were grown for 16-24 hours in 200ml LB buffer 
containing 100p,g/ml ampicillin. The cells were harvested by centrifugation at 5 OOOg 
for 10 minutes in a Sorvall GSA rotor and resuspended in 3ml of GTE (25mM Tris- 
HCl pH8.0, lOmM EDTA, 50mM glucose). The cells were placed on ice and 6ml of 
freshly prepared 0.2N NaOH/1% SDS was carefully added to lyse the cells. When the 
solution had turned clear and viscous, indicating cell lysis, 3.75ml of 3M KAc (pH 4.6) 
was added. After incubation on ice for twenty minutes the sample was centrifuged at 
12 OOOg for 15 minutes in a SS34 rotor. The sample remained at 4°C throughout the 
procedure. The supernatant was removed to a fresh 50ml tube and extracted twice 
with an equal volume of phenol/chloroform/IAA (25:24:1) (section 2.4.10.) and then 
once with chloroform/IAA (24:1). Two volumes of ice cold ethanol were then added 
to the sample which was then incubated at 4°C for 30 minutes. After centrifugation at 
10 OOOg for 15 minutes in a S S34 rotor the pellet was washed with 70% ethanol, dried 
and resuspended in 9ml of TE buffer (pH8.0). Caesium chloride (9g) and 0.6ml of 
lOmg/ml ethidium bromide were added to the sample which was placed in a 16x76mm 
quick-seal Beckman polyallomer ultracentrifuge tube, balanced to within 5mg and 
sealed using the 'quick-sealer'. The sample was centrifuged at 15°C for 15 hours at 
200 OOOg in a 70.1Ti rotor in the ultracentifuge (Beckman). The Quickseal tube was 
removed and examined under UV light. Two bands of DNA could be seen to 
fluoresce in the middle of the tube with the RNA at the bottom of the tube (figure 7).
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Syringe to collect 
lower band
Figure 7. A caesium chloride gradient. The lower of the two bands was taken into a 
syringe and further purified.
The lower o f the two bands was taken into a hypodermic syringe using a 19 gauge 
needle and mixed with water saturated butanol to remove the ethidium bromide. This 
butanol extraction was repeated until the sample was colourless. The DNA was then 
placed in dialysis tubing (section 2.4.5.) and dialysed 4 times at 4°C against 1 litre of 
pH8.0 TE buffer to remove caesium salt. The sample was placed in a 15ml Corex 
tube, and two volumes o f ethanol and 0.1 volumes o f 3M NaAc were added to 
precipitate the DNA (section 2.4.11.). The DNA sediment was washed with 70% 
ethanol, dried and resuspended in 1ml o f pH8.0 TE buffer. The A260\A280 ratio was 




The sequencing method was as recommended in the USB corporation Sequenase® kit. 
The kit uses a modified version of T7 DNA polymerase (known as Sequenase®) which 
has a low 3'—>5' exonuclease activity. The double stranded DNA prepared either from 
a maxiprep (section 2.4.25.) or by a Magic® miniprep (section 2.4.24.) (=5-10pg in 20 
p.1) was denatured using 5fil 1M NaOH and incubated at room temperature for 5 min.
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The sample was then spun through a CL6-B column (section 2.4.14.) to remove all 
traces of alkali. Seven microlitres of the denatured DNA were made up to a final 
volume of 10p.l with lpmol deoxyribonucleotide primer and Sequenase® reaction 
buffer (final concentrations 40mM Tris-HCl pH 7.5, 25mM MgCl2, 50mM NaCl). The 
sample was placed at 75°C for 2 minutes and then cooled slowly from 75°C to 30°C in 
a beaker of water. The annealed template was placed on ice and used within 4 hours.
2.4.26.2. Labelling reaction
The Sequenase® labelling mix (7.5mM each dGTP, dCTP, dTTP) was diluted 1:5 with 
distilled water and the Sequenase® DNA polymerase enzyme was diluted 1:8 with 
enzyme dilution buffer (lOmM Tris-HCl pH 7.5, 5mM DTT, 0.5mg/ml BSA). The 
annealed template (10pl) was mixed with lp.1 0.1M DTT, 2pl diluted labelling mix, 0.5 
jjlI  [35S]-a-dATP and 2pl of diluted enzyme, and incubated for 2 minutes at room 
temperature. On hot days the reaction was performed in a 20°C water bath.
2.4.26.3. Termination.
The composition of the termination mixes are:
ddATP - 80pM each dATP, dCTP, dGTP, dTTP, 8pM ddATP, 50mM NaCl
ddTTP - 80pM each dATP, dCTP, dGTP, dTTP, 8pM ddTTP, 50mM NaCl
ddCTP - 80p.M each dATP, dCTP, dGTP, dTTP, 8pM ddCTP, 50mM NaCl
ddGTP - 80pM each dATP, dCTP, dGTP, dTTP, 8pM ddGTP, 50mM NaCl
Samples (2.5pl) of each termination mix were pipetted into separate wells of a 
microtitre plate and placed in a 37°C water bath. To each of the four termination 
mixes 3.5pi of the labelling reaction mix was added and the tubes incubated at 37°C 
for 5 minutes. An aliquot (4pl) of stop solution (95% formamide, 20mM EDTA, 
0.05% bromophenol blue, 0.05% xylene cyanol) was added to each tube and mixed 
thoroughly. The samples could be stored for up to a week at -70°C before loading 
onto the sequencing gel.
2.4.26.4. Preparation of 6% polyacrylamide gel.
A glass plate, of dimensions 21cm x 40cm (the back plate), was soaked overnight in 
2M KOH, washed with water, dried and then washed with ethanol. A smaller piece of 
glass, the front plate (21cm x 37cm), was washed thoroughly with water and then with 
ethanol. The front plate was siliconised (section 2.4.7.) to make it hydrophobic. The
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back plate was coated with a mixture of 25ml ethanol, 0.6ml 10% acetic acid and 200| l l  
1 of bind silane A174 (Merck BDH). After 5 minutes the mixture was removed and the 
plate washed with water and then ethanol. Spacers (0.35mm) were placed along the 
long edges of the back plate and fixed with glue. The front plate was placed on the 
back plate (separated by the spacers) and three edges of the plates aligned. The 6% 
acrylamide solution was made using the Sequagel® reagents (section 2.3.5.) by mixing 
12ml of concentrate, 33 ml of diluent and 5ml of buffer. The acrylamide was 
polymerised with 25)0.1 of TEMED and 200pl of 16% ammonium persulphate. Before 
the acrylamide had set it was poured between the plates and the flat edge of a 
sequencing comb placed in the top of the gel so it was about 0.5cm under the smaller 
plate. The gel was clamped and allowed to set for 30 minutes. Once set, the outsides 
of the plates were cleaned and the comb carefully removed. The trough made by the 
comb was rinsed thoroughly in TBE buffer and the comb placed into the well with the 
shark's teeth 1mm into the acrylamide. The gel was placed vertically in the gel tank 
and clamped. Running buffer, TBE, was placed in both the upper and lower troughs 
of the tank and then the urea that had gathered in the wells was removed using a glass 
Pasteur pipette filled with TBE buffer.
2.4.26.5. Loading and electrophoresis of DNA samples.
The samples were heated to 75°C for 2 minutes to denature and then loaded onto the 
gel (2|il per lane). The gel was electrophoresed at 700V-1500V for the required time. 
Sequences close to the primer were obtained by terminating the run when the bromo- 
phenol blue reached the bottom of the gel (about 3 hours). For sequences further from 
the primer, the gel was electrophoresed for between 6 and 16 hours. Once the DNA 
had migrated the required distance, the gel was removed and the smaller plate carefully 
lifted off using a small spatula. The gel remained stuck to the larger plate which was 
washed for 20 minutes in 10% v/v methanol, 10% v/v acetic acid to remove the urea 
from the gel. The gel and large plate were rinsed in water for 10 minutes and then 
dried on a hot flat bed. The dry gel was then wafer thin and firmly attached to the 
larger plate. The gel was placed next to a piece of film and left for 16-100 hours 
before developing (section 2.4.8.).
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2.4.26.6. Analysis of the Sequence.
The sequence was read and analysed using the Staden software package for the PC 
and the GCG software package on a UNIX or VAX mainframe.
2.4.27. DNA P o l y m e r a s e  I T r e a t m e n t  o f  DNA
Single stranded overhanging ends were repaired using DNA polymerase I. The DNA 
was incubated at 37°C in 50mM Tris-HCl pH 7.2, lOOmM M gS04, O.lmM DTT, 50|i 
g/ml BSA and 5 units of DNA polymerase I. After 5 minutes dNTPs (125|iM each) 
were added and the sample incubated for a further 20 minutes. The sample was then 
purified by phenol extraction (section 2.4.10.) followed by precipitation using ethanol 
and NaAc (section 2.4.11.).
2.4.28. S o u t h e r n  B l o t t in g  T e c h n iq u e
2.4.28.1. Transfer of DNA
The DNA samples were separated by agarose gel electrophoresis, removed from the 
gel tank and viewed under UV light (section 2.4.2.). A photograph of the gel was 
taken with a ruler next to the gel so that the migration of bands was recorded. The gel 
was placed in denaturing solution (1.5M NaCl, 0.5M NaOH) and gently agitated on an 
orbital shaker until the xylene cyanol had turned from light blue to green. The 
denaturing solution was then replaced with neutralising buffer (1.5M NaCl, 0.5M Tris- 
HCl pH7.2, 0.001M EDTA) and gently shaken until the xylene cyanol returned to its 
original blue colour. About 500ml of 20X SSC (3M NaCl, 0.3M sodium citrate) was 
poured into the transfer tank and two pieces of 3 mm filter paper (Whatman) placed 
across the tank so that they dipped into the SSC on either side. The gel was carefully 
placed in the centre of the filter paper ensuring that bubbles were not trapped under the 
gel. The gel was then covered with the transfer membrane (GeneScreen+™ or 
Hybond-N™) that had been soaked in 2X SSC before use. Again care was taken to 
ensure that bubbles were not trapped between the membrane and the gel. The gel was 
surrounded in polythene so that buffer did not leak up the sides of the gel. Two more 
pieces of 3mm filter paper and about six centimetres of paper towel were placed on top 
of the filter paper to soak up the SSC as it passed through the gel and membrane. A
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Figure 8. Apparatus used to transfer DNA from an agarose gel to a hybridisation 
membrane.
The blotting was checked by viewing the membrane under ultraviolet light. If  the 
DNA had transferred, it was placed on a piece o f 3 mm paper that had been soaked in 
denaturing solution, and then about a minute later on a piece soaked in neutralisation 
solution. After a wash in 2X SSC, the membrane was baked at 80°C for 4 hours.
2.4.28.2. Hybridisation of the Labelled Probe to the Membrane
The membrane was placed in a perspex box containing the pre-hybridisation buffer (6X 
SSC, 5X Denhardt's, 0.5% SDS). One millilitre o f 0.50mg/ml Salmon sperm was 
denatured by boiling for 5 minutes and then cooled rapidly on ice and added to the 
box. The box was shaken for no less than 6 hours at the hybridisation temperature 
before adding the radiolabelled probe and hybridising overnight. If  the probe was an 
oligonucleotide it was 5' end-labelled (section 2.4.16.) with T4 PNK and [32P]-y-ATP; 




2.4.28.3. Washing and Autoradiography of the Labelled Membrane
The hybridisation buffer was removed from the membrane and replaced with 2X SSC, 
0.1% SDS (or 6X SSC, 0.1% SDS for a less stringent wash). The membrane was 
washed at low temperatures (room temperature) initially, and the temperature slowly 
increased to raise the stringency and remove more of the label from the membrane. 
The wash buffer was changed regularly and the amount of radioactivity remaining on 
the filter monitored using a Geiger-Miiller tube. Once enough non-specific 
radioactivity was removed, the membrane was sealed in a polythene bag (to prevent it 
from drying) and exposed to preflashed film (section 2.4.8.).
2.4.29. I s o l a t i o n  o f  T o t a l  G e n o m ic  DNA f r o m  P l a s m o d iu m  f a l c ip a r u m
The cell pellet (2x1010 cells in 400|il) was removed from -70°C storage and thawed on 
ice. The cells were resuspended in 50mM Tris-HCl pH9.0, lOOmM EDTA and 
200mM sodium chloride (Herrmann and Frischauf, 1987). Care was taken to ensure 
that the cells had fully resuspended before the sample was made 1% w/v with sodium 
dodecyl sulphate (Towner, 1991). Proteinase K (0.5mg/ml) was carefully dissolved 
and the reaction mix was incubated at 55°C for 24-48 hours. The sample was then 
extracted twice with an equal volume of TE equilibrated phenol pH8.0 (section 
2.4.10.) and once with phenol/chloroform/IAA (25:24:1) rolling on a horizontal shaker 
for 1 hour each time to mix the layers gently. The sample was centrifuged at 10 OOOg 
for 10 minutes after each phenol extraction to remove any precipitated protein from 
the aqueous layer. The sample was then dialysed four times against one litre of 50mM 
Tris-HCl pH8.0, 20mM EDTA and lOmM NaCl and twice against TE buffer. The 
A260 of the DNA was determined (section 2.4.1.) and a fraction of the sample (~100ng) 
was run on a 0.3% agarose gel (section 2.4.2.) at 25V overnight. If the DNA was 
intact a sample of it (~l|Xg) was digested with 5U of EcoRI (section 2.4.6.). After 2 
hours at 37°C the DNA was run on a 0.7% agarose gel (section 2.4.2.). If the DNA 
was digested by EcoRI further purification of the DNA was unnecessary. Any DNA 
samples that did not cut were transferred to a glass beaker, cooled on ice and 1/4 
volume of prechilled 7.5M ammonium acetate was mixed with the sample before 0.8 
volumes of cold isopropanol was layered on top (Towner, 1991). At the interface the
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DNA precipitated and was spooled out on the end of a sealed glass Pasteur pipette. 
The DNA was washed with ice cold 70% ethanol, air dried, and allowed to dissolve in 
TE buffer for 1 week before the A ^  was taken (section 2.4.1.) and the purity 
determined by digestion with restriction enzymes (section 2.4.6.).
2.4.30. P r e c a u t io n s  T a k e n  t o  P r e v e n t  D e g r a d a t io n  o f  RNA
Wherever possible, dry chemicals were reserved for RNA use and stored in a separate 
cupboard to the other laboratory chemicals. All solutions were prepared using either 
sterile disposable plasticware, glassware that had been baked at 180°C for 8 hours, or 
equipment that had been treated with diethylpyrocarbonate. Water was made RNAse 
free by adding diethylpyrocarbonate (DEPC) to a final concentration of 0.1% (v/v). 
The water was stirred for 1 hour and then autoclaved. As residual traces of DEPC can 
modify RNA, the DEPC treated water was not allowed to come into contact with 
nucleic acids. Automatic pipettes (Gilson), Corex tubes, gel moulds and tanks, and 
other implements that would not stand baking were soaked for 3 hours in 0.1% v/v 
DEPC, washed with RNAse free water and allowed to air dry in a fume cupboard. 
Hydrogen peroxide was used to wash the work area before handling RNA samples. 
All solutions were made with ultra pure water (Milli-Q), placed in RNAse free bottles 
and autoclaved for 2 hours.
2.4.31. E x t r a c t i o n  o f  T o t a l  RNA f r o m  P l a s m o d iu m  y o e l ii
Cell pellets were ground in liquid nitrogen and the cold powder sprinkled at a 
concentration of 107 cells/ml into denaturing solution (4M guanidinium thiocyanate, 
25mM sodium citrate pH7.0, 0.5% N-lauryl sarcosine, 0.1M p-mercaptoethanol) and 
transferred to a 15ml Corex tube (Chomczynski and Sacchi, 1986). A 1/10 volume of 
2M sodium acetate pH4.0 was added and the sample mixed thoroughly. An equal 
volume of water saturated, glass distilled grade phenol (taken directly from the bottle) 
was then mixed with the sample followed by a l/5ih volume of chloroform/IAA (24:1). 
The sample was then shaken for 10 seconds and left on ice for 15 minutes. During this 
time the sample separated into two layers; the brown material moved into the lower 
phenolic layer. The sample was centrifuged for 10 minutes at 4°C and 10 OOOg in a 
Sorvall centrifuge. The RNA, in the upper aqueous layer, was separated from the
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DNA and proteins at the interface and in the lower layer, and sedimented, at -20°C, 
using an equal volume of isopropanol. The RNA was sedimented by centrifuging at 
10 OOOg for 10 minutes in a SS34 rotor. The RNA was washed by re-dissolving in 
denaturing solution and then sedimenting by adding an equal volume of isopropanol. 
The sample was left for at least 1 hour at -20°C and then centrifuged at 10 OOOg for 10 
minutes in a SS34 rotor. The supernatant was removed and the nucleic acid washed in 
10ml of RNAse free 70% v/v ethanol and again centrifuged. The pellet was dried 
under vacuum, resuspended in RNAse free H^O and the A ^0 (section 2.4.1.) taken to 
calculate the amount of RNA purified. A sample of the RNA (l|Jg) was 
electrophoresed on an RNAse free agarose gel. Good quality samples were 
characterised by the appearance of clear, undegraded bands of ribosomal RNA in a 
long streak of fluorescent material.
2.4.32. I s o l a t i o n  o f  M e s s e n g e r  RNA f r o m  P. Yo e l ii  U s in g  DYNA® B e a d s
RNAse free DYNA® beads, which can be purchased coupled covalently to oligo 
(dT)25, were used to purify polyA containing RNA species (Homes and Korsnes, 
1990). The magnetic beads (l.Omg) were dispensed into a 1.5ml Eppendorf tube and 
washed in 2X binding buffer (20mM Tris-HCl pH7.5, 1.0M LiCl, 2mM EDTA) by 
resuspending in the buffer and then placing next to a magnet. The beads stuck to the 
side of the reaction tube while the buffer was carefully removed. The tube was then 
removed from the magnet and the beads resuspended in lOOp.1 of 2X binding buffer. 
The RNA (75|ig in 100(il) was denatured by heating to 65°C for 2 minutes, added to 
the beads and allowed to hybridise for 5 minutes. The tube was then placed next to the 
magnet and the supernatant, containing ribosomal and transfer RNA, removed leaving 
the mRNA bound to the beads. The beads were washed twice with 200pl of washing 
buffer (lOmM Tris-HCl pH7.5, 0.15M LiCl, ImM EDTA). The last traces of washing 
buffer were then removed before the RNA was eluted by adding 5fil of elution buffer 
(2mM EDTA pH7.5) and heating at 65°C for 2 minutes. The solution, containing the 
mRNA, was placed in a fresh tube and either used immediately or stored at -70°C with 
2 volumes of ethanol.
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2.4.33. F ir st  Str a n d  cDNA Sy n t h e sis
The mRNA (~lfig) was heated to 65°C for 3 minutes to denature. The mRNA was 
then resuspended in 50mM Tris-HCl (pH8.15), 6mM MgCl2, 40mM KC1, ImM DTT, 
10U of RNAse inhibitor, 1.5mM dNTPs, 50ng/pl poly-dT oligonucleotide (dT14) and 
25U of murine reverse transcriptase C, and placed in an RNAse free Eppendorf. To 
check that the cDNA was correctly synthesised and that the sample had not degraded 5 
|L il of the sample was labelled. The labelling reaction was performed by placing 50|iCi 
of [32P]-a-dATP in an RNAse free Eppendorf tube, drying in a rotary evaporator and 
adding 5(il of the reaction mixture. Both the labelled and unlabelled tubes were 
incubated at 37°C for 1 hour. The labelled sample was electrophoresed on an alkaline 
agarose gel. The sample was passed down a 1ml G25 column (section 2.4.13.) to 
remove unincorporated radiolabel and then resuspended in 25mM NaOH, 10% v/v 
glycerol and 0.05% bromophenol blue. The alkaline gel was made by melting 0.8g of 
agarose in 80ml of 30mM NaOH and 2mM EDTA. When the agarose had cooled to 
55°C it was poured onto a glass plate over which a comb had been placed. The gel 
was made as thin as possible and the comb was placed as close to the plate as possible 
without touching. The gel was poured using a 10ml glass pipette to layer the molten 
agarose gently onto the plate. When the gel was set it was placed in an electrophoresis 
tank filled with running buffer (30mM NaOH and 2mM EDTA). The sample was 
loaded onto the gel with 5' end-labelled (section 2.4.16.) Hindlll digested X DNA 
which had been resuspended in 25mM NaOH, 10% v/v glycerol and 0.05% 
bromophenol blue. The sample was electrophoresed at 30mA until the bromophenol 
blue had moved halfway. It was then dried on a flat bed gel dryer and exposed to film 
(section 2.4.8.) at -70°C overnight. A long streak of nucleic acids from 500-4000bp 
was seen indicating that large molecular weight cDNA was present.
2.4.34. P o l y m e r a se  Ch a in  R e a c t io n  A m p l if ic a t io n  o f  DNA
The PCR was performed in a final volume of lOOpl using either a Perkin Elmer Cetus 
or a Techne PHC2 thermal cycler. A typical reaction mix was:
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Stock solution Final Concentration Volume added
10X Reaction Buffer IX lOtil
dNTP mix, 1.25mM each dNTP 0.2mM each dNTP 16pl
Primer 1, 25piM 1.25(jM 5 pi
Primer 2, 25|iM 1.25pM 5 pi
Template DNA in distilled FL>0 100 copies/pl 63.5pl
TAQ DNA polymerase 2.5 Units 0.5pl
The 10X reaction buffer was supplied with the enzyme. The PCR reaction mix was 
overlaid with lOOpl of mineral oil and then subjected to temperature cycling. 
Typically, the sample was denatured by heating to 95°C for 5 minutes before the 
addition of the enzyme and then subjected to 45 cycles with melting at 95°C for 1.5 
minutes, annealing at 45°C for 1.5 minutes and extension at 72°C for 3 minutes. The 
exact conditions, however, varied according to the primers used. Once the PCR 
reaction had finished the products were analysed using agarose gel electrophoresis 
(section 2.4.2.).
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3. Cloning of the Malarial Glucose Transporter
3.1. Introduction
Molecular biology has revolutionised biochemistry over the last decade. Since the first 
molecular biology laboratories in the early eighties the cloning of genes has become 
both widespread and routine. There are now over 100 000 sequences deposited in the 
international EMBL and GENBANK databases.
This prolific growth in DNA sequence knowledge is due to the many uses that the 
obtained sequence can be put to. For example, obtaining the sequence of the malarial 
glucose transporter would:
i) allow the malarial sequence to be compared to the other cloned glucose transporters. 
This could allow differences in the structure of the genes to be exploited in the design 
of a specific drug that blocks the malarial transporter, and are ineffective against the 
host's transporters.
ii) facilitate the expression of the gene in a foreign host (e.g. COS cells, baculovirus or 
Xenopus oocytes). Because of the higher levels of protein produced and the absence 
of the red blood cell transporter, the expressed gene would be more amenable to 
kinetic analysis than the transporter in its native environment. The Km and Vmax, and 
the inhibition characteristics of the transporter could be determined.
iii) allow mutagenesis studies of the transporter that may yield important results about 
what function certain residues in the protein have. This is already being accomplished 
for the human glucose transporters where these studies are revealing which residues 
form the internal and external binding sites (Hashiramoto et al, 1992).
iv) help to gain information on the genetics of Plasmodium. This could help to 
position malaria more accurately on the phylogenetic tree, increase the accuracy of 
codon usage tables, and possibly provide information about control and transcription in 
malaria.
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Many methods are available to clone genes. Traditionally, genes were cloned by 
screening either a cDNA or a genomic library. Briefly, either mRNA is reverse 
transcribed or genomic DNA digested and the nucleic acid incorporated into the X 
bacteriophage. The plaques that are formed by the X infected E. coli are blotted with 
either a gene from another organism or an oligonucleotide based on the sequence of 
part of the gene. The positive clones are purified and sequenced. This method is 
comparatively insensitive and it often takes many months before it is known whether 
the clone you have identified is part of your gene or a false positive. Usually this 
method is only successful if a gene from a closely related organism or an 
oligonucleotide with a high match is available.
An adaptation of this method, known as genomic blotting, has also had some success. 
Genomic DNA is prepared, digested with restriction enzymes and run on a low 
percentage agarose gel. This DNA is blotted onto nitrocellulose and probed with a 
gene specific sequence. The nucleic acid that hybridises is purified and used to prepare 
a selected library from which a clone can be isolated. This has similar limitations to 
screening a full genomic library and is only successful where a good gene specific 
probe is available.
It is also possible to clone genes by complementation in E. coli. This method relies on 
the expression of the protein inducing a phenotypic change in a mutant E. coli strain. 
This method has been successfully used to obtain the primary sequence of the 
Plasmodium falciparum  glucose phosphate isomerase gene (Kaslow and Hill, 1990). 
Double mutant Escherichia coli, which had lost the ability to utilise glucose both 
through the pentose phosphate pathway and through glycolysis were complemented 
with a library of mung-bean nuclease digested malarial DNA. The bacteria that grew 
on glucose were found to contain a vector that was expressing the malarial glucose 
phosphate isomerase gene. This method has the advantage that it does not require 
prior knowledge of the gene sequence. It is not thought that this method is feasible for 
cloning the malarial glucose transporter. Firstly, although the glucose transporter 
superfamily do not usually contain a signal sequence and human glucose transporters
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have been functionally expressed in E. coli (Sarkar et al, 1988), it is uncertain whether 
the malarial glucose transporter will insert correctly into the E. coli plasma membrane 
and produce a functional protein. Secondly, as at least six native proteins are known 
to transport glucose in E. coli, it would be difficult to produce a mutant lacking the 
ability to transport glucose.
Another method that does not rely on sequence information is functional expression. 
This method was used to isolate the a-subunit of the Na+/glucose symporter from 
human intestine (Hediger et al, 1987a, b). A cDNA library was prepared in A^zap, 
subdivided, and RNA made from each part of the library. This RNA was injected into 
Xenopus laevis oocytes and the fraction with the largest glucose/Na+ transport activity 
further subdivided. In this way the clone containing the transporter was eventually 
isolated. This method would probably be successful in isolating the malarial glucose 
transporter also. However, this method is very labour intensive and was not feasible in 
our laboratory.
Recently many genes have been cloned using the polymerase chain reaction. For 
example the Plasmodium falciparum  glycolytic enzyme 3-phosphoglycerate kinase has 
been cloned this way (Hicks et al, 1991) and in our laboratory a number of insect 
opsins, a muscarinic acetyl choline receptor from Schistocerca gregaria (locust) and 
the Haemonchus contortus GABA receptor have been isolated. This method is 
sensitive and allows a rapid screening procedure. It has been suggested that the 
sensitivity of the polymerase chain reaction allows genes to be isolated using 
oligonucleotides that would not work using a blotting technique (Hicks et al, 1991). 
A PCR product can be cloned and sequenced followed by isolation of the entire gene 
in a very short time.
The polymerase chain reaction amplifies DNA between two oligonucleotide primers 
(figure 9). Firstly the double stranded DNA is mixed with the two oligonucleotides, 
dNTPs and enzyme. This mixture is heated to 95°C causing the DNA template to 
become denatured and single stranded. The sample is then cooled allowing the primers 
to anneal to the single stranded DNA template. After heating the sample to the
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enzyme's optimal temperature o f 72°C, the TAQ polymerase extends the 
oligonucleotide primer making a complementary strand to the template. This product, 
known as a long product, will usually extend beyond the second oligonucleotide. This 
temperature cycling is repeated many times. During the next cycle the second 
oligonucleotide binds to the long product o f the first round and the enzyme makes 
double stranded DNA until the template stops at the end o f the first oligonucleotide. 
As more cycles are performed the proportion of long products becomes insignificant. 
After 30 cycles 1 molecule o f template will have produced 230 molecules o f product.




Denature and Anneal Primers
\J/_____________________
____________________________________________ 2nd Round Extension
± ______________________
3rd round extension
Figure 9. A diagram showing the theory behind the polymerase chain reaction. 
Double stranded DNA is heated to 95°C to denature and is then cooled, allowing the 
oligonucleotides to bind. During the first round TAQ polymerase extends the 
oligonucleotides producing long products. In the second round, the DNA is again 
melted and the primers anneal. Primers that have annealed to one of the long products 
of the first round will extend only as far as the first oligonucleotide producing short 
products. Because in subsequent rounds the oligonucleotides can bind to either long or 
short products to produce short products, the number of short products increases 
exponentially.
In this project we have used the polymerase chain reaction extensively to rapidly
screen for the malarial glucose transporter. With the polymerase chain reaction
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conditions can be varied and optimised until specific products are produced. Once 
produced the products can be cloned and sequenced rapidly. The polymerase chain 
reaction is fast, specific and sensitive.
A special adaptation of the polymerase chain reaction can be used to amplify the 3' 
ends of genes (Frohman and Martin, 1989; Frohman, 1990). This adaptation, known 
as RACE (Rapid Amplification of 3' cDNA Ends), uses cDNA that was synthesised 
using a special polyT primer containing a 3' stretch of 28 nucleotides (called R) of 
known sequence. In the PCR reaction one of the primers can be made to R so that the 
3' end of the cDNA can be specifically amplified using a probe to the required gene. 
This method amplifies the gene but may also amplify unwanted gene products as well. 
The method can be made much more specific by repeating the method using 2 primers 
(one gene specific and one made to R) made to internal regions of the gene. This use 
of nested primers is a common way of removing unwanted contamination by non­
specific contaminants in PCR reactions (figure 10).
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Gene Specific Oligo 1 Ro Oligo
Product + 
Contaminants Gene Specific Oligo 1 Gene Specific Oligo 1 Ro Oligo
Ro Oligo
Ro Oligo Gene Specific Oligo 1
Second Amplification
Required product
Gene Specific Oligo 2
>
Ri Oligo
Figure 10. Rapid Amplification of 3' cDNA Ends (RACE) PCR (Frohman and Martin,
1989). Messenger RNA is purified and converted to cDNA using a polyT 
oligonucleotide that contains a 3' flanking region R 28 nucleotides long. The cDNA is 
mixed with an oligonucleotide made to the outer half of R (Ro) and a sense gene 
specific primer, and amplified using the polymerase chain reaction. Among the 
products will be the gene of interest. A second amplification using nested primers, i.e. 
to the inner half of R and a second sense gene specific oligonucleotide, will increase the 
specificity of the technique and hopefully yield a single product.
Although similar techniques can be used to clone genes from almost any organism, the 
methods often need to be adapted to suit the peculiarities of the particular organism 
under investigation. With malaria this is certainly the case. The malarial genome is 
extremely AT-rich (70% in coding regions and 92% in non-coding regions), contains 
very short introns and is haploid for the majority of its life cycle. The extreme AT- 
richness makes large pieces of DNA unstable in E. coli, which has made the 
preparation of malarial libraries extremely troublesome. These problems have only 
recently been circumvented using yeast artificial chromosomes (section 1.1.8.). The 
use of YACs however present their own problems: special equipment is required to 
electrophorese the samples and the DNA is propagated in comparatively slow growing
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yeast rather than in Escherichia coli. The extreme AT bias of the malaria genome has 
also made the preparation of cDNA difficult. The first step in preparing cDNA is the 
purification of mRNA from total RNA (using a polyT oligonucleotide). This is 
difficult because contaminating DNA species with long polyA stretches and non­
messenger RNA species containing polyA will copurify with the mRNA. The AT- 
richness lowers the hybridisation temperature of oligonucleotides during PCR, 
Southern and Northern blotting making the detection of non-specific products more 
likely. It has also been suggested that the low efficiency of expression of malarial 
genes is due to the AT-richness of the genome (Weber, 1987). For example, in 
Plasmodium falciparum  the Asn codon AAT is strongly favoured over AAC (table 3); 
the reverse is true for highly expressed genes in both E. coli and yeast. Only in poorly 
expressed genes in these two species is AAT favoured (Saul and Battistutta, 1988). 
When mRNA is injected into Xenopus oocytes it is believed that supplying malarial 
tRNAs aids the efficient expression of malarial genes (Robson, 1991).
Many malarial genes have now been sequenced. It has been noted that many of these 
genes share common features that are unusual in other organisms. One feature is the 
presence of one of the two sequences LFFLI or L F F II in the signal sequences from 
many malarial genes (MacKay, 1987). These pentapeptide sequences are rare in other 
eukaryotic signal sequences (MacKay, 1987). Another feature is the highly repetitive 
nature of many regions of plasmodial genes (MacKay, 1987). For example the P. 
falciparum  circumsporozoite protein (CSP), which covers the surface of the 
sporozoite, consists of a tandem repeat that occupies about a third of the molecule 
(Hyde, 1990). Introns are not common in malarial genes and when they do occur they 
are usually located towards the start of the gene and are usually only a few hundred 
bases long (MacKay, 1987; Saul and Battistutta, 1988).
As mentioned earlier, malaria has an extreme preference for A and T over G and C in 
its DNA. For amino acids where all 4 bases can be used in the last position, A and T 
are equally abundant (table 3). An A or a T in the third position is 3-5 times more 
likely than a G or a C in such cases (Saul and Battistutta, 1988). The high frequency
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of A and T in the 3rd position accounts for the AT-richness of the malarial coding 
region.
It has also been reported that there is an overall bias for the A codon over the T codon 
in the mRNA sense strand (Weber, 1987). This is because the coding strand is purine- 
rich with the bulk of these being A (T:C:A:G is 26:14:43:17). The first base in the 
codon is a purine 70% of the time; the last base is only a purine 51% of the time (Hyde 
and Sims, 1987; Saul and Battistutta, 1988). The purine bias is therefore not 
accounted for by bias in the third position. Rather, the base composition is a reflection 
of the high abundance of asparagine, lysine, aspartate and glutamate (which use AA or 
GA in the first two positions) in malarial proteins (Hyde and Sims, 1987; Saul and 
Battistutta, 1988). Having a high purine/pyrimidine ratio in the sense strand may be 
advantageous to the malarial parasite in the production of mRNA because purines are 
readily available from the host and pyrimidines have to be synthesised de novo (Saul 
and Battistutta, 1988; Gero and O'Sullivan, 1990). Table 3 shows the codon usage in 
Plasmodium falciparum  (Saul and Battistutta, 1988).
F T T T 2 6 6 . S T C T 1 4 9 . Y T A T 3 6 2 . C T G T 7 9 .
F T T C 9 1 . S TCC 9 6 . Y TAC 7 9 . C TGC 1 8 .
L T T A 5 0 2 . S T C A 1 9 8 . * T A A 1 4 . * T G A 2 .
L T T G 1 1 0 . S TCG 2 3 . * TAG 2 . W TGG 3 2 .
L C T T 1 2 4 P C C T 7 2 . H C A T 1 5 4 . R CG T 2 .
L CTC 1 9 . P CCC 2 1 . H CAC 6 5 . R CGC 5 .
L C T A 4 2 . P C CA 1 5 2 . Q C A A 2 9 8 . R CGA 2 6 .
L CTG 7 . P CCG 9 . Q CAG 3 5 . R CGG 0 .
I A T T 2 4 3 . T A C T 1 3 8 . N A A T 1 1 0 4 . S A G T 1 8 0 .
I A T C 5 3  . T AC C 5 3 . N AA C 3 1 0 . S AGC 6 5 .
I A T A 2 4 7 . T A C A 2 2 8 . K A A A 9 7 1 . R A G A 1 5 9 .
M A T G 2 3 8 . T ACG 2 1 . K AA G 2 1 0 . R AGG 2 8 .
V G T T 2 1 4 . A GC T 1 4 4 . D G A T 5 2 5 . G GGT 1 7 5 .
V GTC 2 8 . A GCC 5 4 . D GAC 8 4 . G GGC 1 1 .
V G T A 2 1 5 . A GCA 1 3 1 . E GAA 7 3 0 . G GGA 2 1 9 .
V GTG 3 3 . A GCG 9 . E GAG 8 9 . G GGG 1 9 .
Table 3. The codon usage table for Plasmodium falciparum. The table shows the 
frequency that each codon is used per 10 000 codons for non-repetitive DNA in the first 
17 P. falciparum proteins to be cloned. Reproduced from Saul & Battistutta, 1988.
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Studies have been performed on superfamilies of genes where the malaria homologue
has been sequenced. It has been found that, in general, genes cloned from P. 
falciparum  appear to be most similar to higher eukaryote sequences than to lower 
eukaryotes or to prokaryotic sequences (Hyde et al, 1989). Recently the Plasmodium 
falciparum  enolase gene has been isolated and found to have regions that are only 
found in higher plants (Read et al, 1993). It has been suggested that, where possible, 
oligonucleotide probes designed to clone malarial genes should be based on 
mammalian sequences in preference to trypanosome or yeast sequences (Hyde et al, 
1989). It has also been suggested (Hyde and Sims, 1987) that dinucleotide frequencies 
in Plasmodium falciparum  have characteristics indicative of vertebrates rather than 
lower eukaryotes (particularly the low frequency of CG and the high frequency of TG 
found in the coding strand). A phylogenetic tree based on the divergence of small 
subunit rRNA molecules confirms that Plasmodium is closer to Saccharomyces and 
mammalian sequences than to other lower eukaryotes like Trypanosoma brucei and 
Euglena gracilis (Hyde, 1990). The phylogenetic tree does suggest however that 
yeast sequences may be a good basis for the design of oligonucleotide probes.
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—  Chlamydomonas reinhrdtil 
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Figure 11. A phylogenetic tree showing the convergence of small subunit rRNAs from 
a wide range of organisms. Note that Plasmodium is closer to yeast and mammalian 
sequences than to trypanosome and Euglena sequences. Redrawn from Hyde (1990).
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There is no sequence information for the malarial glucose transporter and such data 
would be very hard to obtain. For this reason, an accurate alignment o f the sugar 
transporters from other species is necessary so that conserved regions can be identified 
and oligonucleotides can be designed to them. The alignment used during this project 
is shown in Appendix 1. Since this alignment was produced further members o f this 
superfamily have been isolated (section 1.2.3.). Visual alignment o f these new 
sequences confirms that the regions chosen are indeed conserved. Figure 12 shows 
these conserved regions in a two dimensional model o f the glucose transporter.
A comparison o f the alignment with alignments from other superfamilies suggests that 
the facilitative sugar superfamily may not be highly conserved. For instance the 
Leishmania transporter appears to be lacking both the PESPRFL and VPETKG 
regions completely. Both GABA receptors and insect opsins have a much tighter 
conservation.
Figure 12. Human GLUT1 glucose transporter showing regions that are conserved 
with other members of the superfamily.
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3.2. Methods
3.2.1. P r e p a r a t i o n  o f  cDNA f r o m  P l a s m o d iu m  y o e l ii
Plasmodium yoelii parasites were cultured in albino CDC mice (section 2.2.10.) until 
the parasites occupied more than 90% of the mouse erythrocytes. The blood from ten 
mice was pooled and passed through a cellulose column to remove contaminating 
white blood cells (section 2.2.12.). The red blood cells were then lysed with saponin 
(section 2.2.6.) to yield free parasites. The haemoglobin and red blood cell debris were 
washed away, by two washes with PBS, and then RNA was extracted from the 
parasites using guanidinium isothiocyanate (section 2.4.31.). Messenger RNA was 
purified from the total RNA, using DYNA™ beads (section 2.4.32.) and used 
immediately to make cDNA (section 2.4.33.). The cDNA was synthesised using polyT 
oligonucleotide containing a 28bp trailer sequence so the cDNA was suitable for 
RACE PCR (3 .2.4 ).
3.2.2. P r e p a r a t i o n  o f  G e n o m ic  DNA F r o m  P l a s m o d iu m  f a l c ip a r u m
Plasmodium falciparum  parasites were grown in culture (section 2.2.), harvested and 
the red blood cells lysed using saponin (section 2.2.6.). Genomic DNA was then 
prepared from the cells using Proteinase K and phenol (section 2.4.29.).
3.2.3. A m p l if ic a t io n  U s in g  T w o  G e n e  Sp e c if ic  P r im e r s
The genomic DNA or cDNA was used in the polymerase chain reaction (section 
2.4.34.) using two internal primers. The products were electrophoresed on a 1% 
agarose gel (section 2.4.2.) and any bands of the anticipated molecular weight were 
excised from the gel using a new razor blade. The DNA was extracted from the 
agarose by the freeze squeeze method (section 2.4.3.) and 1/1000* of it reamplified 
using the same primers. The single products were again electrophoresed on a 1% 
agarose gel (section 2.4.2.). The band of DNA was excised and purified from the 
agarose using the GeneClean™ method (section 2.4.4.), blunt ended with T4 DNA 
Polymerase I (section 2.4.27.), and ligated (section 2.4.19.) overnight with Smal 
digested (section 2.4.6.), phosphatased (section 2.4.18.) pUC19 vector (Promega). 
Competent Escherichia coli cells (section 2.4.22.) were transformed with the ligated
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vector (section 2.4.19.) and screened for inserts using the alkaline lysis miniprep 
method (section 2.4.23.). Vector from cultures containing the correct size inserts were 
purified using MagicMiniprep™ columns (section 2.4.24.) and sequenced (section 
2.4.26.).
3.2.4. A m p l if ic a t io n  U s in g  t h e  RACE M e t h o d
The cDNA (20ng) was amplified (section 2.4.34.) with a primer to the outer half of the 
trailing sequence (R0) and an internal sense oligonucleotide. A sample (1/1000th) of 
the above reaction was subjected to a second round of amplification using an 
oligonucleotide to the inner region of the trailing sequence (Rj) and a second gene 
specific primer downstream of the first. For the control, the sample was 
electrophoresed (section 2.4.2.), transferred to hybridisation membrane (section
2.4.28.1.) and blotted (section 2.4.28.2.) with a third gene specific oligonucleotide. 
The samples were cloned by reamplifying (section 2.4.34.) with a gene specific 
oligonucleotide containing a 5' restriction site and Rj (which also contains a restriction 
site), and ligating (section 2.4.19.) with pUC19 vector which has been digested with 
the same restriction enzymes. Competent Escherichia coli cells (section 2.4.22.) were 
transformed with the ligated vector (section 2.4.19.) and screened for inserts of the 
correct size (section 2.4.23.). Vector from cultures containing the correct size inserts 
was purified on a large scale (section 2.4.25.) and sequenced (section 2.4.26.).
3.2.5. C h e c k in g  t h e  Q u a l it y  o f  t h e  cDNA
During the cDNA synthesis a fraction of the sample was labelled with 32P and then 
electrophoresed on an alkaline gel (section 2.4.33.). Once the synthesis was complete, 
a sample of the cDNA was used to amplify the Plasmodium yoelii actin gene. For this 
the RACE method was used. Two rounds of amplification were performed and the 
products electrophoresed on an agarose gel (section 2.4.2.). The PCR products were 
transferred to nitrocellulose and blotted with a third actin specific oligonucleotide 
(section 2.4.28.). Only cDNA that successfully amplified actin was used.
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3.2.6. C h e c k in g  t h e  Q u a l it y  o f  t h e  G e n o m ic  DNA
Only genomic DNA that had a molecular weight larger than X and that could be 
digested with EcoRI was used for PCR amplification. As an internal control a portion 
of the P. falciparum  TATA-binding protein (TBP) was amplified. The 
oligonucleotides for this reaction were supplied by Dr J. E. Hyde. Whenever PCR on 
the genomic DNA was performed a tube was prepared containing the genomic DNA 
and the two TBP oligonucleotides. After electrophoresis (section 2.4.2.) it was always 
found that these oligonucleotides produced a single intense product that was 700bp 
long.
3.2.7. A n a l y s is  o f  t h e  C l o n e s  u s in g  a  C o m p u t e r
Sequences were read from the autoradiograph and translated to protein using the 
Staden suite of programs and an IBM compatible personal computer. The sequences 
were then transferred to a Silicon Graphics computer and further analysed using the 
Wisconsin GCG computer package. Codon usage and a search for similarity with 
sequences held in the EMBL database were performed on each sequence using the 
GCG programs COMPOSITION and FAST A respectively.
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3.3. Results
3.3 .1 . T e s t in g  t h e  I n t e g r i t y  o f  P . y o e l i i  cD N A
The integrity o f the cDNA prepared from P. yoelii was confirmed by two methods 
(figure 14). Firstly, during synthesis a fraction of the cDNA was radiolabelled and then 
electrophoresed on an alkaline gel. As can be seen in figure 14a molecules between 
200 and 4000 nucleotides were labelled during the synthesis. This suggests that a large 
proportion o f the mRNA was intact during the synthesis producing full length cDNA 
transcripts. Secondly, actin was amplified from the cDNA pool using the RACE PCR 
method and two rounds o f amplification (Goodyer et al, 1991). To do this, three actin 
specific oligonucleotides were synthesised based on the published P. falciparum 
PFActinI gene (Wesseling et al, 1988). The method of amplification and the sequence 
o f the actin specific oligonucleotides is shown in figure 13. The results (figure 14b) 





PFActinl-2 1000 bp product
PFActinl-1 = GTT GCA GGA GAT GAT
PFActinl-2 = GTT GGT GAT GAA GCA C
PFActinl-3 = GAT AGT GGA GAT GGT GTA T
Southern Blot
PFActinl-3
Figure 13. The strategy used to amplify Plasmodium yoelii actin. In the first PCR 
reaction P. yoelii cDNA is amplified with Ro and PFActinI-1 oligonucleotides 
producing a 1100 nucleotide long product. In the second round l/1000th of the products 
formed in the first reaction were reamplified with Ri and PFActinl-2 oligonucleotides 
producing a 1000 nucleotide product. An aliquot (l/lO411) of both the first and second 
round reactions are then blotted with a third actin specific oligonucleotide PFActinl-3.
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Figure 14. Testing the integrity of P. yoelii cDNA. a) The synthesised cDNA has a 
molecular weight ranging between 200 and 4000 nucleotides b) Southern blot showing 
amplification of actin from P. yoelii cDNA by two rounds of RACE PCR.
3.3.2. T e s t in g  t h e  I n t e g r i t y  o f  P. f a l c ip a r u m  G e n o m ic  DNA
The Plasmodium falciparum genomic DNA appeared to be o f a high quality. Figure 
15a shows that the malarial DNA is larger than bacteriophage X and shows virtually no 
shearing. Figure 15b shows that the genomic DNA can be digested by the common 
restriction endonucleases EcoRI and Hindlll. The digestion is important as it shows 
that the DNA is purified from histones and other DNA associated proteins and 
suggests that it will also be accessible to TAQ polymerase during the polymerase chain 
reaction.
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<
Figure 15. Plasmodium falciparum genomic DNA used during this project, a) The 
malarial genomic DNA is larger than X and shows little shearing, b) The DNA can be 
digested by either Hindlll or EcoRI endonuclease.
3.3.3. P r im a r y  S c r e e n  - C lo n in g  o f  t h e  P. y o e l ii  G l u c o s e  T r a n s p o r t e r
3.3.3.1. Design of Oligonucleotides
In the early attempts to clone the malarial glucose transporter oligonucleotides were 
designed using the rules accepted at the time (Hyde et al, 1989; Hicks et al, 1991). 
These included:
i) the malarial sequence will be most similar to previously isolated vertebrate 
sequences (Hyde et al, 1989).
ii) the redundancy of the oligonucleotides should be kept low so that the 
matching oligonucleotide is not diluted by probes that do not match. The 
degeneracy can be kept low when cloning malaria genes by utilising the unusual 
codon usage found in Plasmodium (table 3). For example, the proline residue 
is coded for by the triplet codons CCA, CCC, CCG and CCT, but in malaria
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approximately 90% of prolines are encoded for by CCA or CCT. For prolines 
we therefore chose the less degenerate CCA/T combination (Hyde et al, 1989).
iii) the oligonucleotides can be slightly degenerate at the 3' end. It is believed 
that TAQ polymerase requires the 3' end bases to be an exact match for 
efficient translation. Mismatches are less serious at the 5' end of the 
oligonucleotide. For this reason, redundancy was incorporated into the 3' end 
of the probe to help ensure an exact match in at least a fraction of the 
oligonucleotides (Hicks et al, 1991).
iv) the probes should be quite long (-35-40 nucleotides). This increases the 
melting temperature of the oligonucleotide and thus increases the probability of 
efficient priming (Hyde et al, 1989). It was not possible to follow this strictly 
because the conservation found in the glucose transporter superfamily is quite 
low and the conserved regions that exist are often short. In practice primers 
were synthesised that were as long as possible.
Five oligonucleotides were synthesised to four conserved regions in the facilitative 
sugar transporter superfamily. All these regions were highly conserved in the 
mammalian sequences and showed extensive conservation throughout the superfamily.
The sequence of these oligonucleotides are shown in table 4.
Protein
Sequence
Position Sense or 
antisense
Length Nucleotide sequence




468-479 Sense 36mer CAA CAA TTA T/AC/0T/A GGA/T ATa/t 
AAT GT/r a/t A/r TA/T TTT TAT TAT
VERAGRRTL 518-526 Sense 26mer GTa/t GAA AGA GCa/x AGA 
AGA ACATT
VERAGRRTL 526-518 Antisense 27mer TAA TGT TCT TCT A/TCC/G A/TGC TCT 
TTC t /aAC
KVPETKG 670-663 Antisense 17mer CC TTT AGT TTC T/ AGG t / aAC
Table 4. Oligonucleotides synthesised to the facilitative glucose transporter 
superfamily. The numbers in the position column refer to the place the protein 
sequence occurs in the alignment in Appendix 1.
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3.3.3.2. PCR conditions
Using these oligonucleotides in combination there are six possible pairings. Every 
combination was tried using a variety of PCR conditions. The target was in each case 
the cDNA prepared from P. yoelii that was found to be intact by the amplification of 
actin. It has been reported that the concentration of magnesium in the reaction mixture 
is critical (Innis and Gelfand, 1990). The magnesium concentration affects primer 
annealing, the formation of primer-dimer artefacts and enzyme activity. We found that 
the concentration of magnesium in the 10X TAQ buffer (1.5mM) was sufficient and 
extra magnesium did not increase either the number or yield of products. Initially the 
annealing temperature was set high (55°C) in an attempt to reduce non-specific 
binding. At 55°C however, no products were obtained. The amplification was 
repeated lowering the temperature until discreet products were observed. The optimal 
temperature was found to be 42°C. At this temperature the following conditions were 
used.
Denaturation - 95°C for 5 minutes before the enzyme was added followed by
40 cycles of
94°C - 1 minute, 42°C - 1 minute 30 seconds, 72°C - 3 minutes.
3.3.3.3. Products cloned and sequenced
Four bands were evident following the PCR reaction: one band (550 nucleotides) was 
produced using the PESPRFL sense and the VERAGRRTL antisense oligonucleotides; 
two bands (400bp and 700bp) were produced using VERAGRRTL sense and 
KVPETKG antisense; and one band (350bp) was produced using QQLSGINAVFYY 
sense and KVPETKG antisense. Each band was excised from an agarose gel, 
reamplified and cloned into pUC19 vector. After minipreps and sequencing it was 
found that 8 different clones were produced. A summary of these products is shown in 
table 5 and the sequences of these products are found in appendix 2.
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Clone Sense primer Antisense
primer





A PESPRFL VERAGRRTL FORWARD = 59% 
REVERSE = 60%
386 550
B VERAGRRTL KVPETKG 55% 390 342
C VERAGRRTL KVPETKG FORWARD = 69% 
REVERSE = 54%
390 700
D VERAGRRTL KVPETKG FORWARD =47% 
REVERSE = 56%
390 700
E VERAGRRTL KVPETKG 49% 386 450
H QQLSGINAVFYY KVPETKG FORWARD = 37% 
REVERSE = 46%
530 550
I QQLSGINAVFYY KVPETKG 47% 530 350
J QQLSGINAVFYY KVPETKG FORWARD = 50% 
REVERSE = 47%
500 350
Table 5. The size and base composition of cloned PCR products using P. yoelii cDNA.
The AT composition was determined by sequencing the cloned product with either 
forward or reverse primer.
Product A, which was produced with the sense PESPRF/YL and the antisense 
VERAGRRTL oligonucleotides, is slightly larger than the size predicted for human 
GLUT1. It is AT-rich, and a homology screen revealed that this sequence has not 
been reported before and has no homology to previously reported sequences. Both the 
sense and antisense oligonucleotides have been identified in the clone but there is an 
unambiguous stop sequence in frame with the sense oligonucleotide. This suggests 
that the sense oligonucleotide in not in the coding strand. Another reading frame of 
the forward sequence is open and the antisense primer is also in an open reading frame. 
This product shows no homology to the facilitative glucose transporter superfamily.
Product B was sequenced in full and found to be slightly AT-rich (55%). Only one 
oligonucleotide (VERARRRTL) was found in the clone. The product was about the 
anticipated size and had stretches of hydrophobic residues that suggested that the 
sequence may encode a membrane protein. A homology search revealed that this 
sequence had not previously been described. Despite extensive searching this 
sequence did not show any homology to the facilitative transporters.
Products C and D were larger than predicted by homology to the other members of the 
glucose transporter superfamily. As malarial gene products are frequently larger than 
their vertebrate homologues it was decided to clone and sequence these products.
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Product C was very AT-rich (about 60%), product D is only slightly AT-rich. Both 
contained the sense oligonucleotide VERARRRTL but in both the antisense 
oligonucleotide was missing. Neither sequence had been reported before, but the 
forward sequence of D was 70% homologous to the three long terminal repeats H l l ,  
H29 and H I6 from rat (Furter et al, 1992). In the reverse direction sequence D 
appears to have approximately 70% homology to many rat and mouse clones 
suggesting, along with the only slight AT bias, that product D may be a contaminant 
from the murine host.
Product E is not AT-rich, lacks an oligonucleotide at either end, is not found in the 
EMBL database, is smaller than expected and does not show any homology to 
facilitative glucose transporters. It is most likely that this clone is a contaminant.
Product H is not AT-rich and does not have the sense oligonucleotide present. Initially 
these findings led us to discard this sequence. However, on performing a homology 
search we found that this was a cDNA clone of the human Glut4 sequence: a clone 
that had been used in the laboratory. A very small amount of this must have 
contaminated the PCR reaction because the band that was cloned was not particularly 
strong and contained other bands that were also sequenced (clones I and J). This 
demonstrates clearly that because an oligonucleotide is not found at one end of a clone 
it should not be dismissed without thorough investigation.
Clones I and J were both obtained from the same band on the gel; both are novel 
sequences with very little similarity to any other sequences reported to date. Both lack 
oligonucleotides at either end of the clone, and neither are AT-rich or show any 
homology to facilitative transporters.
RACE PCR was also performed on the P. yoelii cDNA using the three sense 
oligonucleotides shown in table 4 and the oligonucleotide Ro. It was found that 30 
cycles with an annealing temperature of 48°C gave the best results. This method 
produced a band with the VERAg/rRRTL sense oligonucleotide. This product was 
1500 nucleotides long, which was the expected size for the product, considering the 
inclusion of the 3' untranslated region. The product was purified and reamplified with
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Ri and an oligonucleotide to the VERAg/rRRTL region that was synthesised with a 
GC-rich 5' anchor and a PstI site to aid directional cloning. The sequence of the 




CG-pst-VERAGRRT GCGCGGCG-CTGCA-GTa/t GAA AGA GCA/T CGA/T AG
Table 6. Oligonucleotides synthesised for RACE PCR. Both Ro and Ri have a series 
of restriction sites. The gene specific oligonucleotide has a 5' GC-rich region that 
allows the restriction enzyme to anchor efficiently, a PstI restriction site and the gene 
specific sequence.
In the Ri oligonucleotide is an Xbal site. The PCR product was purified (section 
2.4.24.) and digested with Xbal and PstI. The PCR product had an internal Xbal site 
460 nucleotides from the terminal PstI. This 460 bp fragment was directionally cloned 
into pUC19 vector and sequenced. The product was found to be a novel sequence that 
was 51% AT and showed no significant homology to facilitative transporters. In frame 
with the oligonucleotide is a stop codon. It is therefore extremely unlikely that this 
clone is part of the malarial glucose transporter.
During my project the successful cloning of genes using PCR with highly redundant 
oligonucleotides (over 100 000 degeneracy) was reported (Criado, 1992). It was 
important to ensure that the redundancy was low at the 3' end of the oligonucleotide, 
preferably with an exact match, whereas the 5' end could be highly redundant 
(Compton, 1990).
The advantage of highly degenerate probes is that it is possible to make longer 
oligonucleotides based on fairly poor amino acid conservation. Two conserved 
regions with an intervening variable region can be used to make a probe by allowing 
high redundancy in the variable region. High degeneracy allows the covering of many 
amino acids in one particular position. For example if a residue is hydrophobic 
(phenylalanine, leucine, isoleucine or valine) all these can be covered adequately in 
malaria genes by NTa/t .
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The certainty required for the 3' end of the oligonucleotide requires a careful design. 
Residues that are encoded by one triplet (i.e. methionine and tryptophan) are most 
favourable because if this residue is present redundancy in not required. In an 
organism with a pronounced AT bias, residues encoded by two triplets, one ending in 
an A or a T and the other ending in a C or a G are almost as favourable, and can 
usually be predicted with certainty. Hyde et al (1989) ranked the amino acids in order 
of preference for the designing of oligonucleotides in cloning malaria genes. He 
produced a numeric measure of the favourability of each residue that he called the 
match index. This was used in the design of oligonucleotides with low degeneracy at 
the 3' end.
Initially two new oligonucleotides were synthesised which were multiply degenerate. 
The sequences of these probes are shown in table 7.
Protein
Sequence





312-321 Sense 28mer g/ca/t GAA N t /c g /a /t  t /a /g g /c a /t  CCa/t 
a /g /t a /c /t T  N a /c /g t / a N t / a t / a AGA GG
VERAGRRTL 526-518 Antisense 27mer c /a /t g /c /t c / t / g t /a t /a /c t /a /c  T ^ T  TCT t /aCC 
c / t / ac /a /p  A/r  TC/tT t /aTC t/a AC
Table 7. Multi-redundant oligonucleotides raised against conserved regions in the 
mammalian sugar transporter superfamily. Note the comparatively low redundancy at 
the 3' end of the probes. The position column refers to the place the amino acid 
sequence occurs in the alignment in appendix 1.
These two oligonucleotides were used in combination with the ones synthesised 
previously using the same conditions. This produced one more product that was 800 
nucleotides in length, using the sense QQLSGINAVFYY and the antisense 
VERAGRRTL multiply redundant oligonucleotides. The expected size for this 
product is approximately 190 nucleotides so it is much larger than expected. The 
antisense VERAGRRTL probe was found; but the sense oligonucleotide could not be 
located. A homology search revealed that this sequence was novel but does not have 
homology to facilitative transporters. The sequence is 58% AT and hence probably of 
malarial origin.
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3.3.4. S e c o n d  S c r e e n  - C lo n in g  o f  t h e  P. f a l c ip a r u m  G l u c o s e  
T r a n s p o r t e r
3.3.4.1. Design of Oligonucleotides
More oligonucleotides were synthesised using the highly redundant strategy. The 
sequences of these oligonucleotides are shown in table 8. These sequences, especially 
the sense ones, are based more on the non-mammalian sequences. Some are based 
generally on the non-mammalian (yeast and bacterial sequences) and some are biased 
towards the trypanosome sequences. It was decided to try these non-mammalian
sequences because it was thought that the mammalian sequences had been exhausted.
Protein
Sequence















303-313 Sense 26mer GGa/t t /cTN Gt/gt/a CCt/a ATG TAt/c 
g/aTt/a GGAT GA
PESPRf /y L 392-386 Antisense 21mer NAa/T/Pt T/A/rf / AJr T NT/ g/t NGG 
Nc/nT/AT/PTCNGG
QLSGINa /G/v  
VFYY (General 
Probe)
479-468 Antisense 23mer A/CrC a/gTT Na/t t /c/g NCC N% a/t





479-468 Antisense 20mer A/g c  A/g t t  Na/tt/c/g n c c  n % a/t 
naA/g T/cTG
g p g p ip w f Vm
VAE
593-582 Antisense 36mer c/t TC a/t/g GC t /aAC NAT a/gAA CCA 
a/t GG a/t AT a/t GG a/t CC a/t GG a/t CC
Table 8. Sequences of oligonucleotides synthesised after alignment of facilitative 
glucose transporters lfom various species. The position column describes the position 
the residues appear in the alignment in appendix 1. Note the high redundancy at the 5' 
end and the lower redundancy at the 3' end of the oligonucleotides.
3.3.4.2. PCR conditions
Using all the sense and antisense oligonucleotides in combination gives 52 pairings that 
could be tried. Every oligonucleotide combination was prepared with P. falciparum  
genomic DNA. The samples were denatured at 95°C for 5 minutes before the enzyme
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was added and then subjected to 40 cycles in the PCR machine. Each cycle consisted 
of:
95°C for 1 minute to denature,
42°C for 1 minute 30 seconds to anneal,
72°C for 3 minutes to extend.
After the first round of amplification an aliquot of each sample was electrophoresed 
(section 2.4.2.). None of the reactions gave bands on the gel (except for the positive 
control that was a fragment of the malarial TATA-binding protein). There have been 
reports (Criado, 1992) that reamplification in these circumstances produces the desired 
gene. For this reason 1/20* of the PCR products were reamplified with the same 
probes used in the first round. This time, after electrophoresis, products were evident 
in 5 lanes of the gel produced by 5 different combinations of oligonucleotides. These 
bands, which were named P, Q, R, S and T were purified and subsequently cloned into 
pUC19 vector. Each band (except Q) contained more than one product. A summary 
of the products that were produced are shown in table 9 and the partial sequences of 
the products are found in appendix 2.
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P2 GGLFGYD (norm) VERAGRRTL FORWARD = 60% 
REVERSE = 67%
950 800
P4 GGLFGYD (norm) VERAGRRTL FORWARD = 56% 
REVERSE = 61%
950 850
Q GEVSPT RG QQLSGIN (norm) FORWARD = 64% 
REVERSE = 67%
450 560
R2 GFVPMYVGE QQLSGIN (norm) FORWARD = 59% 450 500
R6 GFVPMYVGE QQLSGIN (norm) FORWARD = 48% 450 500
R7 GFVPMYVGE QQLSGIN (norm) 71% 450 400
RIO GFVPMYVGE QQLSGIN (norm) FORWARD = 49% 
REVERSE = 51%
450 500
R14 GFVPMYVGE QQLSGIN (norm) FORWARD = 70% 
REVERSE = 61%
450 520
SI GFVPMYVGE QQLSIN (Trp) 70% 450 480
S3 GFVPMYVGE QQLSIN (Trp) FORWARD = 65% 
REVERSE = 65%
450 450
S6 GFVPMYVGE QQLSIN (Trp) FORWARD = 67% 
REVERSE = 67%
450 580
S8 GFVPMYVGE QQLSIN (Trp) FORWARD = 77% 
REVERSE = 56%
450 480
S ll GFVPMYVGE QQLSIN (Trp) FORWARD = 59% 
REVERSE = 59%
450 450
T3 GFVPMYVGE VERARRRTL FORWARD = 75% 597 520
T8 GFVPMYVGE VERARRRTL FORWARD = 57% 
REVERSE = 58%
597 582
Table 9. PCR products cloned and sequenced using P. falciparum genomic DNA as a 
target. The forward and reverse primers are shown along with the AT-richness and the 
actual and predicted sizes of the products.
Clone P2 does not have significant homology to any sequence in the EMBL database. 
The antisense oligonucleotide is located at the end of this AT-rich sequence. The 
sequence is probably malarial but is unlikely to be the malarial glucose transporter 
because there does not appear to be any homology to the facilitative sugar transporter 
superfamily.
Like P2 the sequence of P4 is AT-rich and is not similar to any sequence found in the 
EMBL database. The clone also does not show significant homology to the glucose 
transporter superfamily.
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Clone Q is AT-rich and typically malarial. The sequence has not been reported before 
and the clone does not show any homology to the glucose transporters.
Clone R2 has 96% identity with human a-satellite DNA indicating that it is a 
contaminant from the host. The antisense oligonucleotide (QQLSGINAVFYY) is 
found and has homology to the repetitive DNA sequence.
Clone R6 is not AT-rich, does not have significant homology to any known sequence 
and is not similar to glucose transporters.
Clone R7 is extremely AT-rich and has high homology to the enolase family of 
proteins. The clone is most similar to mammalian and yeast sequences and is a 
fragment of the P. falciparum  enolase gene. The complete sequence of the 
Plasmodium falciparum  enolase gene has recently been reported (Read et al, 1993). 
In appendix 2 the enolase amino acid sequence is shown in bold.
Clone RIO is a contaminant. The sequence is identical with the rat glut2 sequence 
(commonly known as RATGTL). This clone has been used for probing libraries by 
other workers in our laboratory.
Clone R14 is extremely AT-rich but neither oligonucleotide could be observed. A 
homology search revealed no significant identity with any sequence in the EMBL 
database.
Clone SI is extremely AT-rich, but has the same oligonucleotide at each end of the 
clone. This sequence was also cloned from band R that used the GFVPMYVGE sense 
oligonucleotide. A comparison with sequences previously deposited in the EMBL 
database revealed that this sequence had 70% identity to human line-1 repetitive DNA 
and was probably a contaminant from the host.
Both clones S3 and S6 are highly AT-rich (65%) and have no homology with any 
sequence in the EMBL database. After the sense oligonucleotide, however, both 
sequences contain an in frame, unambiguous stop codon.
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Clone S8 is AT-rich and has 60% identity to a number of Plasmodium falciparum  
genes (including calmodulin and tubulin) suggesting that this DNA has a malarial 
origin. This sequence however has the same oligonucleotide (GFVPMYVGE) on both 
ends of the clone.
Clone S ll  is AT-rich, contains the sense oligonucleotide and does not have any 
homology to previously reported sequences. The clone also does not have homology 
to the facilitative glucose transporter superfamily.
Clone T3 leaves the oligonucleotide and enters a polyAT region. The sequence has 
identity as the nucleotide level with a number of malarial proteins including 69% 
identity with the P. falciparum  knob protein. It does not have homology with 
facilitative glucose transporters.
Clone T8 is AT-rich and has significant homology to glucose transporters. It has, 
however, over 90% identity with the human glucose transporter pseudogene 
(GLUT6). The clone changes reading frame and contains stops at the same positions 
as the pseudogene and so is almost certainly a variant of it.
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3.4. Discussion
The size and the specific amplification of malarial actin suggests that the cDNA used 
during the experiments was of a high quality. Similarly the size and digestion by 
restriction enzymes suggests that the P. falciparum  genomic DNA was also of a 
suitable standard for cloning using the polymerase chain reaction.
The amplification of actin from P. yoelii cDNA was the first corroboration of the 
RACE method (Frohman and Martin, 1989; Frohman, 1990) and the first time it was 
used in an organism as AT enriched as Plasmodium (Goodyer et al, 1991).
The polymerase chain reaction is a very sensitive and specific technique. There are a 
large number of variables that can be altered during PCR and each one will affect the 
products formed both quantitatively and qualitatively. Among the variables are 
different oligonucleotide pairings, differing magnesium concentrations, differing 
annealing temperatures, different number of cycles, different ramp times (the time 
taken to move between temperatures) and different extension protocols after the 
reaction has finished. Ideally all possible combinations will be tried, but with over 50 
reactions using all the oligonucleotide combinations only a few specific conditions can 
be tested in full. This means that finding the correct conditions and hence obtaining 
the desired product is often a matter of chance.
Apart from PCR there are a number of other methods that have successfully been used 
to isolate genes. Complementation in E. coli is unlikely to be successful in the 
isolation of the malarial glucose transporter because, although a very powerful method 
for cytostolic enzymes, it has never been successfully used to isolate a membrane 
protein. It is uncertain whether the malarial glucose transporter would fold and insert 
correctly in a prokaryotic membrane and obtaining a Aglucose transport mutant of E. 
coli would be very hard.
Cloning by functional expression in a eukaryotic host, however, may be a possible 
route for isolating the gene. Xenopus laevis oocytes appear to be an ideal host for
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such studies. Basal Xenopus oocyte glucose transport levels are very low and glucose 
transporters from mammals have been successfully expressed in this host (Gould and 
Lienhard, 1989; Gould et al, 1991). These expression studies involved the injection of 
mRNA. Using in vitro transcription of a cDNA library large amounts of malarial 
mRNA could be obtained. It is unclear how much mRNA would have to be injected, 
but it is possible that the capacity of the egg may be a limiting factor. The unusual 
codon usage of malarial genes may also pose a problem. It has been noticed that 
malarial genes have a poor rate of expression in hosts such as Xenopus laevis oocytes 
unless Plasmodium derived tRNAs are also injected (Robson, 1991).
Unlike PCR, where oligonucleotides can be synthesised to only poorly conserved 
regions by incorporating large amounts of degeneracy, screening libraries with highly 
degenerate probes will produce a very high background of unwanted non-specific 
binding. For this reason, combined with the difficulty of producing an intact and stable 
Plasmodium library it was decided not to try and clone the malarial glucose transporter 
by library screening.
Although cloning genes by 'genomic blotting' suffers similar limitations to screening a 
library an attempt was made to clone the malarial glucose transporter using this 
method. Each oligonucleotide shown in table 4 (and a cDNA rat GLUT2 probe) was 
used as a probe on a Southern blot of EcoRI or Hindlll digested P. falciparum  
genomic DNA. Unfortunately it was not very successful. Only one oligonucleotide 
(VERAg/rRRTL) annealed. The blots had to be exposed to film for approximately 3 
months, indicating that the hybridisation was very weak. The long exposure times 
made repeating the experiment more than twice impractical. The band also had to be 
cloned. Plasmodium falciparum  DNA that has been digested with EcoRI or Hindlll 
does not show a typical banding pattern as seen with other organisms. In humans the 
large amount of repetitive DNA produces bands after digestion. Also with organisms 
with a smaller genome than malaria (e.g. most archaebacteria) banding is seen after 
restriction digestion of genomic DNA due to the non-uniform size distribution of the 
DNA fragments. The absence of banding in digested malarial DNA made the exact 
location of the hybridising band harder to achieve.
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The cloning of genes is much easier if information about the protein sequence of the 
gene is known. Designing oligonucleotides to conserved regions in an alignment has 
its disadvantages. Firstly the amino acid sequence has to be guessed and then the 
codons encoding the sequence must be guessed. This 'double guessing' makes 
oligonucleotides synthesised in this way less reliable than ones designed against a 
known protein sequence. Unfortunately, obtaining a partial protein sequence for the 
malarial glucose transporter was not possible. Purification of membrane proteins is 
notoriously difficult. For standard purification techniques the protein must be 
extracted from the lipid. The loss of function associated with the disruption of the 
lipid bilayer makes monitoring the purification difficult. Another problem is that a 
large amount of material is needed. Huge quantities of erythrocytes are readily 
available and the glucose transporter protein is at an unusually high concentration (5% 
of total membrane protein) in erythrocytes. It is no coincidence that the only glucose 
transporter that has been successfully purified is GLUT1 from human erythrocytes 
(B aldw in^al, 1982; Baldwin andLienhard, 1989).
The large number of PCR products that have been cloned and sequenced during this 
project demonstrates that the PCR, 'magic' minipreps and sequencing form an efficient 
method of screening for genes.
None of the clones that were obtained were the malarial glucose transporter, however 
important information can be obtained from their analysis. Looking at the 
contaminating glucose transporter-like clones, whose sequences are already known, it 
is possible to gain an insight into how close the oligonucleotides need to be to the 
target sequence for them to be successful using PCR. Figure 16 shows the published 
sequences of the rat GLUT1, human GLUT4 and human GLUT6 sequences where the 
oligonucleotides bound. Also shown in figure 16 is the sequence of the closest 
oligonucleotide in the redundant probe. This confirms that the oligonucleotides must 
have a high match to the target sequence especially at the 3' end (Compton, 1990). 
Each oligonucleotide has at least 6 bases of exact match at the 3' end. Although most 
have a high match throughout the sequence (100% for the sense rat GLUT2 primer),
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some (e.g. human GLUT6 antisense) have only a poor match at the 5' end. This 
indicates that the match at the 5' end is less important than that at the 3' end. Clone 
R2, which has been found to be human a-satellite DNA, has the antisense 
oligonucleotide in the clone. This oligonucleotide has, by chance, an exact match with 
the first seven 3' end bases in the human repetitive sequence.
Sense oligonucleotide GGACTGGTTCCAATGTACATTGGTGA
I M i l l  I I 1 1 I I I I 1 1 I I I I  M l  I I I
Rat GLUT2 sequence GGACTGGTTCCAATGTACATTGGCGA
Antisense Oligonucleotide ACATTGATTCCACAGAACTGCTG
I II II I I I I I I I II I II I I I I I
Rat GLUT2 rev comp CCATTGATTCCACAGAACTGCTG
Sense oligonucleotide CAACAATTATCTGGAATAAATGTTGTTTTTTATTAT
II II I Mi l l  II INI  Mi l l  l l l l l l
Human Glut4 sequence CAGCAGCTCTCTGGCATCAATGCTGTTTTCTATTAT
Antisense oligonucleotide CCTTTAGTTTCAGGTAC
M l  M i l l  l l l l l l
Human Glut4 sequence rev comp CCTCGAGTTTGAGGTAC
Sense Oligonucleotide GGTTTTGTTCCAATGTACATTGGAGA
l l l l l l l  ll l l l l l l i l l l l l l l
Human GLUT6 SEQUENCE AGTTTTGTGCCCATGTACATTGGAGA
Antisense Oligonucleotide TAATGTTCTTCTTCGTGCTCTTTCAAC
I I 1111 III 11111111
Human Glut6 sequence rev comp ATGTAAAGTCCTTCCTGCCCTTTCAAC
Figure 16. Sequences of the oligonucleotides and targets that hybridised to produce 
glucose transporter like sequences using PCR.
It is also interesting to consider how these clones came to contaminate the malarial 
nucleic acid. With rat GLUT2 and human GLUT4 it is fairly obvious that a small 
fraction of the cDNA clones that have been used previously in our laboratory 
contaminated the PCR reaction. The human GLUT4 sequence obtained is from a 
cDNA clone because in genomic DNA the sequence would have been interrupted by 
an intron (Fukumoto et al, 1989). The human GLUT6 sequence must have been a 
contamination from the very small number of white blood cells that contaminated the 
P. falciparum  genomic DNA preparation. During in vitro culturing of the malarial 
parasites packed blood cells are obtained from the transfusion service. These cells are 
washed extensively and each time a generous top layer of blood cells is removed to 
remove the majority of white blood cells in the Buffy coat. During microscopic
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examination of thin smears of Giemsa stained cultures it is extremely rare to find a 
white blood cell. Using these procedures however, very small amounts of nucleic acid 
are required. One molecule of human genomic DNA can produce 240 (lxlO12) 
molecules or 1.7pmoles of GLUT6 during the first round. Although this small amount 
of DNA could not be detected by electrophoresis, reamplification using 1/20* of this 
sample could produce in theory produce up to ((1012x240)/20) molecules or 83mmoles 
of target. As 83mmoles of a 400bp fragment of double stranded DNA would weigh 
approximately 21 kilograms, it is obvious that less DNA than the theoretical maximum 
will be produced, and that easily enough DNA to clone will be present even if only one 
copy of the human genome is present.
Being a non-functional protein mutations in this region are unlikely to be fatal, and so 
the mutation rate in this gene would be expected to be high. This may explain why the 
sequence of the published human pseudogene differs (by about 5%) from the sequence 
found in this project. It is also possible that our clone differs from the published one 
due to TAQ polymerase introduced changes in our sequence.
Human white blood cells contain about as much DNA as 500 malarial parasites (Hyde, 
1990b) and a major proportion of human DNA is repetitive. It is therefore not too 
surprising that some of the clones appear to be human repetitive DNA.
Analysis of clone R7 revealed that this clone encodes part of the P. falciparum  enolase 
gene. An alignment of this clone with the known enolase genes is shown in figure 17. 
Analysis of the clone revealed the binding sites for the oligonucleotides. The clone had 
an exact match to the last 10 3' bases of the sense G ^lV PM Y ^G E oligonucleotide. 
The antisense primer QLSGINa/g/vVFYY was not a such good match with only 9 of 
the 13 3' most bases matching (table 10).
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Sense oligo GF/LVPMYV/IGE 
Enolase Sequence 






Table 10. Alignment of two oligonucleotides used during this project (raised against 
conserved regions of the glucose transporter superfamily) to the recently published P. 
falciparum sequence (Read et al, 1993). The sense oligonucleotide is displayed as 5'->
3', the antisense oligonucleotide has been reversed and complemented and is displayed 
as 3'->5'. The 3' ends of each oligonucleotide show a significant match to the reported 
enolase sequence.
The P. falciparum  enolase sequence reported here differs slightly from the previously 
reported sequence (Read et al, 1993). This is almost certainly due to inaccurate 
sequencing during this project. The differences are only in the middle of my clone with 
the two ends being identical to the sequence of Read et al (1993). Using the rapid 
screening procedure employed during this project the clones are only sequenced once 
and only with oligonucleotides complimentary to pUC. This means that with clones 
longer than 300bp the middle part of the sequence is inaccurate because it is located 
towards the top of the sequencing gel and is difficult to read accurately. It is 
interesting to notice that at either end of the clone the sequence in this project is 
identical to the reported sequence. My clone is almost certainly part of the same gene 
cloned by Read et al, 1993. Most of the other clones obtained during this project were 
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An alignment of the putative malarial enolase gene with other enolase
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There are many reasons why the cloning of the malarial glucose transporter may have 
been unsuccessful. The sensitivity of the polymerase chain reaction led to misleading 
contaminants. Also the infinite variation with the polymerase chain reaction is a 
problem. Although a lot of time was spent altering the PCR conditions, with so many 
variables (e.g. different oligonucleotide variations, different ramp times, varying 
magnesium concentrations, different numbers of cycles and annealing temperature) 
optimising the conditions is very hard. The project was harder due to the peculiarities 
of the malarial genome. The oligonucleotides were AT-rich and therefore had a lower 
annealing temperature. The gene may have a large intervening coding sequence as 
found in many other malarial proteins. This would make it less likely to be amplified 
during PCR, make it harder to clone and, as the sequence would be larger than 
predicted by homology with other glucose transporter sequences, mean it may not be 
selected for further analysis.
It is also possible that either Plasmodium falciparum  does not possess a glucose 
transporter (see discussion in section 4.) or that the glucose transporter is not 
homologous to the facilitative sugar superfamily.
Assuming malaria does possess a functional glucose transporter probably the best way 
to clone the gene is by expression cloning in Xenopus oocytes. It may also be possible 
that the glucose transporter gene is linked to either glycolytic or pentose phosphate 
enzymes that have already been isolated. By using YACs and chromosome walking 
the transporter sequence may be obtained. This method was used to determine the 
Zymomonas glucose transporter sequence (section 1.2.3.3.5.).
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4. Characterisation of Glucose Transport in Human 
Red Blood Cells Infected with Plasmodium falciparum 
Trophozoites
4.1. Introduction
The malarial parasite requires a large amount of glucose for growth. A mature 
Plasmodium falciparum schizont inside a human red blood consumes about 100X as 
much glucose per cell as a normal, mature, uninfected red blood cell (Sherman and 
Tanigoshi, 1974; Sherman, 1979). The increased demand for glucose by infected 
erythrocytes has been known for some time (Sherman and Tanigoshi, 1974), but the 
mechanism by which it enters the cell has remained unclear. The intraerythrocytic life 
style of the asexual parasite has many advantages including protection from the host's 
immune system. One of the disadvantages, however, is that the substrates that are 
required for growth are harder to obtain.
4.1.1. M a l a r i a  I n d u c e d  T r a n s p o r t  S y s t e m s
Four routes have been proposed that may help the intraerythrocytic parasite obtain the 
large quantity of nutrients they require and to excrete the large amount of waste 
products they produce. These four methods (a malaria induced anionic pore, direct 
diffusion across the membrane, through a parasitophorous duct, and by modification of 
the host's native transporter) are discussed below.
4.1.1.1. The Anionic Pore
The first parasite induced transport pathway to be described was the pore. Early 
experiments used the specific band 3 modifier Hj-DIDS (figure 18). In erythrocytes 
infected with ring stage parasites only band 3 was labelled. Using erythrocytes infected 
with Plasmodium falciparum trophozoites and schizonts it was found that Hj-DIDS 
entered the red blood cell and labelled haemoglobin as well as band 3 (Cabantchik et 
al, 1982; Kutner et al, 1982). This suggested that malaria induced another transport 
pathway in infected red blood cells that facilitated the uptake of the normally 
impermeant H2-DIDS.
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Sorbitol has also been used to study transport processes in malaria-infected red blood 
cells. Sorbitol enters normal red cells through the host's glucose transporter (GLUT1 - 
see section 1.2.3.1.1.), but enters trophozoite and schizont-infected cells much faster. 
The uptake into infected cells appears to be unsaturable (Ginsburg et al, 1983). The 
entry of sorbitol causes a large osmotic stress that lyses infected erythrocytes (Lambros 
and Vanderberg, 1979). The release of haemoglobin has been used as a measure of 
transport (Ginsburg et al, 1983). A potent inhibitor of the host's glucose transport 
system, cytochalasin B (figure 18), does not protect the cells from lysis indicating that 
sorbitol enters through a novel transport pathway (Ginsburg et al, 1983). Phloretin, 
phlorizin (figure 18) and maltose block the sorbitol induced lysis of infected cells, 
suggesting that these compounds specifically inhibit the induced pathway (Ginsburg et 
al, 1983).
It was later found that the rate of transport of glutamine, (3-alanine, Hj-DIDS, alanine, 
glycine, sorbitol, myoinositol, glutamine, isoleucine, fructose and sorbitol (Kutner et 
al, 1985; Ginsburg et al, 1986), and the export of NBD-taurine (Cabantchik et al, 
1982), all increase with parasite age. These compounds have widely differing charges 
and sizes suggesting that the induced pathway is non-specific. In the presence of 
cyclohexamide, a specific inhibitor of protein synthesis, the new transport pathway 
does not develop (Kutner et al, 1985). It has been suggested, based on these results, 
that a protein forms a pore that transports all of these compounds and the number of 
pores increases with parasite age (Ginsburg et al, 1986). It has also been suggested 
(Ginsburg et al, 1983, 1986) that the pore is an anionic transporter. It has been found 
that negatively charged molecules, like lactate, are transported by the pore more 
efficiently than neutral molecules, and that cations are poorly transported by this 
pathway (Ginsburg et al, 1986).
The induced pathway is impermeant to disaccharides, but permeant to 
monosaccharides (Homewood and Neame, 1974; Ginsburg etal, 1986) suggesting that 
the pore has a diameter of about 7A (Ginsburg et al, 1986). Using the rate of uptake, 
the area of the cell, the width of the membrane and the concentration of the solute, it
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has been estimated that there are 8-16 pores/cell on a trophozoite-infected cell 
(Ginsburg et al, 1986).
There has recently been provided very strong evidence that a pore also exists in the 
parasitophorous vacuolar membrane (PVM) of Plasmodium falciparum-infected red 
blood cells (Desai et al, 1993). Using patch-clamp studies on malaria cells, which have 
been removed from the erythrocyte, the authors found channels in the PVM. These 
channels were large enough to allow the entry of fairly large molecules (lysine+ and 
Tris+) into the cell. The authors suggested that these pores had a diameter of about 
11A and were open about 98% of the time. These pores had some similarities to those 
reported in the erythrocyte membrane, i.e. a preference for anions over cations, and the 
capacity to transport amino acids and monosaccharides. The authors did not 
investigate the pores found in the erythrocyte membrane to find out if they had 
identical characteristics.
4.1.1.1.1. Inhibitors of the Malaria Induced Pore
The anti-malarial action of anion transport inhibitors (figure 18) has been investigated 
(Cabantchik et al, 1982). Two classes of inhibitors were tested: i) hydrophilic 
compounds that are impermeant to uninfected cells (e.g. DEDS, DNDS, and phlorizin) 
and ii) relatively lipophilic compounds that can permeate through membranes (e.g. 
niflumic acid and fiirosemide). Although relatively poor antimalarials, niflumic acid 
and fiirosemide, which are considered inhibitors of chloride channels, have more 
recently been shown to specifically inhibit this malaria induced pathway (Kirk et al, 
1992b). Phlorizin was worst at inhibiting anion transport but was the most effective 
antimalarial (Cabantchik et al, 1982).
The effect of phlorizin (figure 18) on malaria-infected red blood cells has been 
investigated in detail (Cabantchik et al, 1982; Tripatara and Yuthathong, 1986; Kutner 
et al, 1987). It has been reported that phlorizin inhibits sorbitol uptake into P. 
falciparum trophozoite-infected red blood cells with a Ki of 17|iM and arrests parasite 
growth with an IC50 of 16fiM (Kutner et al, 1987). Uninfected red blood cells are 
impermeable to phlorizin, whereas the inhibitor entered infected cells through the
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malaria induced pore (Kutner et al, 1987). The uptake of phlorizin was measured 
directly using radiolabelled inhibitor. Phlorizin, at lOOpM, reached equilibrium after 
about 1 hour in trophozoite-infected cells, but was hardly transported at all in ring- 
infected cells. Phlorizin blocked the uptake of sorbitol, whether present during the 
experiment or after pre-incubation and extensive washing of the cells in phlorizin free 
buffer. This is because the phlorizin that entered the cell was effective at inhibiting 
sorbitol uptake into infected cells. Phloretin inhibited to a similar extent when present 
during the sorbitol lysis but did not have any effect with the pre-incubation experiment 
(Kutner et al, 1987). This indicates that the probable site of action of phlorizin is on 
the cytoplasmic side of the membrane. Phlorizin did not inhibit uptake into ring stage 
parasites because phlorizin is impermeant to erythrocytes infected with ring stage 
parasites. An estimate of 6000 phlorizin binding sites per cell was obtained (Kutner et 
al, 1987).
Because phlorizin is a potent inhibitor of the Na+/glucose symport system in 
mammalian small intestine and kidney (Koepsell and Madrala, 1987), it cannot be used 
as an antimalarial drug in vivo (Silfen et al, 1988). Various analogues of phlorizin 
have been tested to determine whether a drug, which inhibits malarial transport but 
which is ineffective as a Na+/glucose symport inhibitor, could be found. The 
compound 3-isothiocyano-phlorizin (figure 18) was found to bind irreversibly (unlike 
phlorizin that was reversible) to the malarial pore with a high affinity and was 
ineffective against the mammalian Na+/glucose symporter (Silfen et al, 1988). The 
transport of small molecules into malaria-infected red blood cells was totally blocked 
by incubating with the phlorizin analogue at 50|iM for 5 minutes (Silfen et al, 1988). 
As phlorizin is selectively permeant to infected cells, an experiment has been performed 
to determine whether phlorizin interacted with the parasite as well as being a blocker 
of the malaria induced red blood cell transporter (Silfen et al, 1988). Using Sendai 
virus treated cells (that can freely transport anything up to a M.W. of 10 000 across 
the red blood cell membrane) it appeared that phlorizin inhibits the in vitro growth of 
P. falciparum in a concentration dependent fashion (Silfen et al, 1988). This showed
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that phlorizin not only inhibits the transport into the red blood cells but also has some 
effect directly on the parasite.
At pH9.0, I^-DIDS blocks uptake through the pore possibly by chemically modifying 
the pore protein (Breuer et al, 1987). Using this method, three proteins of parasite 
origin have been identified in the red blood cell membrane that may be constituents of 
the pore (Breuer et al, 1987).
It has been noticed that phloretin (figure 18) partially blocked the labelling of 
haemoglobin by Hj-DIDS in trophozoite-infected cells suggesting that phloretin may 
be an inhibitor of the induced pathway (Kutner et al, 1983). As well as being a 
powerful inhibitor of sugar transport, there have been reports of phloretin acting as a 
non-specific inhibitor of transport by disrupting the plasma membrane lipid structure 
(Melnik ef al, 1977).
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Figure 18. The inhibitors used in malaria transport experiments.
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4.1.1.2. Non-Stokesian Diffusion Across the Membrane
Although the pore model explains many of the transport properties observed in 
malaria-infected cells, it is now generally accepted that it cannot explain the 
permeability of many neutral molecules (Cabantchik, 1989a, 1990). The transport of 
glycerol, thiourea and cysteine, although markedly increased during parasite 
development, is not inhibited by phlorizin (Cabantchik, 1989a). It is thought that non­
electrolytes cross an artificial lipid bilayer by a process termed non-Stokesian diffusion 
(Lieb and Stein, 1986). This model suggests that the lipid chains form a soft polymer­
like network, and that the diffusing molecules move across the membrane by 
occupying temporary holes formed in this network. Non-Stokesian diffusion predicts 
that small molecules move faster than large molecules (as opposed to Stokesian 
diffusion where diffusion rate is independent of size). In biological membranes the 
lateral movement of the hydrocarbon chains is constrained to a large extent by 
cholesterol and proteins (some of which are bound to the cytoskeleton) resulting in 
limited transport of large volume non-electrolytes (Lieb and Stein, 1986). It has been 
proposed that during malaria development these constraints in the erythrocyte 
membrane are relaxed allowing these molecules to diffuse across the membrane 
(Ginsburg and Stein, 1987).
4.1.1.3. The Duct
Large molecules appear to have direct access to the aqueous space surrounding the 
parasite (Pouvelle et al, 1991). It has been shown that fluorescently labelled dextrans 
and antibodies label the parasite membrane under conditions that do not allow 
endocytosis (i.e. without ATP and at 4°C). These molecules are too large to enter the 
erythrocyte through the pore. It has been postulated that these molecules have access 
to the parasite membrane through a 'parasitophorous duct' (Pouvelle et al, 1991). This 
malaria induced structure is continuous with the host plasma membrane and the 
parasitophorous plasma membrane. It is also believed that small molecules have direct 
access to the parasite membrane through the duct.
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Since the proposal of the parasitophorous duct, its presence has been a matter of some 
debate (Sherman and Zidovetzki, 1992). An early criticism was that the fluorescently 
labelled dextrans could break-down to dextran and the fluorescent tag, and only the 
fluorescent tag gain access to the parasite (through the pore). This was conclusively 
refuted (Schneider et al, 1992; Taraschi et al, 1992). Experiments indicated that the 
free dye had not dissociated and work with free ruthenium red dye showed that this 
electron dense dye only entered the parasite under conditions that allow endocytosis. 
Under no circumstances was the cytosol of the erythrocyte labelled (Schneider et al, 
1992) suggesting that the parasite had direct access to the dye and that it could not 
enter the erythrocyte through the pore. At 4°C and in the absence of ATP, it has been 
shown that ruthenium red labels the host and parasite plasma membranes, (showing 
that the parasite has direct access to the dye) but it does not enter the parasite 
(Schneider et al, 1992; Taraschi and Pouvelle, 1993). If this labelling is genuine, even 
if the dye had dissociated from the dextran the result would have been the same, as the 
dye labels the parasite membrane by the same mechanism as the labelled dextran 
(Schneider et al, 1992). Recently it has been reported that ruthenium red is excluded 
from malaria-infected human erythrocytes at 4°C (Ferguson and Elford, 1993) but 
these experiments may have been incorrectly performed (Taraschi and Pouvelle, 1993).
Another criticism of the duct model is that the confocal fluorescent electron 
micrographs that claimed to visualise the duct (Pouvelle et al, 1991) are in fact 
pictures of the tubovesicular system that had been known for many years (Elford et al, 
1985; Elford and Ferguson, 1993). However, even if the micrographs are not of the 
duct this does not preclude its existence. There are many reasons why the duct may be 
hard to visualise. Firstly the electron microscopy procedure could easily destroy a 
fragile structure like the parasitophorous duct. Secondly, it has been noted that the 
parasite does not occupy the centre of the red blood cell; rather the parasite is found 
close to an edge of the erythrocyte. This means that the duct may be very short or 
even that the host's plasma membrane and the parasitophorous vacuolar membrane 
may come into contact.
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Evidence for a duct is quite strong. It was suggested in 1985 that a 'metabolic 
window' connecting the parasitophorous vacuolar membrane and the host's plasma 
membrane was the most reasonable explanation for results obtained when studying L- 
glutamine uptake (Elford et al, 1985). The authors found that L-glutamine was 
transported into infected cells reaching equilibrium after about an hour in trophozoite- 
infected cultures, but that the parasite used the L-glutamine immediately (i.e. the rate 
of protein synthesis was constant throughout the experiment). The authors suggested 
that the best explanation for this was that 'the parasite was effectively in direct 
communication with the extracellular medium, which was at almost constant specific 
activity during the influx period' (Elford et al, 1985).
Further evidence for the parasitophorous duct has been provided by work using iron 
chelators. Desferrioxamine (DFO) and N-methylanthranilic-desferrioxamine (MA- 
DFO) are both effective antimalarials. They have IC50 values of 3±lpM  when placed 
in culture with Plasmodium falciparum-infected red blood cells over a 24 hour period 
(Loyevsky et al, 1993; Lytton et al, 1993). These compounds are too large to enter 
the infected cells through the pore, and so for a while their method of entry into the 
parasite was not known. In an elegant experiment, red blood cells were lysed in the 
presence of millimolar concentrations of DFO or MA-DFO, and resealed (Loyevsky et 
al, 1993). The resealed red blood cells encapsulated the iron chelator at 
concentrations far in excess of the amount required for antiplasmodial activity. 
Despite this, when these resealed erythrocytes were added to a malaria culture it was 
found that P. falciparum merozoites invaded these cells and developed into mature 
parasites normally. This experiment conclusively showed that the iron-chelators 
bypass the red blood cell and have direct access to the parasite (Loyevsky et al, 1993) 
presumably via the parasitophorous duct.
4.1.1.4. Modification of the Host's Transporters
Along with the pore, the non-Stokesian route, and the duct, a fourth method that 
increases substrate flux across the plasma membrane of a malaria-infected erythrocyte 
has been proposed. Many of the compounds that have increased rates of transport in 
malaria-infected cells are transported by uninfected cells using its constitutive
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transporters (e.g. glucose, adenosine, lactate, tryptophan and choline). It has been 
suggested that malaria modifies these constitutive transporters thereby increasing their 
capacity (Ginsburg and Krugliak, 1983; Ancelin et al, 1985; Tripatara and Yuthathong, 
1986; Gero et al, 1988; Cabantchik, 1990; Kanaani and Ginsburg, 1991). Figure 19 
shows all the routes that are currently believed to transport small molecules in an 
erythrocyte infected with a Plasmodium falciparum trophozoite or schizont.
Modified
Normal erythrocyte Host's transporter
catabolites (e.g. glucose, /  
adenosine) . /
Malarial transporter
Non Ionic Molecules enter 
by non-Stokesian diffusion







hydrophilic and anionic 
molecules
Figure 19. Small molecules can enter the parasite-infected red blood cell by one of four 
methods: i) through the host's constitutive transporter (there have been suggestions that 
the properties of the constitutive transporters are altered by the parasite), ii) through the 
malaria induced pore, iii) through the parasitophorous duct and a transporter in the 
malarial parasite, and iv) by non-Stokesian diffusion through the lipid bilayer.
4.1.2. T r a n s p o r t  o f  S m a l l  M o l e c u l e s  in t o  M a l a r ia -In f e c t e d  
Er y t h r o c y t e s
4.I.2.I. Nucleoside Transport
The transport o f nucleosides and their analogues (figure 20) into malaria-infected and 
uninfected red blood cells has been extensively investigated (Gati et al, 1987; Gero et 
al, 1988). In uninfected red blood cells transport o f nucleosides (e.g. adenosine) and 
their analogues, such as tubercidin, occurs through a facilitative nucleoside transporter 
(Gero et al, 1988). This transporter is inhibited by nitrobenzylthioinosine (NBMPR),
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dipyridamole and dilazep (figure 20). These inhibitors are known to bind reversibly to 
the nucleoside binding site of the transporter (Gero et al, 1988; Cabantchik, 1989b). 
Plasmodium falciparum is incapable of de novo purine biosynthesis being totally 
reliant on its host for their supply (Gero and O'Sullivan, 1990). Human erythrocytes 
infected with P. falciparum show a marked decrease in sensitivity to NBMPR, 
nitrobenzylthioguanosine (NBTGR), dipyridamole and dilazep (Gati et al, 1987; Gero 
et al, 1988). After thirty minutes incubation with 50|liM  adenosine or 5 0 jjM  tubercidin 
all the available nucleoside is utilised (converted into higher molecular weight 
molecules that cannot leave on the nucleoside transporter) in infected and uninfected 
cells when no inhibitors are present (Gero et al, 1988). In the presence of an inhibitor, 
the uptake into uninfected red blood cells is reduced to about 80% of the total amount. 
Plasmodium falciparum-infected red blood cells use all the radiolabel available to them 
(Gero et al, 1988). It has been suggested that the inhibitors are ineffective in malaria- 
infected cells due to a decreased sensitivity of the host's transporter and the presence 
of an inhibitor insensitive transport system (Gero et al, 1988).
Many of the experiments on nucleoside transport use adenosine itself as a substrate 
(Gero, 1989). In these experiments, uptake rather than transport is measured. Uptake 
is the amount of compound that has been transported. Uptake will be higher if the 
compound is metabolised and retained within the cell. In contrast, transport rate is the 
rate at which the molecule crosses the membrane. Transport is independent of 
metabolism but can only be effectively measured using an analogue that remains 
unaltered (i.e. is not metabolised). Labelled adenosine is transported into the parasite 
and the erythrocyte at comparable rates. The cells reach equilibrium after 3 seconds, 
but then the adenosine begins to accumulate as it is converted into metabolites that 
cannot leave the cell. NBMPR completely blocks the uptake into normal cells and cuts 
the accumulation by over half for the P. falciparum-infected cells. Similar results are 
obtained using tubercidin instead of adenosine (Gero et al, 1988).
Tubercidin transport into trophozoite-infected cells is rate limiting for its subsequent 
metabolism. The majority is not inhibited by NBMPR in infected cells, whereas in 
uninfected cells the uptake is linear and almost totally abolished by the nucleoside
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transport inhibitor, indicating that the rate limiting step has changed in malaria-infected 
cells (Gero et al, 1988). Tubercidin is toxic to cells when it is incorporated into 
nucleic acids. In mice its toxic effect can be resisted by administering a nucleoside 
inhibitor at the same time (Gati eta l, 1987; Gero et al, 1989; Gero and Upston, 1992). 
This is because the nucleoside protects the host cells from the cytotoxic effect of 
tubercidin but does not protect malaria infected cells. In mice with malaria, tubercidin 
and NBMPR effectively cleared malaria from the system without being cytotoxic to the 
host (Gero et al, 1989). This has potential as a therapeutic approach to treat malaria 
infected patients.
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Figure 20. Nucleosides, nucleoside analogues and inhibitors of mammalian nucleoside 
transport.
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4.1.2.2. Glucose Transport
An increased rate of L-glucose uptake has been found in P. berghei-infected mouse 
erythrocytes (Homewood and Neame, 1974; Tripatara and Yuthathong, 1986). It has 
been reported that this uptake is insensitive to the classic sugar transport inhibitors 
cytochalasin B and phloretin.
Using Plasmodium lophurae-infected duck erythrocytes, an increased rate of uptake of 
D-glucose was observed compared to uninfected cells (Sherman and Tanigoshi, 1974). 
The rate of transport of 3-O-methyl-D-glucose was also found to be increased in these 
malaria-infected duck cells. The transport into these cells was, however, very slow. 
Uninfected duck erythrocytes took 8 hours to equilibrate the sugar analogue at 2.5mM 
(Sherman and Tanigoshi, 1974). This is in contrast to human erythrocytes that reach 
equilibrium within seconds.
Some experiments on D-glucose uptake into malaria-infected erythrocytes suggested 
that it was transported by a two-step process (Izumo et al, 1989; Tanabe, 1990). It 
was suggested that glucose diffuses into the red blood cells through the malaria 
induced pore and then is actively transported into the parasite by a glucose/H+ 
symporter in the malarial membrane (Izumo et al, 1989; Tanabe, 1990). These 
conclusions were based on experiments using 2-deoxy-D-glucose (Izumo et al, 1989) 
or D-glucose itself (Sherman and Tanigoshi, 1974; Tripatara and Yuthathong, 1986). 
It was found that the levels of 2-deoxy-D-glucose in the parasite were at a 
concentration 16X higher than in the surrounding mouse erythrocyte and that the 
metabolic poisons DCCD, and CCCP, inhibited this accumulation (Izumo et al, 1989). 
These inhibitors prevent the production of ATP: DCCD is an inhibitor of the 
H+/ATPase, and CCCP is a proton ionophore. However, it could be argued that these 
poisons exert their effect by preventing the phosphorylation of 2-deoxy-D-glucose and 
that a H+ dependent mechanism is not required.
4.1.2.3. Lactate Transport
The efflux of lactate has also been investigated (Kanaani and Ginsburg, 1991). The 
infected cell has to transport lactate much faster than the host, and it has been shown
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that the host's lactate transporter does not have sufficient capacity to export all the 
lactate produced by the parasite. It has been suggested that lactate leaves the cell 
through the malaria induced pore. Good evidence for this is that lactate transport in 
malaria infected erythrocytes does not saturate up to 50mM (Kanaani and Ginsburg, 
1991). Lactate is smaller than glucose and negatively charged; it is for these reasons 
that it is believed that lactate is transported efficiently by the pore (Cramner and 
Halstrap, 1993).
4.1,2.4. Aim of this Study
The aim of this study is to characterise the transport of glucose into human 
erythrocytes infected with Plasmodium falciparum trophozoites and schizonts. In this 
study we make extensive use of the glucose analogue 6-deoxy-D-glucose. The 
advantage with this analogue is that it cannot be metabolised. Unlike 2-deoxy-D- 
glucose this analogue is not a substrate for hexokinase. For this reason, it is believed 
that 6-deoxy-D-glucose only measures transport and not uptake. This compound has 
previously been used successfully to analyse glucose transport into trypanosomes 
(Eisenthal et al, 1989) and Chlorella (Komor and Tanner, 1974).
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4.2. Methods
4.2.1. M a n ip u la t io n  o f  P l a s m o d iu m  f a l c ip a r u m
Plasmodium falciparum was cultured in 50ml cultures as described in section 2.2. and 
purified from contaminating red blood cells to at least 85% parasitaemia using gelatine 
(section 2.2.4.). The cells were washed in complete medium (section 2.1.3.) and, 
unless stated otherwise, stored in this buffer until ready to use. The cells were 
maintained at 37°C throughout, unless otherwise stated. Uninfected cells, which were 
used as controls, were of the same age as infected cells and treated identically to 
infected cells before use. For some experiments mature Plasmodium falciparum 
parasites were released from the surrounding red blood cell by N2-cavitation (section 
2.2.7.) and purified from unreleased parasites and uninfected erythrocytes using a 
Percoll™ gradient (section 2.2.8.). Released parasites were stored in artificial 
intracellular medium (AIM).
4.2.2. Pr e p a r a t io n  o f  M e t a b o l ic  In h ib it o r s
Inhibitors of transport were dissolved in ethanol before use. Table 11 shows the 
concentrations of the inhibitors used, unless otherwise stated.
Inhibitor Concentration of Working
stock - in ethanol concentration
Cytochalasin B 10mM(200X) 50pM
Phloretin 320mM(1000X) 320(jM
Phlorizin 200mM (1000X) 200p.M
Niflumic Acid lOOmM (200X) 500p.M
Table 11. Concentrations of inhibitors. The inhibitors were dissolved in ethanol to the 
stated concentration and then diluted to the working concentration in buffer. After 
stirring to dissolve, the temperature of the inhibitor solution was adjusted.
4.2.3. So u r ce  o f  R a d io l a b e l l e d  Su g a r  A n a l o g u e s
Although unlabelled 6-deoxy-D-glucose is commercially available (Sigma), a 
radiolabelled analogue had to be synthesised 'in house'. The synthesis of [C6-3H]-6- 
deoxy-D-glucose has previously been described (Game, 1988). Briefly, 6-iodo-6- 
deoxy-a-methyl-D-glucoside was supplied to Amersham, where a halogen/tritium 
exchange reaction was performed to yield [C6-3H]-6-deoxy-oc-methyl-D-glucoside.
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The methyl group was removed and the product purified from its precursors using 
paper chromatography (Game, 1988).
[ l-14C]-L-glucose and l - 14C]-2-deoxy-D-glucose were purchased from Amersham.
4.2.4. P r o t e i n  E s t i m a t i o n
The sample, in a final volume of 5 pi, was mixed with 5|il of 0.1M NaOH, and placed 
in a microtitre plate. The assay was performed in duplicate and a range of BSA 
concentrations also used to produce a standard curve. The BCA reagent consisted of 
1% BCA-Na^ 2% N a^C ^, 0.16% Na^artrate, 0.4% NaOH, 0.95% NaHC03 and 
4% CuS04 pH 11.25. To each sample 200|il of BCA reagent was added. After 
incubation at 37°C for 30 minutes the absorbance of each well of the microtitre plate 
was determined and the standard BSA concentrations used to determine the protein 
concentration in the sample.
4.2.5. E s t i m a t i o n  o f  P a c k e d  C e l l  V o lu m e
Cell volume was estimated by taking a haematocrit. A sample of the cell suspension 
was drawn up through a capillary tube and then the end of the tube plugged with 
Plasticine. The capillary tube was centrifuged at 500g for 5 minutes, the height of cells 
measured, and used to calculate the percentage of cells in the suspension and the 
volume of packed cells.
4.2.6. C e l l  C o u n t in g  u s in g  a  H a e m o c y t o m e t e r
An aliquot of the cell suspension was diluted appropriately and the number of cells 
determined using a haemocytometer. The cells were counted using a Zeiss microscope 
at X40 magnification. The haemocytometer consisted of a grid of 25 squares. The 
cells in all the squares were counted and this number divided by 25 to give the number 
of cells per square. This number was multiplied by the dilution factor and divided by 
the volume of liquid under one square of the haemocytometer (lCH ml) to give the 
number of cells per ml in the undiluted cell suspension.
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4.2.7. Z e r o -T r a n s  In fl u x  In to  R ed  B lo o d  C e l l s  In fe c t e d  b y  L a t e  Stag e  
Pa r a sit e s
All reactions were performed in 3 ml reaction tubes (NUNC) and all centrifugations 
were performed in an Ole Dich cooling centrifuge set to 4°C. The cells were 
maintained at 37°C in RPMI before the transport assay. The cells were washed free of 
glucose by washing 3X with 3ml 37°C PBS (± inhibitor depending on the assay), by 
centrifugation followed by aspiration with a glass Pasteur pipette attached to a 
vacuum. The cells were then resuspended in 50pl of prewarmed PBS (± inhibitor). 
The cells were added to 50pl of the labelled sugar mix (l|iC i of label was used per 
tube for 3H and 0.2p,Ci for 14C-labelled sugar analogues), which may also contain 
inhibitor, and left at 37°C to transport the analogue. After the required time the 
transport was stopped by the addition of 3ml of stop buffer (ice-cold PBS containing 
200|fM phlorizin and 320pM phloretin). All time-points were performed in duplicate. 
Non-specific uptake, or background values, were obtained by adding this stopping 
buffer to the cells before adding labelled substrate. The cells were concentrated by 
centrifugation at 10 OOOg for 40 seconds, the supernatant removed, and the cells 
washed twice with 3ml of stop buffer. The cell pellet was then lysed with 500(il of 
0.5% Triton X-100, rotary mixed and the proteins precipitated with 500(0.1 of 5% 
trichloroacetic acid. After incubation at 4°C for 30 minutes the samples were 
centrifuged for 2 minutes at 10 OOOg to pellet the proteins. The supernatant was 
counted with 5ml of scintillation fluid (optiphase 'safe') using a (3-counter (LKB).
4.2.8. Z e r o - T r a n s  I n f l u x  o f  6 - D e o x y - D - G lu c o s e  i n t o  P a r a s i t e s  F r e e  o f  
t h e  H o s t  M e m b r a n e
The cells were prepared as described (sections 2.2.7. and 2.2.8.) and washed free of 
glucose by washing three times with 37°C glucose-free AIM (120mM KC1, 20mM 
NaCl, lOmM Pipes and ImM MgCl2 pH 6.7) (Mikkelsen et al, 1986). The cells were 
resuspended to a final volume of 20pl in the same buffer. A 20(il sugar stock 
consisting of lOmM 6-deoxy-D-glucose and ljuCi [3H]-6-deoxy-D-glucose in 37°C, 
glucose-free, AIM was prepared. At zero time the cells and sugar stock were mixed 
together. For inhibitor studies the cells were resuspended in AIM containing the 
inhibitor and mixed with a sugar solution that also contained the inhibitor at the same
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concentration. The cells were incubated at 37°C in the sugar solution (± inhibitor) for 
the required time before the assay was stopped using 3 ml of stop solution. The stop 
solution consisted of ice-cold, glucose free AIM containing 60p.M phloretin and 200|li 
M  phlorizin. After washing the cells twice with 3ml of stop solution, the cells were 
lysed with 500}il 0.5% Triton X-100 and 500pl of 5% trichloroacetic acid. After 
incubation at 4°C for 30 minutes, the samples were centrifuged for 2 minutes at 10 
OOOg and the 1ml of supernatant removed into a scintillation vial containing 5ml of 
scintillant. The samples were counted in a LKB (3-counter.
4.2.9. Z e r o -T r a n s  E f fl u x
For efflux measurements, the influx protocol (section 4.2.8.) was modified to include a 
pre-incubation step. The cells were washed free of glucose using 3X 3ml PBS and 
then pre-incubated with lOOfil radiolabelled sugar mix for 5 minutes. The cells were 
then diluted to 1ml with PBS and the efflux terminated with stop buffer (ice-cold PBS 
containing 320|iM phloretin and 200|iM phlorizin) at the desired time. Efflux studies 
using L-glucose were performed at 37°C; studies using 6-deoxy-D-glucose were 
performed at room temperature due to the rapid efflux of 6-deoxy-D-glucose at 37°C.
4.2.10. R e p r o d u c t io n  o f  R e su l t s
Unless otherwise stated, the results presented in the next section are representative of 
many experiment repetitions.
4.2.11. M o d e ll in g  u sin g  t h e  C o m pu te r
The kinetics of the system was modelled iteraratively using the FigP v5.0 computer 
package on an IBM compatible personal computer.
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4.3. Results
4.3.1. T h e  E f f e c t  o f  P r e - I n c u b a t io n  T e m p e r a t u r e  o n  t h e  U p t a k e  o f  6- 
D e o x y - D - G l u c o s e
Before the transport of glucose and glucose analogues could be successfully studied, a 
reliable transport assay was required. The effect of temperature on 6-deoxy-D-glucose 
uptake was investigated. Many previous studies on transport in malaria-infected 
erythrocytes have cooled the cells to 4°C (Tripatara and Yuthathong, 1986; Izumo et 
al, 1989; Choi and Mikkelsen, 1990) before use. Adding cold medium to cultures of 
P. falciparum cultures severely inhibits their growth so an experiment was performed 
to study the precise effect of temperature on Plasmodium falciparum. The experiment 
showed that exposure to 4°C for even 1 minute was detrimental and after 1 hour the 
cells were non-viable (figure 21).
A zero-trans uptake experiment was performed on malaria-infected red blood cells that 
had been incubated at either 4°C, 20°C or 37°C for 3 hours before use (figure 22). 
The experiment showed that the cells could be stored at 20°C or 37°C before use but 
not at 4°C. If the cells were stored at 4°C, they could not transport glucose at the 
same rate as cells kept at higher temperatures (figure 22). These results indicate that 
red blood cells infected with mature Plasmodium falciparum parasites should not be 
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Figure 21. The effect of incubation at 4°C on the viability of P. falciparum. A 50ml 
culture was split into 10x5 ml aliquots and left on ice for between 10 seconds and 24 
hours before returning to the incubator. After 48 hours Giemsa stained slides of the 
cultures were made and the percentage parasitaemia calculated. One minute at 4°C 
inhibits the growth of Plasmodium falciparum. After 1 hour the parasitaemia dropped 
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Figure 22. The effect of pre-incubation temperature on the subsequent rate of 20mM 6- 
deoxy-D-glucose uptake. Trophozoite and schizont-infected human red blood cells 
were purified using gelatine and then stored in RPMI-1640 medium for 3 hours. The 
cells were stored at either 4°C, 20°C or 37°C and then returned to 37°C before the 
uptake experiment was performed. Cells stored at 4°C transport 6-deoxy-D-glucose 
slower than cells stored at 20°C or 37°C.
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4.3.2. T he  E f fe c t  o f  G l u c o se  D e pr iv a t io n  a n d  St o r a g e  o n  P la s m o d iu m
FA L Cl PA R f/M-lNFE CT ED ERYTHROCYTES
The phenomenon of counterflow means that transport assays must be performed in 
cells that are free of glucose. Practical considerations also mean that after purification, 
infected cells must be stored while the transport assay is prepared, and cells used 
towards the end of the experiment may have been stored for 3 hours. The effect of 6 
hours (considered the longest time between purification and completion of the 
experiment) of glucose starvation and storage was investigated using gelatine purified 
P. falciparum-infected erythrocytes.
Malaria-infected cells stored in glucose-free PBS for 6 hours, at 37°C, showed 
substantial red blood cell lysis, and the released parasites were clumped at the bottom 
of the tube. Many trophozoites appeared to have been released prematurely from the 
erythrocytes and some parasites had begun to shrivel up. This indicated that the cells 
should be placed in PBS for the minimum time required to perform the transport assay 
(usually about 20 minutes). After 30 minutes in glucose-free PBS the cells appeared 
normal and no lysis was observed.
Very little lysis of the erythrocytes was apparent with cells stored in RPMt-1640 
(probably due to the release of merozoites) for 6 hours. A Giemsa stained smear 
revealed that many of the cells had developed to the late schizont stage and stopped 
growing. These cells looked healthy and were viable if given fresh blood and medium. 
After 6 hours of storage in RPMI-1640 at 37°C the cells showed normal uptake of 6- 
deoxy-D-glucose (figure 23).
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Figure 23. Zero-trans uptake of 20mM 6-deoxy-D-glucose in trophozoite/schizont- 
infected red blood cells. The infected cells were purified by gelatine flotation and stored 
in complete RPMI-1640 at 37°C for 6 hours. Examination of the cells revealed a little 
lysis of the erythrocytes and many cells in the late schizont stage. The graph indicates 
that cells have normal 6-deoxy-D-glucose uptake characteristics.
4 .3 .3 . T h e  U p t a k e  o f  2 -d e o x y -D -G l u c o s e  in t o  T r o p h o z o it e -I n f e c t e d  R e d  
B l o o d  C e l l s
Following the work o f Izumo el al (1989) 2-deoxy-D-glucose was used as a substrate. 
These researchers performed their experiments at 4°C and on the mouse malaria 
Plasmodium yoelii. When the zero-trans uptake o f 2-deoxy-D-glucose was 
investigated using P. falciparum different results were obtained depending on the pre­
incubation and assay temperature. If  the experiment was performed at 4°C, which 
prevents the depletion o f ATP but reduces native transport, results similar to those of 
Izumo el al (1989) were obtained (figure 24). The faster metabolism of malaria- 
infected erythrocytes compared to uninfected cells causes a faster accumulation in 
infected cells (figure 24). If  the cells are maintained at 37°C, ATP depletes quickly in 
infected cells causing 2-deoxy-D-glucose to equilibrate in trophozoite/schizont- 
infected cells (figure 25). Due to their slow metabolism, ATP does not deplete in 
uninfected cells and hence 2-deoxy-D-glucose continues to accumulate (figure 25).
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Figure 24. Zero-trans uptake of lOOpM 2-deoxy-D-glucose by trophozoite/schizont- 
infected and uninfected red blood cells. The malaria-infected cells were purified from 
contaminating uninfected cells using gelatine and stored in RPMI-1640 buffer at 4°C 
before the transport assay was performed at 4°C. Uninfected cells were also stored at 4° 
C in RPMI-1640 buffer. The cells were washed 3X in PBS buffer and then resuspended 
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Figure 25. Zero-trans uptake of lOOjiM 2-deoxy-D-glucose at 37°C by 
trophozoite/schizont-infected, and uninfected red blood cells. The malaria-infected 
cells were purified from contaminating uninfected cells using gelatine and stored in 
RPMI-1640 buffer at 37°C before the transport assay. Uninfected cells were also stored 
in RPMI-1640 buffer. The cells were washed 3X in glucose-free PBS and then 
resuspended in this buffer. The cells were added to an equal volume of 200|iM 2- 
deoxy-D-glucose, the transport was allowed to proceed and then stopped with ice-cold 
stop buffer.
125
Chapter 4. Glucose Transport Kinetics
4 .3 .4 . L -G l u c o s e  T r a n s p o r t  in t o  T r o p h o z o it e - I n f e c t e d  a n d  U n in f e c t e d  
R e d  B l o o d  C e l l s
Unlike 2-deoxy-D-glucose, L-glucose is not a substrate for hexokinase and does not 
undergo metabolism within infected or uninfected cells. As L-glucose is the mirror 
image o f D-glucose it is not surprising, using the 'lock and key' hypothesis, that it is not 
a substrate for hexokinase. This is advantageous in these studies because it allows the 
transport to be studied in isolation from metabolism. In uninfected cells, L-glucose 
uptake is very slow due to its relatively poor interaction with the host's glucose 
transporter, GLUT1, and its impermeability across the lipid bilayer. The uptake o f L- 
glucose into uninfected cells is facilitated completely by GLUT1; this is demonstrated 
by total inhibition using D-glucose (figure 26). Further evidence for this is provided by 
work using phloretin, which is a specific inhibitor o f facilitative glucose transporters. 
This inhibitor totally abolishes L-glucose uptake into uninfected cells (figure 27).
Uninfected cells
Uninfected cells with 100mM D- 
Glucose
M alaria-infected cells
M alaria-infected cells with 100mM 
D-Glucose
Figure 26. Zero-trans uptake of 35pM L-glucose into malaria-infected and uninfected 
cells and its inhibition by lOOmM D-glucose. Gelatine purified trophozoite and 
schizont-infected, and uninfected, erythrocytes were stored in RPMI-1640 buffer.
Before the uptake experiment, the cells were washed 3X in glucose-free PBS and 
resuspended in this buffer. The cells were mixed with an equal volume of 70pM L- 
glucose (± lOOmM D-glucose) and left for the required time.
The increased uptake o f L-glucose (figures 26 and 27) into malaria-infected cells has 
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1986). In red blood cells infected with mature stage parasites, the transport o f L- 
glucose is much faster than in uninfected cells, and is not inhibited by D-glucose (figure 
26). This suggests that L-glucose enters by another route in infected erythrocytes and 
is consistent with previous reports (Homewood and Neame, 1974; Izumo et al, 1989) 
which state that a second malaria induced pathway for transport o f hexoses exists in 
malaria-infected erythrocytes. Figure 27 shows that this induced pathway is inhibited 
to an equal extent by 200|nM phlorizin and 320|iM  phloretin. This is in contrast to 
transport in uninfected erythrocytes where phloretin is a more effective inhibitor at 
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Figure 27. Zero-trans uptake of 35pM L-glucose into uninfected and malaria-infected 
red blood cells and its inhibition by phloretin and phlorizin. Infected cells were purified 
to over 90% parasitaemia using gelatine and stored in RPMI-1640 medium before use. 
Uninfected cells were stored in RPMI-1640 medium before use. To start the experiment 
the cells were washed 3X with glucose-free PBS (± 320pM phloretin or 200pM 
phlorizin) and then resuspended in wash solution. The cells were added to an equal 
volume of 70pM L-glucose (± 320pM phloretin or 200pM phlorizin) and stopped after 
the required time.
The identity o f the malaria induced pathway was elucidated using the chloride channel 
inhibitor niflumic acid, which has been shown to be an inhibitor o f transport through 
the malaria induced pore (Kirk et al, 1992b). Uninfected cells transported L-glucose 
at the same rate in the presence and absence o f 500|liM niflumic acid (figure 28). This 
suggests that niflumic acid does not affect the transport o f hexoses through GLUT1.
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The increased L-glucose transport rate into trophozoite-infected red blood cells is 
abolished by niflumic acid, reducing it to the same rate as found in uninfected cells 
(figure 28).
U ninfected cells
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Figure 28. Zero-trans uptake of L-glucose and its inhibition by 500pM niflumic acid. 
Uninfected and gelatine purified malaria-infected red blood cells were stored in RPMI- 
1640 medium before use. The cells were washed 3X in glucose-free PBS (± 50()pM 
niflumic acid) and then resuspended in the wash buffer. An equal volume of 70pM L- 
glucose (± 500pM niflumic acid) was added to the cells and the reaction stopped after 
the required time.
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4 .3 .5 . T h e  E x p o r t  o f  L -G l u c o s e  f r o m  T r o p h o z o it e -In f e c t e d  R e d  B l o o d  
C e l l s
The export o f L-glucose from cells that had already been pre-loaded with L-glucose, 
and its inhibition by phloretin and phlorizin was also studied. Again phloretin and 
phlorizin had similar effects in infected cells (figure 29). Both inhibitors caused the 
partial inhibition o f efflux but were unable to inhibit the efflux completely. Niflumic 
acid, which is a specific inhibitor o f transport through the pore, caused total inhibition 
o f L-glucose efflux in malaria-infected red blood cells (figure 30). In uninfected cells 
L-glucose could not exit in the presence or absence o f niflumic acid during the time 
course o f the experiment (figure 30).
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Figure 29. The efflux of 35pM L-glucose and its inhibition by 200pM phlorizin or 320 
fiM phloretin. Gelatine purified, trophozoite-infected, red blood cells were washed free 
of glucose using 37°C glucose-free PBS and incubated in 35pM L-glucose for 15 
minutes. The cells were then incubated in 35pM L-glucose (± the inhibitor) and 
incubated for a further 5 minutes. The cells were then diluted 10 fold with 37°C PBS (
± phloretin or phlorizin) and the efflux monitored with time.
4 .3 .6 . 6 -D e o x y -D -G l u c o s e  T r a n s p o r t  in t o  T r o p h o z o it e -In f e c t e d  R e d  
B l o o d  C e l l s
As mentioned previously, 6-deoxy-D-glucose is an ideal substrate for these studies: it 
is non-metabolisable, and indistinguishable to D-glucose by the human facilitative 
transporter. The rate o f influx o f 6-deoxy-D-glucose into malaria-infected and 
uninfected cells is identical (figures 31, 32 and 34). This is in contrast to L-glucose
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where the transport is much faster into infected cells (figures 26, 27 and 28). L- 
glucose uptake into uninfected red blood cells was inhibited more by phloretin than in 
infected cells (figure 27). In contrast, the transport o f 6-deoxy-D-glucose into infected 
and uninfected cells are similar in the presence o f phloretin (figure 31). The inhibitor 
seems to be equally effective at inhibiting 6-deoxy-D-glucose uptake into both malaria- 
infected and uninfected red blood cells suggesting that 6-deoxy-glucose enters both 
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Figure 30. The efflux of 35pM L-glucose and its inhibition by 500pM niflumic acid. 
Malaria-infected erythrocytes were gelatine purified and stored in RPMI-1640 medium 
before use. Uninfected cells were also stored in RPMI-1640 medium. The cells were 
washed free of glucose and incubated, at 37°C, in 35pM L-glucose for 15 minutes. The 
cells were then incubated in 37°C, 35pM L-glucose (± niflumic acid) and incubated for 
a further 5 minutes. The cells were then diluted 10 fold with 37°C PBS (± niflumic 
acid), and the efflux monitored.
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Figure 31. Zero-trans uptake of 5mM 6-deoxy-D-glucose in the presence and absence 
of 320pM phloretin. Gelatine purified, malaria-infected, and uninfected red blood cells 
were stored in RPMI-1640 before use. The cells were then washed 3X in 37°C, 
glucose-free PBS (± 320(liM phloretin) and resuspended in the wash buffer. The cells 
were added to an equal volume of 37°C, lOmM 6-deoxy-D-glucose (± 50[iM 
cytochalasin B) and left for up to 60 seconds before stopping the reaction.
Cytochalasin B is a non-competitive inhibitor o f sugar uptake, acting on the inside o f 
the cell (Tavema and Langdon, 1973; Lin and Spudich, 1974). At a concentration o f 
50p,M this compound inhibited uptake o f 6-deoxy-D-glucose by over 99.9% in 
uninfected erythrocytes (figure 32). In parasitised cells cytochalasin B was also an 
effective inhibitor o f 6-deoxy-D-glucose uptake achieving inhibition o f 87.0% over the 
first 5 seconds o f transport (figure 32). As cytochalasin B was less effective at 
inhibiting 6-deoxy-D-glucose uptake into malaria-infected cells than into uninfected 
cells the Ki for cytochalasin B was determined for both cell populations (figure 33). 
Uninfected cells have an apparent Ki for cytochalasin B of 3.1xlO'8M; infected cells 
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Figure 32. Zero-trans uptake of 20mM 6-deoxy-D-glucose in the presence and absence 
of 50|iiM cytochalasin B. Gelatine purified, malaria-infected, and uninfected red blood 
cells were stored in RPMI-1640 before use. The cells were washed 3X in glucose-free, 
37°C PBS (± 50|iM cytochalasin B) and resuspended in the wash buffer. The cells were 
added to an equal volume of 37°C, 40mM 6-deoxy-D-glucose (± 50|iM cytochalasin B) 
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Figure 33. Differential inhibition of zero-trans uptake of 20mM 6-deoxy-D-glucose by 
cytochalasin B. Gelatine purified, malaria-infected, and uninfected red blood cells were 
stored in RPMI-1640 before use. The cells were then washed 3X in 20°C, glucose-free 
PBS (± cytochalasin B at 10'9M—>10'4M concentration) and resuspended in the wash 
buffer. The cells were added to an equal volume of 20°C, 40mM 6-deoxy-D-glucose (± 
cytochalasin B at 10'9M->10'4M concentration) and left for 5 seconds before stopping 
the reaction. We have assumed that the transport rate is linear over the first 5 seconds 
to obtain the initial rate estimates. Uninfected cells have a Ki for cytochalasin B of 
3. 1x10'8M; infected cells have a Ki of 10‘6M.
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It has been reported that the malaria induced pathway has characteristics similar to 
chloride channels, and is inhibited by niflumic acid and furosemide, both potent specific 
inhibitors o f this channel (Kirk et al, 1992b). Niflumic acid was used in conjunction 
with cytochalasin B to inhibit uptake into infected cells further (figure 34). This 
suggests that some 6-deoxy-D-glucose enters the parasite through the malaria induced 
pore. Niflumic acid alone has no inhibitory effect on the uptake confirming that a large 
proportion o f the hexose is transported through the host's, niflumic acid insensitive, 
hexose transporter.
Malaria-infected red blood cells were subjected to N2-cavitation (section 2.2.7.) to 
release parasites (and the parasitophorous vacuolar membrane) from the red blood 
cells. Zero-trans uptake o f 6-deoxy-D-glucose into these released parasites revealed 
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Figure 34. Zero-trans uptake of 5mM 6-deoxy-D-glucose into trophozoite and 
schizont-infected red blood cells in the presence and absence of 50pM cytochalasin B 
and/or 500pM niflumic acid. Gelatine purified, malaria-infected, red blood cells were 
stored in RPMI-1640 before use. The cells were then washed 3X in 37°C, glucose-free 
PBS (± cytochalasin B and/or niflumic acid) and resuspended in the wash buffer. The 
cells were added to an equal volume of 37°C, lOmM 6-deoxy-D-glucose (± cytochalasin 
B and/or niflumic acid) and left for up to 60 seconds before stopping the transport.
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Figure 35. Zero-trans uptake of 5mM 6-deoxy-D-glucose into Plasmodium falciparum 
parasites that were released from erythrocytes. Malaria-infected red blood cells were 
purified using gelatine and then the red blood cells were lysed by N2-cavitation. The 
cells were stored in 37°C, AIM containing 5mM D-glucose before use. When ready the 
cells were washed 3X in glucose-free AIM and resuspended in the wash buffer. An 
equal volume of 37°C, lOmM 6-deoxy-D-glucose in AIM (± 50pM cytochalasin B) was 
added to the cells and the uptake of sugar allowed to proceed. The transport was 
stopped by the addition of stop buffer. Due to the technical difficulties of performing 
this assay this experiment was not repeated.
4 .3 .7 . T h e  E x p o r t  o f  6 -D e o x y -D -G l u c o se  fr o m  T r o p h o z o it e -In f e c t e d  R ed  
B lo o d  C e l l s
By studying the export o f 6-deoxy-D-glucose from infected and uninfected red blood 
cells the transport characteristics of the parasite can be investigated. The hexose left 
uninfected red blood cells faster than infected cells (figure 36). Cytochalasin B is a 
competitive inhibitor o f efflux (Taverna and Langdon, 1973; Lin and Spudich, 1974). 
When cytochalasin B was used at 50(iM it was able effectively to inhibit efflux o f 
20mM 6-deoxy-D-glucose (figure 37). This indicates that cytochalasin B is a good 
inhibitor o f 6-deoxy-D-glucose efflux and that most o f the sugar leaves on a facilitative 
carrier. Further evidence for this is provided by the effect o f phloretin and phlorizin on 
the efflux o f glucose from malaria-infected cells. Unlike L-glucose efflux, 6-deoxy-D- 
glucose efflux is totally inhibited by 320|iM phloretin and only partially inhibited by 
phlorizin (figure 38).
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Figure 36. Zero-trans efflux of 6-deoxy-D-glucose in malaria-infected and uninfected 
red blood cells. Gelatine purified, malaria-infected, and uninfected red blood cells were 
stored in RPMI-1640 before use. The cells were then washed 3X in glucose-free PBS 
and resuspended in the wash buffer. The cells were incubated at 20°C in 20mM 6- 
deoxy-D-glucose for 15 minutes to pre-load the cells with the hexose. The cells were 
then incubated for 2 minutes in 20mM 6-deoxy-D-glucose. The cells were diluted 10 
fold with 20°C, glucose-free PBS and the egress of the sugar followed. The results are 
expressed as fractional filling [ (Sj-S^^Sq-S^) ] versus time.
Uninfected cells
Uninfected cells + 50pM 
cytochalasin B
0 .9  -
Malaria-infected cells
0.8 - Malaria-infected cells + 50yM 
cytochalasin BH  0 .7  - ■
_ i  0 . 6  - -
O  0 .5  -•
^  0 .3  -
0.2 -
0.1
500 10 20 3 0 40 6 0
Tim e /s e c o n d s
Figure 37. Zero-trans efflux of 20mM 6-deoxy-D-glucose in malaria-infected and 
uninfected red blood cells in the presence of absence of cytochalasin B. Gelatine 
purified, malaria-infected, and uninfected red blood cells were stored in RPMI-1640 
before use. The cells were then washed 3X in glucose-free PBS and resuspended in the 
wash buffer. The cells were incubated in 20mM 6-deoxy-D-glucose for 10 minutes to 
pre-load the cells with the hexose. The cells were then incubated for 2 minutes in 
20mM 6-deoxy-D-glucose (± 50pM cytochalasin B). The cells were diluted 10 fold 
with 20°C, glucose-free PBS (± 50pM cytochalasin B) and the egress of the sugar 
followed. The results are expressed as fractional filling [ (Sj-S.J/CSo-S.J ] versus time.
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The export o f 6-deoxy-glucose is completely inhibited by phloretin and partially 
inhibited by phlorizin in malaria-infected cells. In uninfected cells phlorizin does not 
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Figure 38. Zero-trans efflux of 20mM 6-deoxy-D-glucose in malaria-infected red blood 
cells in the presence of phloretin or phlorizin. Gelatine purified, malaria-infected, red 
blood cells were stored in RPMI-1640 before use. The cells were then washed 3X in 20 
°C, glucose-free PBS and resuspended in the wash buffer. The cells were then 
incubated at 20°C in 20mM 6-deoxy-D-glucose for 10 minutes to pre-load the cells with 
the hexose. The cells were then incubated in 20mM 6-deoxy-D-glucose (± 200pM 
phlorizin or 320pM phloretin). The cells were diluted 10 fold with glucose-free, 20°C 
PBS (± 200pM phlorizin or 320pM phloretin) and the egress of the sugar followed. 
The results are expressed as log fractional filling [log (Si-Soo)/(S0-Seo) ] versus time.
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The efflux o f 6-deoxy-D-glucose was studied at different concentrations o f 6-deoxy-D- 
glucose in an attempt to estimate the kinetic parameters and to help determine the 





















Figure 39. Zero-trans efflux of 6-deoxy-D-glucose in malaria-infected red blood cells. 
Gelatine purified, malaria-infected, red blood cells were stored in RPMI-1640 before 
use. The cells were then washed 3X in 20°C, glucose-free PBS and resuspended in the 
wash buffer. The cells were then incubated in 6-deoxy-D-glucose (at 5, 10, 15 or 
30mM) for 5 minutes to pre-load the cells with the hexose. The cells were diluted 10 
fold with 20°C, glucose-free PBS and the egress of the sugar followed. The results are 
expressed as intracellular concentration versus time. Each point is the average of 3 
experiments and the SEM are displayed.
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4.4. Discussion
The observations that cooling malaria-infected red cells inhibits its growth (figure 21) 
and its uptake of 6-deoxy-D-glucose (figure 22) is consistent with the results of 
Wunderlich et al (1982). He studied the protein distribution in Plasmodium-infected 
erythrocytes. About 30% less protein is found on the periplasmic side of the red blood 
membrane after incubation at 4°C for 10 minutes (Wunderlich et al, 1982), suggesting 
specific translocation of proteins from the outside face of the membrane at low 
temperatures. If these proteins normally transport 6-deoxy-D-glucose it would explain 
the reduced transport after incubation at 4°C. This mechanism may have biological 
significance as a rapid drop in temperature in the wild would mean the parasites have 
left the human host and entered the cold blooded Anopheles mosquito. Under these 
conditions the asexual stages of the parasite (the merozoites, rings, trophozoites and 
schizonts) do not survive. The sudden reduction in metabolism may prevent the 
mosquito from starving under the increased demand from the asexual parasite.
It has also been reported that synchronised P. falciparum trophozoites that were 
maintained at 28°C matured slowly. These cultures also appeared to reinvade 
inefficiently at later stages in the life-cycle (Rojas and Wasserman, 1993).
To gain insight into how D-glucose is transported into the cell, a D-glucose analogue 
must be used. One of the main investigations into glucose transport in malaria-infected 
erythrocytes used 2-deoxy-D-glucose (Izumo et al, 1989) and the mouse parasite P. 
yoelii. This analogue is far from ideal because 2-deoxy-D-glucose is also a substrate 
for hexokinase (Sols and Crane, 1954; Sols et al, 1958). On entering the cell, 2- 
deoxy-D-glucose is phosphorylated to 6-phospho-2-deoxy-D-glucose, which is not 
transported by the glucose transporter, and becomes trapped within the cell. Because 
many studies on glucose transport to date have used this analogue, the conclusion that 
transport into malarial parasites is active requires further investigation. The use of D- 
glucose to study transport (Sherman and Tanigoshi, 1974; Tripatara and Yuthathong, 
1986) suffers from similar limitations to using 2-deoxy-D-glucose. The sugar is rapidly
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metabolised, being converted to lactate and expelled, or incorporated into high 
molecular weight compounds.
Using metabolisable analogues of D-glucose means that the results that are obtained 
depend on the metabolic state of the cell. Zero-trans influx experiments require the use 
of starved parasites as glucose must not be present inside the cell. This means that 
ATP is likely to deplete in the metabolically active parasite during the transport assay. 
If the assay is performed at 4°C, the malaria-infected cell has ATP available for some 
time but the cells are not viable. At 37°C, ATP is depleted while the cells are being 
washed free of glucose and before the uptake experiment is commenced.
At 4°C, Plasmodium falciparum-infected red blood cells accumulate 2-deoxy-D- 
glucose for about 60 seconds, after which time the cell's ATP stores deplete and the 
unphosphorylated 2-deoxy-D-glucose equilibrates across the erythrocyte membrane 
(figure 24). At 37°C 2-deoxy-D-glucose equilibrates at a lower level in infected cells 
because the cellular ATP levels were depleted before the assay was started (figure 25). 
In uninfected cells similar results are obtained at 4°C and at 37°C (except that the 
transport and subsequent metabolism is faster at 37°C); the sugar equilibrates quickly 
and then sugar levels increase steadily as the hexose is phosphorylated.
L-glucose has one main advantage over 2-deoxy-D-glucose: it is not modified. L- 
glucose diffuses into the cell and diffuses out again. It is not phosphorylated and does 
not accumulate in the cell. Another property of L-glucose is its slow transport rate by 
the host's glucose transporter. This allows the malaria induced pathways to be studied 
in isolation from the host's transporter.
The transport of L-glucose into uninfected cells is totally inhibitable by both D-glucose 
and phloretin (figures 26 and 27). This indicates that L-glucose enters into uninfected 
red blood cells exclusively through the D-glucose mammalian transporter GLUT1. 
Phlorizin, a specific inhibitor of the Na+/glucose intestinal symporter protein (Koepsell 
and Madrala, 1987), does inhibit the uptake of L-glucose into uninfected cells, but not 
to the same extent as phloretin. Compared to 6-deoxy-D-glucose, which reaches 
equilibrium at 5mM in 10 seconds (figures 31 and 34), the transport rate of L-glucose
139
Chapter 4. Glucose Transport Kinetics
is very slow. After 10 minutes 35|LiM L-glucose does not reach equilibrium (figures 
26, 27 and 28).
The increased uptake of L-Glucose into infected red blood cells has been reported 
before. Previous work (Homewood and Neame, 1974) suggests that the space 
available for L-glucose increases in samples containing P. berghei-infected mouse 
cells, i.e. L-glucose enters the cells. These authors were unable to detect a similar 
increase in space using uninfected cells. Tripatara and Yuthathong (1986) reported 
that phloretin was ineffective as an inhibitor of L-glucose uptake into both P. berghei- 
infected and uninfected erythrocytes.
We have found that in trophozoite-infected human red blood cells, L-glucose is 
transported faster than in uninfected cells and shows different inhibition characteristics 
(figures 26, 27 and 28). The uptake of L-glucose into infected cells is almost totally 
insensitive to D-glucose (figure 26) and less sensitive to phloretin (figure 27). In P. 
falciparum-infected human erythrocytes we have found that the inhibition by phloretin 
is only partial in infected cells but complete in uninfected erythrocytes (figures 27). 
The discrepancy between our results and those of other authors is probably due to the 
high L-glucose concentration used in their experiments (5mM), and to the use of 
mouse instead of human erythrocytes. These results suggest that L-glucose is 
imported into malaria-infected erythrocytes by a pathway that is not present in 
uninfected cells. As this transport is totally inhibited by 500pM niflumic acid (figure 
28) and significantly inhibited by 200pM phlorizin (figure 27) it is likely that the 
majority of the L-glucose enters the infected cells through the malaria induced pore 
(Kutner et al, 1987; Kirk et al, 1992b). It is unclear from zero-trans uptake studies 
whether L-glucose enters the parasite or only enters the infected red blood cell.
The export of L-glucose is similarly inhibited by phloretin and phlorizin (figure 29). In 
infected cells both 320pM phloretin and 200|iM phlorizin are equally effective at 
inhibiting L-glucose efflux (figure 29). In uninfected cells the efflux is so slow that 
after 10 minutes none had appeared to leave the cells (figure 30). In infected cells the 
efflux is inhibited totally by niflumic acid. Efflux from the parasite does not appear to
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follow a simple first-order mechanism (figure 30). This would suggest that L-glucose 
is leaving from two compartments and suggests that L-glucose has access to the 
parasite as well as the erythrocyte.
Although a useful tool for studying the properties of the pore, L-glucose is not 
transported as efficiently as D-glucose in either infected or uninfected cells. To gain 
insight into how D-glucose is transported into the cell, a D-glucose analogue must be 
used. Although 2-deoxy-D-glucose is commercially available and appears to have 
similar Km and Vmax values for the mammalian transporters, this analogue is far from 
ideal. As mentioned earlier, not only does the glucose transporter protein recognise it 
as glucose but so does hexokinase (Sols and Crane, 1954; Sols et al, 1958). Once 
phosphorylated it cannot leave the cell on the transporter and accumulates within the 
cell. The rate of accumulation is proportional to the rate of phosphorylation and not 
related to the rate of transport so it is very hard to study transport using these 
analogues. A solution to the problem is to use a D-glucose analogue where the C6 OH 
group has been replaced with a hydrogen atom. This analogue, called 6-deoxy-D- 
glucose (or epifucose), cannot be phosphorylated by hexokinase making the study of 
transport possible in the absence of metabolism.
An unexpected result was that the 6-deoxy-D-glucose transport rate into malaria- 
infected and uninfected cells was the same (figures 31, 32 and 34). This result was 
unexpected because it is known that infected cells use much more glucose than 
uninfected cells (Sherman and Tanigoshi, 1974; Sherman, 1979) and it has been 
suggested that a malaria induced pathway (the pore) is required to supply the infected 
cell with enough glucose to grow (Tanabe, 1990). This result indicates that the native 
mammalian glucose transporter has a sufficient capacity to supply the mature parasite 
with glucose, and that in uninfected mature human erythrocytes glucose is transported 
below capacity.
Cytochalasin B, at a concentration of 50pM, which is a specific inhibitor of facilitative 
sugar transporters (Tavema and Langdon, 1973; Lin and Spudich, 1974), inhibited 
uptake of 6-deoxy-D-glucose by over 99.9% in uninfected erythrocytes (figure 32). In
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parasitised cells, cytochalasin B was also an effective inhibitor of 6-deoxy-D-glucose 
uptake, achieving inhibition of about 87.0% over the first 5 seconds of transport 
(figure 32). These results confirm that the majority of 6-deoxy-D-glucose is 
transported into malaria-infected red blood cells through GLUT1. This is in contrast 
to L-glucose where the majority is transported through the malaria induced pore. As 
cytochalasin B appears to be a less potent inhibitor of 6-deoxy-D-glucose transport in 
infected cells (figure 33), it seems likely that either the kinetics of the host transporter 
is modified or some of the hexose enters through a cytochalasin B insensitive pathway.
The suggestion of a modified host transporter is consistent with several reports of 
modified transporters in Plasmodium-irtfected erythrocytes, e.g. glucose (Tripatara and 
Yuthathong, 1986), adenosine (Gero et al, 1988), lactate (Kanaani and Ginsburg, 
1991), tryptophan (Ginsburg and Krugliak, 1983) and choline (Ancelin et al, 1985).
The theoretical results obtained for differential inhibition by a competitive inhibitor are 
depicted in figure 40. A graph of initial velocity against log inhibitor concentration 
gives a sigmoid curve (see figure 40A) and the difference between these two curves 
gives a peak (figure 40B).
Plasmodium falciparum is known to place its own proteins in the red blood cell 
membrane (Howard, 1988; Gormley et al, 1992) and to alter the lipid composition of 
this membrane (Hsiao et al, 1991). Either of these processes could, in theory, alter the 
host's transporter. Although our results initially confirm that the malaria parasite has 
changed the sensitivity of GLUT1 to cytochalasin B (compare figure 40B and figure 
41) it appears unlikely that this is true. Altering GLUT1 would not be of any 
advantage to the malarial parasite. The native transporter is sufficient to supply all the 
D-glucose that the parasite requires, and the parasite does not increase the rate of 6- 
deoxy-D-glucose transport into infected cells (figures 31, 32 and 34). Furthermore, 
the results that we have obtained can be explained using a simple hypothesis that does 
not involve modification of the host's native transporter. The small amount of 6- 
deoxy-D-glucose that enters through the parasite induced pore competes with 
cytochalasin B for its internal binding site lowering its effectiveness. Some hexose
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might also enter the parasite directly through the parasitophorous duct and the less 
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Figure 40. Theoretical graphs showing differential inhibition of two systems by a 
competitive inhibitor. The equation for competitive inhibition is v = 
(Vmax.S)/(Km(l+(I/Ki))+S)). The following values were set: Vmax = 10, Km = 10'5M 
and S = 5x10'3M and then the inhibitor concentration was varied between 10'9M—>1M 
for two different systems (with Ki values of 10'7M and 10'5M). A.) A graph of velocity 
against log inhibitor concentration produced a sigmoid curve. The larger the Ki the 
further the curve is shifted to the left. B.) The difference in the two velocities against 
log inhibitor concentration. The difference peaks and then falls off rapidly. The curve 
is symmetrical.
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Figure 41. Inhibition of 6-deoxy-D-glucose uptake by cytochalasin B. Difference 
between transport rate in malaria-infected cells and uninfected cells using data shown 
in figure 33.
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Figure 42. A hypothesis to explain the lowering of the Kiapp of cytochalasin B on 6- 
deoxy-D-glucose uptake. This hypothesis does not predict the modification of the host's 
constitutive transporter. The small amount of 6-deoxy-D-glucose that enters through 
the pore in infected cells competes with cytochalasin B lowering its effectiveness. The 
situation is further complicated by some 6-deoxy-D-glucose entering the parasite 
directly through the duct and the parasite's less cytochalasin B sensitive transporter.
It has been reported that the malaria induced pathway has characteristics similar to 
chloride channels and is inhibited by niflumic acid and furosemide - both potent specific
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inhibitors of these channels (Kirk et al, 1992b). Niflumic acid was used in conjunction 
with cytochalasin B to inhibit uptake into infected cells further (figure 34). This 
suggests that some 6-deoxy-D-glucose enters the parasite through the malaria induced 
pore. Figure 34 also shows that niflumic acid in the absence of cytochalasin B has no 
inhibitory effect on the uptake. This confirms that much of the hexose is transported 
through the host's niflumic acid insensitive hexose transporter, and that the main 
function of the malaria induced pore is not to transport glucose. The host's glucose 
transporter supplies all the glucose the intraerythrocytic parasite requires.
Although niflumic acid has a synergistic effect on the inhibition of 6-deoxy-D-glucose 
uptake when used in conjunction with cytochalasin B, the inhibition is not complete 
(figure 34). At 50|iM cytochalasin B completely inhibits transport through the host's 
transporter (figure 32) and at 500fiM niflumic acid completely stops transport through 
the malaria induced pore (figure 28). This raises the possibility that some of the 
hexose enters through a pathway that is either insensitive or less sensitive to 
cytochalasin B or niflumic acid. It is possible that some of this sugar has direct access 
to the parasite by way of the parasitophorous duct (Pouvelle et al, 1991). This model 
is displayed is figure 43.
This hypothesis is supported by data on adenosine influx into P. falciparum-infected 
red blood cells. It has been reported (Gati et al, 1987) that nucleosides enter infected 
cells through one of three pathways: the host's constitutive transporter, a non­
saturable, non-inhibitable transporter (the pore), and a pathway that is weakly inhibited 
by nucleoside specific inhibitors (like NBMPR). When this paper was published the 
presence of the duct was unknown and so it was assumed that all these three 
transporters were located in the erythrocyte's plasma membrane. It is possible that the 
mildly inhibited pathway is located in the parasite membrane in a similar way to the 
mildly cytochalasin B sensitive glucose transport system found in this study. Similar 
results have been obtained when studying lactate efflux. It was found (Kanaani and 
Ginsburg, 1991) that Plasmodium falciparum infection induced another saturatable, 
CAD (cinnamic acid derivative) sensitive pathway in human red blood cells. This
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transporter could also be located in the parasite's plasma membrane (Cramner and 
Halstrap, 1993).
Further evidence for this is provided by work on parasites released from their 
erythrocyte. Transport into these cells showed incomplete inhibition by cytochalasin B 
and suggests that the parasite's hexose transporter may be less sensitive to cytochalasin 
B. This agrees with work by other authors who reported that 2-deoxy-D-glucose 
uptake into released parasites was only weakly inhibited by cytochalasin B (Izumo et 
al, 1989; Tanabe, 1990). It seems likely that some glucose enters directly into the 
parasite through the malaria induced parasitophorous duct and its native transporter. 
This would explain the incomplete inhibition o f 6-deoxy-D-glucose uptake by 500pM 











Figure 43. A model to explain the kinetics of 6-deoxy-D-glucose uptake into a human 
erythrocyte infected by a mature Plasmodium falciparum parasite. The sugar can enter 
the cell by three methods i) through the host's constitutive transporter, ii) through the 
malaria induced pore and iii) through the parasitophorous duct and a transporter in the 
malarial parasite. Due to the large number of OH groups it is unlikely that the sugar 
enters the parasite by non-Stokesian diffusion (Ginsburg and Stein, 1987)
Technically, the zero-trans uptake experiments on released parasites were hard to 
perform. Many workers have expressed difficulty in obtaining intact free parasites
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suitable for transport studies (Sherman, 1988; Gero and O'Sullivan, 1990). There are 
many reasons for this including:
i) The released parasites are hard to obtain in a form that have their membranes 
intact. It has been reported that lysis of erythrocytes using saponin or 
antiserum complement, alters the membrane properties of the released parasite 
and has been shown to cause protein leakage (Sherman, 1979, 1988; Gero and 
O'Sullivan, 1990). Instead of using saponin a high pressure method was 
employed where the cells were placed under 30 atmospheres of N2, and the 
erythrocytes lysed on returning the cells to atmospheric pressure (Mikkelsen et 
al, 1986; Choi and Mikkelsen, 1990). This method has been reported to 
release the parasites gently and not disrupt their delicate membranes as 
detergent is not used. Unfortunately, many of the malaria-infected erythrocytes 
remained intact and some of the parasites lysed using this method. The 
released parasites were purified from contaminating erythrocytes using Percoll 
™. Although partially successful, and despite many attempts, most of the free 
parasites clumped in the Percoll™.
ii) The low yield of free parasites and the small internal volume meant that the 
radioactive counts in the assay were low (~300cpm) and errors high.
It is unfortunate that obtaining free parasites suitable for transport studies proved so 
troublesome because many further experiments could have been performed on them. 
Uptake could have been studied at different substrate concentrations to obtain 
estimates of Km and Vmax for the malarial transporter, and the effect of phloretin, 
phlorizin and niflumic acid on malarial transport could also have been investigated. 
There is some evidence that phlorizin directly affects the parasite, as well as inhibiting 
transport through the pore in the erythrocyte membrane (Silfen et al, 1988).
A criticism of the work on free parasites is that the parasites are still surrounded by an 
intact parasitophorous membrane (Choi and Mikkelsen, 1990). The volume of the 
vacuolar space is however very small compared to the intraparasitic volume. Also, the 
presence of a very high concentration of pores in the parasitophorous vacuolar
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membrane (Desai et al, 1993), and presumably comparable levels of GLUT1 to the 
host's plasma membrane, suggests that the transport of sugar across the 
parasitophorous vacuolar membrane is not rate limiting.
Other useful experiments in the area could be performed using Sendai virus treated red 
blood cells (Silfen et al, 1988). These cells have large holes punched in the erythrocyte 
plasma membrane and the parasitophorous vacuolar membrane that are large enough 
to allow the entry of small proteins. This treatment induces cell-cell fusion, the almost 
complete release of haemoglobin and permeabilisation of the host cell membrane to 10 
000 Dalton FITC-dextran (Silfen et al, 1988) but does not interfere with parasite 
maturation and release of merozoites. Malaria-infected cells treated with this virus will 
essentially behave like free parasites. These cells could be obtained in large quantities 
and would allow the characteristics of the parasite transporter to be determined.
When the zero-trans efflux of 6-deoxy-D-glucose into infected erythrocytes was 
studied it was found that export from uninfected cells was faster than export from 
malaria-infected cells (figures 36 and 37). This would be expected if the transport 
across the red blood cell membrane was faster than the export across the parasitic 
membrane (or the parasite vacuolar membrane). All the 6-deoxy-D-glucose left the 
uninfected cell through a fast route (GLUT1). This means that the export of hexose 
from uninfected cells follows first order kinetics, and that a graph of log fractional 
filling vs. time gives a straight line (figure 44).
In erythrocytes infected with a mature Plasmodium falciparum parasite the efflux is 
more complex. Assuming that the volume of space around the parasite 
(parasitophorous vacuolar space and the duct) is very small, the hexose will be in two 
main compartments: the red blood cell, and the parasite. From uptake studies it is 
likely that the 6-deoxy-D-glucose located in the erythrocyte will leave at a similar rate 
to the efflux from uninfected cells (figures 31, 32 and 34). The hexose located in the 
parasite can leave through 2 main routes: i) through the malarial transporter and the 
duct, ii) through the malarial transporter and across the parasitophorous and red blood
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cell membranes via the pore or the host's transporter (figure 45). This complicated 
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Figure 44. Zero-trans efflux of 20mM 6-deoxy-D-glucose in malaria-infected and 
uninfected red blood cells in the presence or absence of cytochalasin B. The data in 
figure 37 is expressed as log fractional filling [log (Sj-S^/fSo-S^) ] versus time. The 
hexose leaves uninfected cells faster than infected cells. The efflux from uninfected 
cells appears to be first order (as it is reasonably close to linearity) and the efflux from 
infected cells a higher order. Cytochalasin B appears to be a good inhibitor in both 
malaria-infected and uninfected erythrocytes.
It is interesting to note that the 6-deoxy-D-glucose is not retained within the parasite. 
It can diffuse freely into and out o f infected cells. This is further evidence that the 
malarial glucose transporter is facilitative and not a proton symporter as suggested by 
other workers (Izumo et al, 1989; Tanabe, 1990).
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Figure 45. A model showing the predicted efflux of 6-deoxy-D-glucose from 
uninfected and malaria-infected red blood cells. In uninfected cells the sugar leaves the 
cells through the host's transporter. In infected cells the 6-deoxy-D-glucose in the 
eiythrocyte leaves the cell either through the pore or through the host's transporter and 
the 6-deoxy-D-glucose in the parasite leaves through the parasite's transporter and then 
either through the duct or via the erythrocyte. The uptake experiments and the effective 
inhibition by 50pM cytochalasin B suggests that the pore has a minimal effect on the 
flux of sugar in infected cells; most leaves through GLUT1. The egress from the 
parasite is slower than from the red blood cell.
It has been attempted to model the efflux o f 6-deoxy-D-glucose. The data from 6- 
deoxy-D-glucose efflux experiments (figure 39) was fitted to a two compartment, 
biphasic efflux model. This model is shown is figure 46.
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e
Figure 46. A simplified model of the flux of substrate out of a malaria infected cell. In 
the model there are three compartments called E (extracellular), C (red blood cell) and 
P (parasite). Initially sugar concentration in compartments C and P are at 1 unit and 
the concentration in compartment E is 0 units. As time proceeds sugar leaves C and P 
and enters E. In the model there will eventually be no sugar remaining in C or P. The 
rate at which sugar leaves C is described by the rate constant kj and the rate at which 
sugar leaves P is described by the rate constant k2. Sugar leaves C faster than it leaves 
P.
The amount of sugar inside the malaria infected cell in figure 46 (i.e. Sc+Sp) is 
described by the biexponential equation:
Si = ae”k,t+ be-k2t+ c
where is the amount of sugar at time t, a, b, and c are constants that depend on the 
substrate concentration, and and k2 are the rate constants. This approach has been 
used previously to model the flux of 3-O-methyl-D-glucose into intracellular 
compartments in Xenopus oocytes expressing GLUT1 or GLUT4 (Nishimura et al, 
1993).
In malaria infected erythrocytes this equation is a necessary simplification. Not only is 
it possible that some 6-deoxy-D-glucose has direct access to the parasite through the
151
Chapter 4. Glucose Transport Kinetics
duct (i.e. the two compartments are in parallel as well as in series) but also the sugar 
leaves at least one of the compartments through two systems (through GLUT1 and the 
pore). When the initial concentration is standardised (i.e. the fractional filling is used) 
the constants a and b are proportional to the relative volumes of the compartments. At 
time = 0 Sj will be 1 and so a+b+c will equal 1. It can be shown that in this case that c 
will be zero and the constants a and b will be the fraction of the cells volume occupied 
by the compartments P and C respectively. The model also assumes that there is no 
flux of sugar back into the cell (i.e. that compartment E is very large compared to C 
and P). Using the data shown in figure 39 and the FigP iterative model solving 
program estimates of a=0.64 and b=0.42 were obtained at each substrate 
concentration. The constancy of a and b gives some confidence that a model of this 
nature has some validity. The estimates for a and b are in good agreement with the 
quoted volumes of the parasite and red blood cytosol from the literature (Choi and 
Mikkelsen, 1990).
Using these values of a and b the rate constants shown in table 12 were obtained. 
These constants were used to graphically display the excellent fit obtained (figure 47).





Table 12. Values of constants (to 3 decimal places) obtained for the biexponential 
model using values of a=0.64 and b=0.42 in the equation shown above. The values are 
obtained using an iterative program and the data displayed in figure 39. Using these 
values the data is shown to be in good agreement with the model (figure 47).
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Figure 47. Replot of data shown in figure 39. The data is plotted as fractional filling 
[(Sj-SJ/(S0-S J l versus time. The lines were generated using the FigP iterative 
program and the model shown in figure 46. The SEM are shown.
The data was insufficient to propose the involvement o f saturatable carriers, and hence 
estimates for the Km and Vmax o f the malaria transporter could not be accurately 
determined. More data points both at these concentrations and other concentrations 
would be required in order to calculate these constants. Released parasite studies 
could confirm the estimates obtained by this method.
Since the discovery o f the parasitophorous duct (Pouvelle et al, 1991) the function of 
the malaria induced pores has become unclear. Our work shows that the pore is not 
important in the transport o f glucose, which it transports relatively inefficiently. It has 
been suggested that the pore has specificity for small negatively charged molecules 
(Kirk et al, 1992b) like lactate (Kanaani and Ginsburg, 1991; Cramner and Halstrap, 
1993). However, with the discovery o f the duct it is clear that the parasite has direct
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access to the periplasm and that transporters of these molecules are not required in the 
red blood cell membrane.
Treatment of normal red blood cells with the oxidising agent diamide has been shown 
to induce pores in the red blood cell membrane that have similar properties to those 
found in malaria-infected cells (Deuticke et al, 1983). Diamide cross-links spectrin, 
produces pores of diameter -6.5A, and allows the entry of molecules smaller than 
sucrose (Deuticke et al, 1983). Diamide induced pores do not increase the rate of D- 
glucose transport into uninfected human erythrocytes and it appears that the uptake is 
equally sensitive to cytochalasin B whether or not the cells are treated with diamide 
(Gero etal, 1991).
It has been suggested (Moulder, 1962) that in the course of evolution, the malarial 
parasite has lost many of the specific transporters in its plasma membrane. Moulder 
goes on to suggest that the parasite loses its specificity and becomes permeable to 'all 
sorts' of molecules. This suggestion has also been made by Sherman (1979) who 
suggested that the difficulty associated with obtaining released parasites that were not 
leaky was due to an inherent leakiness of plasmodial cells. If this were so, it would 
appear that some D-glucose would gain direct entry into the parasite, travelling down 
the duct and into the parasite through its leaky membrane. The mechanism of leakage 
may have been recently elucidated (Desai et al, 1993). These workers have studied a 
pore found in the parasitophorous vacuolar membrane of malaria-infected erythrocytes. 
They have suggested that these pores must exist in one of two configurations. In the 
first, the pore only spans the PVM; in the second, the pore has properties similar to a 
gap junction and joins both the PVM and the parasite's plasma membrane (Desai et al, 
1993). If the second configuration is closer to the truth it would explain the leakage 
from malarial parasites. However, there is also some evidence against this hypothesis. 
First, inhibition data on freed parasites suggests that 6-deoxy-D-glucose uptake is 
inhibited by the glucose transporter specific cytochalasin B, albeit weakly. If the cells 
were leaky the effects of cytochalasin B on released parasites would have to be non­
specific. A second piece of evidence is the different ion concentration in the parasite 
and the erythrocyte (Tanabe et al, 1983; Nillni et al, 1985). The pore in the PVM has
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been reported to be an efficient mediator of both cation and anion flux (Desai et al, 
1993). If the pore spans both these membranes it would be difficult to envisage a 
mechanism by which these different ion concentrations could be maintained. An 
increased leak of potassium ions from malaria infected red blood cells has been 
reported (Kirk et al, 1992a).
Other useful experiments in this area could be performed using P. yoelii-mfected 
mouse erythrocytes. Unlike their human counterparts, mouse erythrocytes have a low 
basal glucose transport rate. This may partly explain the increased rate of transport of 
2-deoxy-D-glucose into P. yoelii-infected erythrocytes when compared to uninfected 
control cells observed by Izumo et al (1989). Our results showed similar accumulation 
characteristics when the experiment was performed at 4°C, but using human cells the 
initial transport rate was unaltered by a malarial parasite. Experiments using 6-deoxy- 
D-glucose and P. yoe/zz-infected mouse erythrocytes would allow the malaria induced 
pathways (the pore and the duct) to be studied in more detail because the transport 
would be unlikely to be masked by the host's transport system.
The following conclusions on glucose transport into P. falciparum-infected red blood 
cells may be drawn from the present work.
•  Incubation of the cells at 4°C before the experiment lowers the transport rate.
•  The results of 2-deoxy-D-glucose uptake depends on the pre-incubation 
temperature.
•  L-glucose is transported into uninfected cells through the host's transporter.
•  Most L-glucose is transported into infected cells through the malaria induced pore.
Some enters through the host's transporter.
•  Most L-glucose leaves infected cells through the malaria induced pore.
155
Chapter 4. Glucose Transport Kinetics
•  The majority of 6-deoxy-D-glucose enters the infected cell through the host's 
native transporter. Some enters through the malaria induced pore and some may 
enter through the parasitophorous duct.
•  It is unlikely that the parasite modifies the host's native glucose transporter.
•  6-deoxy-D-glucose is transported into the cell at the same rate in infected and 
uninfected cells.
•  Glucose is not actively transported either into the erythrocyte or the parasite.
•  The parasite transporter is sensitive to cytochalasin B but is not inhibited to the 
same extent as the host's transporter.
•  The efflux of 6-deoxy-D-glucose from uninfected cells is faster than from infected 
cells. Cytochalasin B is a good inhibitor of efflux from both cell types.
•  The efflux of 6-deoxy-D-glucose from uninfected cells is first order. The efflux 
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Appendixl. Glucose Transporter Alignment
Appendix 1. Alignment of Glucose Transporters from
Various Species
HUMGLUTl Human GLUT1 - ATHALIANA Arabidopsis glucose
Erythrocyte type transporter - higher plant
RATGLUTl Rat GLUT1 - Erythrocyte CKESS_GLUT Chlorella - Glucose/H+
type transporter
MUSGLUT1 Mouse GLUT1 - SYNECHOCYS Synechocystis glucose
Erythrocyte type transporter
RABGLUT1 Rabbit GLUT1 - SCERESNF3 Yeast high affinity (SNF3)
Erythrocyte type glucose transporter
PIGGLUTl Pig GLUT1 - Erythrocyte Z_MOB_GLUT Zymomonas mobilis glucose
type transporter
HUMGLUT2 Human GLUT2 - Liver ECOARAB/H+ E. coli Arabidopsis/H+
type transporter
RATGLUT2 Rat GLUT2 - Liver type ECOXYLO/H+ E. coli xylose/H+ transporter
MUSGLUT2 Mouse GLUT2 - Liver type SCERE GAL2 Yeast galactose transporter
HUMGLUT3 Human GLUT3 - Brain KLACTRAG1 Kluyveromyces glucose
type transporter
HUMGLUT4 Human GLUT4 - Insulin KLACT_LACP Kluyveromyces lactose
regulatable permease
RATGLUT4 Rat GLUT4 - Insulin LENRIGLUT Leishmania glucose
regulatable transporter
MUSGLUT4 Mouse GLUT4 - Insulin NCRASSQTR Neurospora quinate
regulatable transporter
HUMGLUT5 Human GLUT5 - Fructose ANIGQPERM Aspergillus quinate
transporter transporter
H U M G L U T l
R A T G L U T l
M U S G L U T 1
R A B G L U T 1
P I G G L U T l
H U M G L U T 2
R A T G L U T 2
M U S G L U T 2
H U M G L U T 3
H U M G L U T 4
R A T G L U T 4
M U S G L U T 4
H U M G L U T 5
A _ T H A L I A N A
C K E S S _ G L U T
S Y N E C H O C Y S
S C E R E _ S N F 3
Z _ M O B _ G  L U T
E C O A R A B / H +
E C O X Y L O / H +
S C E R E _ G A L 2
K L A C T _ R A G l
K L A C T _ L A C P
L E N R I _ G L U T
N _ C R A S S Q T R
A _ N I G Q P E R M
1 . . . . .
M D P N S N S S S E T L R Q E K Q G F L D K A L Q R V K G I A L R R N N S N K D H T T D D T T G S I R T P T S L Q R Q N
------------------------------------------------------------------------------------M A V E E N N V P W S Q Q P Q A G E D V I S S L S K D S H L
----------------------------------------------------------------------------------------------------------- M S N Q M T D S T S A G S G T E H S V D T N T
--------------------------------------------------------------------------------- M A D H S S S S S S L Q K K P I N T I E H K D T L G N D R D H K
------------------------------------------------------------------------------------------------------------------------------------------------------------------- m s d r
1 7 7
Appendixl. Glucose Transporter Alignment
/ / / / / / / / / / M l / / / / / / / / /  
6 1  . . . . .
H U M G L U T l  :  M E P S S K K L T G R L -------- M L A V G G A V L  -  G  S L Q F G  Y N T G V
R A T G L U T l  :  M E P S S K K V T G R L -------- M L A V G G A V L - G S L Q F G Y N T G V
M U S G L U T 1  :  M D P S S K K V T G R L -------- M L A V G G A V L - G S L Q F G Y N T G V
R A B G L U T 1  :  M E P S S K K V T G R L ---------M L A V G G A V L - G S L Q F G Y N T G V
P I G G L U T l  : ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
H U M G L U T 2  :  M T E D K V T G T L -------- V F T V I T A V L - G S F Q F G Y D I G V
R A T G L U T 2  :  M S E D K I T G T L -------- A F T V F T A V L - G S F Q F G Y D I G V
M U S G L U T 2  :  M S E D K I T G T L -------- A F T V F T A V L  -  S S F Q F G  Y D I G  V
H U M G L U T 3  :  M G T Q K V T P A L ---------I F A I T V A T I - G S F Q F G Y N T G V
H U M G L U T 4  :  M P S G F Q Q I G S E D G E P P Q Q R V T G T L -------- V L A V F S A V L - G S L Q F G Y N I G V
R A T G L U T 4  :  M P S G F Q Q I G S E D G E P P Q Q R V T G T L -------- V L A V F S A V L - G S L Q F G Y N I G V
M U S G L U T 4  :  M P S G F Q Q I G S D V K D G E P P R Q R V T G T L -------- V L A V F S A V L - G S L Q F G Y N I G V
H U M G L U T 5  :  M E Q Q D Q S M K E G R L T L V L -------- A L A T L I A A F G S S F Q Y G Y N V A A
A _ T H A L  I  A N A :  M P A G G F W G D G Q K A Y P G K L T P F V L F T C W A A M G G L I F G Y D I G I
C K E S S _ G L U T :  M A G G G W W S G R G L S T G D Y R G G L T V Y W M V A F M A A C G G L L L G Y D N G V
S Y N E C H O C Y S : --------------------------------------------------------- M N P S S S P S Q S T A N V K F  V L L I S G V A A L G G F L F G F D T A V
S C E R E _ S N F 3 : S D R Q S N M T S V F T D D I S T I D D N S I L F S E P P Q K Q S M M M  S I C V G V F V A V G G F L F G Y D T G L
Z _ M O B _ G  L U T : ---------------------------------------------------------------------------M S S E S S Q G L -----------V T R L A L I A A I G G L L F G Y D S A V
E C O A R A B / H +  :  M V T I N T E S A L T P R S L R D T R R M -------- N M F V S V A A A V A G L L F G L D I G V
E C O X Y L O  / H  +  :  M N T Q Y N S S Y ---------I F S I T L V A T L G G L L F G Y D T A V
S C E R E _ G A L 2 : S A Q S Q K Y S N D E L K A G E S G P E G S Q S V P I E I P K K P M S E Y V T V S L L C L C V R F G G F M F G W D T S T
K L A C T _ R A G 1 : A L K A G S P N D L K V S H E E D L N D L E K T A E E T L Q Q K P A K E Y I F V S L C C V M V A F G G F V F G W D T G T
K L A C T _ L A C P : E A L N S D N D N T S G L K I N G V P I E D A R E E V L L P G Y L S K Q Y Y K L Y G L C F I T Y L C A T M Q G Y D G A L
L E N R I _ G L U T : V E V N E R R S D S V S E K E P A R D D A R K D V T D D Q E D A P P F M T A N N A R V M L V Q A I G G S L N G Y S I G F
N _ C R A S S Q T R : -----------------------------------------------------M T L L A L K E D R P T P K A V Y N W R V Y T C A A I A S F A S C M I G Y D S A F
A _ N I G Q P E R M : -----------------------------------------------------M S I  L A L V E D R P T P R E V Y N W R V Y L L A A V A S F T S C M I G  Y D S A F
H U M G L U T l
R A T G L U T l
M U S G L U T l
R A B G L U T l
P I G G L U T l
H U M G L U T 2
R A T G L U T 2
M U S G L U T 2
H U M G L U T 3
H U M G L U T 4
R A T G L U T 4
M U S G L U T 4
H U M G L U T 5
A _ T H A L I A N A
C K E S S _ G L U T
S Y N E C H O C Y S
S C E R E _ S N F 3
Z _ M O B _ G  L U T
E C O A R A B / H +
E C O X Y L O / H +
S C E R E _ G A L 2
K L A C T _ R A G 1
K L A C T _ L A C P
L E N R I _ G L U T
N _ C R A S S Q T R
A _ N I G Q P E R M
-V H R Y -  
-N H R Y -  
-N H R Y -  
- I H R Y -  
- L H R Y -
/
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I N A P Q K V ----------I E E F Y N Q T W -----------
I N A P Q K V ----------I E E F Y N Q T W -----------
I N A P Q K V ----------I E E F Y N Q T W -----------
I N A P Q K V ----------I E E F Y N Q T W -----------
---------------------------------- E F Y N Q T W -------------
I N A P Q Q V  I I S H Y R H V L G V P L D D R K A I N N Y V I N S T D E L P T I S Y S M N P K P T P W ----------------
I N A P Q E V  I I S H Y R H V L G V P L D D R R A T I N Y D I N G T D T P L I V T P A H T T P D A W -------------------
I N A P Q E V  1 I S H Y R H V L G V P L D D R K A A I N Y D V N G T D T P L T V T P A Y T T P A P W -------------------
I N A P E K I ---------- I K E F I N K T L -----------------------T D K ------------------------------------------------------------------------------------
I N A P Q K V ---------- I E Q S Y N E T W -----------------------L G R Q G P ---------------------------------------------------------------------------
I N A P Q K V ----------I E Q S Y N A T W -----------------------L G R Q G P ----------------------------------------------------------------------------
I N A P Q K V ----------I E Q S Y N A T W -----------------------L G R Q G P ---------------------------------------------------------------------------
V N S P A L L ----------M Q Q F Y N E T Y -----------------------Y G R ------------------------------------------------------------------------------------
S G G V T S M P S F L K R F F P S V Y ----------------------R K Q Q E G ------------------------------------------------------------------------------
T G G W S L E A -  F E K F F P D V W A K K Q E -------------------------------------------------------------------------------------------------------
I N G A V A A  L Q K H F Q -------------------------------------------------------------------------------------------------------------------------------
I N S I T S M ---------------- N Y V K S -------------------------------------------------------------------------------------------------------------------------
I A A I G T P  V D I H F I -------------------------------------------------------------------------------------------------------------------------------
I A G A L P F  I T D H F ----------------------------------------------------------------------------------------------------------------------------------
I S G T V E S  L N T V F V -------------------------------------------------------------------------------------------------------------------------------
I S G F V ---------------L Q T D F L R R F G ------------------------------------------------------------------------------------------------------------------
I S G F V N ------------- Q T D F L R R F G -------------------------------------------------------------------------------------------------------------------
M G S I Y T ---------------E D A Y L K Y Y ---------------------------------------------------------------------------------------------------------------------
V G V Y S T L F G Y S T N C A S F L Q E N S C T T V P N A D C K W F V S P T G S S Y C G W P E V T C R K E Y A Y S S P A
I G T T L A L --------------P S F T K E F ----------------------------------------------------------------------------------------------------------------------
I G T T L S L ------------- Q S F Q N E F ----------------------------------------------------------------------------------------------------------------------
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Appendixl. Glucose Transporter Alignment
/ / / / / / / / m i / / / / / / / / / /  
1 8 1  . . . . .
H U M G L U T l  : ------------------------------------------------------------G E S I L P T T L T T - L W S L S V A I F S V G G M I G S F S V G L F V N R F
R A T G L U T l  : ------------------------------------------------------------G E S I P S T T L T T - L W S L S V A I F S V G G M I G S F S V G L F V N R F
M U S G L U T 1  : ------------------------------------------------------------G E P I P S T T L T T - L W S L S V A I F S V G G M I G S F S V G L F V N R F
R A B G L U T 1  : ------------------------------------------------------------G E R I L P T T L T T - L W S L S V A I F S V G G M I G S F S V G L F V N R F
P I G G L U T l  : ------------------------------------------------------------G E S I S P A T L T T - L W S L S V A I F S V G G M I G S F S V G L F V N R F
H U M G L U T 2  : ------------------------------------------------------ A E E E T V A A A Q L I T M L W S L S V S S F A V G G M T A S F F G G W L G D T L
R A T G L U T 2  : ---------------------------------------------------------E E E T E G S A H I V T M L W S L S V S S F A V G G M V A S F F G G W L G D K L
M U S G L U T 2  : ------------------------------------------------------ D E E E T E G S A H I V T M L W S L S V S S F A V D G M V A S F F G G W L G D K L
H U M G L U T 3  : ------------------------------------------------------------ G N A P P S E V L L T S L W S L S V A I F S V G G M I G S F S V G L F V N R F
H U M G L U T 4  : --------------------------------------------------------- E G P S S I P P G T L T T L W A L S V A I F S V G G M I S S F L I G I I S Q W L
R A T G L U T 4  : --------------------------------------------------------- G G P D S I P Q G T L T T L W A L S V A I F S V G G M I S S F L I G I I S Q W L
M U S G L U T 4  : --------------------------------------------------------- G G P D S I P Q G T L T T L W A L S V A I F S V G G M I S S F L I G I I S Q W L
H U M G L U T 5  : ------------------------------------------------------------ T Q E F M E D F P L T L L W S V T V S M F P F G G F I G S L L V G P L V N K F
A _ T H A L I A N A : --------------------------------------------------------- A S T N Q Y C Q Y D S P T L - T M F T S S L Y L A A L I S S L V A S T V T R K F
C K E S S _ G L U T : --------------------------------------------------------- V H E D S P Y C T Y D N A K L Q L F V S S L F L A G L V S C L F A S W I T R N M
S Y N E C H O C Y S : -------------------------------------------------------------------------- T D S L L T --------G L S V S L A L L G S A L G A F G A G P I A D R H
S C E R E _ S N F 3 : ------------------------------------------------------------ H V A P N H D S F T A Q Q M S I L V S F L S L G T F F G A L T A P F I S D S Y
Z _ M O B _ G L U T : ------------------------------------------------------------ A P R H L S A T A A A S L S G M V W A V L V G C V T G S L L S G W I G I R F
E C O A R A B / H + : -------------------------------------------------------------------------------- V L T S R L Q E W W S S M M L G A A I G A L F N G W L S F R L
E C O X Y L O / H + : ------------------------------------------------------------A P Q N L S E S A A N S L L G F C V A S A L I G C I I G G A L G G Y C S N R F
S C E R E _ G A L 2 : --------------------------------------------------------- M K H K D G T H Y L S N V R T G L I V A I F N I G C A F G G I I L S K G G D M Y
K L A C T _ R A G 1 : --------------------------------------------------------- Q E K A D G S H Y L S N V R T G L I V S I F N I G C A V G G I V L S N I G D R W
K L A C T _ L A C P : ------------------------------------------------------------------------H L D I N S S S G T G L V F S I F N V G Q I C G A F F V P L M D - W K
L E N R I _ G L U T : E M P G A L A R C E A D S R C R W S Y S D E E C Q N P S G Y S S S E S G I F A G S M I A G C L I G S V F A G P L A S K -
N _ C R A S S Q T R : ------------------------------------------------------------D F A S Y T P G A L A L L Q S N I V S V Y Q A G A F F G C L F A Y A T S Y F L
A _ N I G Q P E R M : ---------------------------------------------------------------------N W E S L N T D L I S A N I V S L Y Q R G A F F G A L F A Y P I G H F W
/ / / / / / / / / M 3 I I I  I I I  I I I /  / / / / M 4 / /
2 4 1  . . . . . .
H U M G L U T l  : - G R R N S M L M M N L L A F V S A V L M G F S K L G K S ------------------------- ---------------- F E M L I L G R F I I G V Y C G
R A T G L U T l  : - G R R N S M L M M N L L A F V S A V L M G F S K L G K S ------------------------- ---------------- F E M L I L G R F I I G V Y C G
M U S G L U T l  : - G R R N S M L M M N L L A F V A A V L M G F S K L G K S ------------------------- ---------------- F E M L J L G R F U G V Y C G
R A B G L U T 1  : - G R R N S M L M M N L L A F V S A V L M G F S K L A K S ------------------------- ---------------- F E M L J L G R F U G V Y C G
P I G G L U T l  : - G R R N S M L M M N L L A F I S A V L M G F S K L G K S ------------------------- ---------------- F E M L J L G R F U G V Y C G
H U M G L U T 2  : - G R I K A M L V A N I L S L V G A L L M G F S K L G P S ------------------------- ---------------- H I L I I A G R S I S G L Y C G
R A T G L U T 2  : - G R I K A M L A A N S L S L T G A L L M G C S K F G P A ------------------------- ---------------- H A L I I A G R S V S G L Y C G
M U S G L U T 2  : - G R I K A M L A A N S L S L T G A L L M G C S K F G P A ------------------------- ---------------- H A L I I A G R S V S G L Y C G
H U M G L U T 3  : - G R R N S M L I V N L L A V T G G C F M G L C K V A K S ------------------------- ---------------- V E M L I L G R L V I G L F C G
H U M G L U T 4  : -G R K R A M L V N N V L A V L G G S L M G L A N A A A S ------------------------- ---------------- Y E M L I L G R F L I G A Y S G
R A T G L U T 4  : - G R K R A M L A N N V L A V L G G A L M G L A N A A A S ------------------------- ---------------- Y E I L I L G R F L I G A Y S G
M U S G L U T 4  : - G R K R A M L A N N V L A V L G G A L M G L A N A V A S ------------------------- ---------------- Y E I L I L G R F L I G A Y S G
H U M G L U T 5  : -  G R K G  A L  L F N N I F S I  V P  A I L M G C  S R V A T S ------------------------- ---------------- F E L m S R L L V G I C A G
A _ T H A L I A N A : - G R R L S M L F G G I L F C A G A L I N G F A K H V W ---------------------------- ---------------------- M L I V G R I L L G F G I G
C K E S S _ G L U T : - G R K V T M G I G G A F F V A G G L V N A F A Q D M ------------------------------- ------------------- A M L I V G R V L L G F G V G
S Y N E C H O C Y S : - G R I K T M I L A A V L F T L S S I G S G L P F T I W D ------------------------- ---------------- F --------I F W R V L G G I G V G
S C E R E _ S N F 3 : - G R K P T I I F S T I F I F S I G N S L Q V G A G G ------------------------------ ---------------- I T L L I V g r v i s g i g i g
Z _ M O B _ G L U T : F G R R G G L L M S S I C F V A A G F G A A L T E K L F G T G G S A ---------- ---------------- L Q I F C F F R F L A G L G I G
E C O A R A B / H + : - G R K Y S L M A G A I L F V L G S I G S A F A T S V ------------------------------- ------------------- E M L ! A A R W L G I A V G
E C O X Y L O / H + : - G R R D S L K I A A V L F F I S G V G S A W P E L G F T S I N P D N T V P V Y L A G Y V P E F V I Y R I I G G I G V G
S C E R E _ G A L 2 : - G R K K G L S I W S V Y I V G I I I Q I A S I N K W ---------------------------- ---------------- Y Q Y F I - G R I I S G L G V G
K L A C T _ R A G l : - G R R I G L I T V I I I Y V I G I I I Q I A S V D K W Y ------------------------- ---------------------- Q Y F I G R I I S G L G V G
K L A C T _ L A C P : - G R K P A I L I G C  L G W I G A I  I S S L T T T K S A ------------------------- ------------------------- L I G G R W F V A F F A T
L E N R I _ G L U T : I G A R L S F L L V G L V G W A S V M Y H A S C A A ------------------------------- ---------- D E F W V L I V G R F V I G L F L G
N _ C R A S S Q T R : - G R R K S L I A F S W F I I G A A I M L A A D G Q G R G ---------------------- ---------------- I D P H A G R V L A G I G V G
A _ N I G Q P E R M : - G E R W G L M F S A L I F F L G A G M M L G A N G D R G ------------------------- ---------------- L G L I Y G G R V L A G I G V G
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Appendixl. Glucose Transporter Alignment
H U M G L U T l
R A T G L U T l
M U S G L U T l
R A B G L U T 1
P I G G L U T l
H U M G L U T 2
R A T G L U T 2
M U S G L U T 2
H U M G L U T 3
H U M G L U T 4
R A T G L U T 4
M U S G L U T 4
H U M G L U T 5
A _ T H A L I A N A
C K E S S _ G L U T
S Y N E C H O C Y S
S C E R E _ S N F 3
Z _ M O B _ G L U T
ECOARAB/H+
E C O X Y L O / H +
S C E R E _ G A L 2
K L A C T _ R A G 1
K L A C T _ L A C  P
L E N R I _ G L U T
N _ C R A S S Q T R
A _ N I G Q P E R M
/ / / / / M 4 / / / / / /  / / / / / / / / / / M 5 / / / / / / / / /
3 0 1  . . . . .
L T T G F V P M Y V G E V S P T A F R G A L G T L H Q L G I W G I L I A Q V F G L - D S I M — G N K D  L  
L T T G F V P M Y V G E V S P T A L R G  A L G T L H Q L G I W G I L I A Q V F G L  -  D S I M — G N A D  L  
L T T G F V P M Y V G E V S P T A L R G A L G T L H Q L G I W G I L I A Q V F G L - D S I M — G N A D  L  
L T T G F V P M Y V G E V S P T A L R G A L G T L H Q L G  I W G  I L I  A Q V F G L  -  D S  I M — G N E D  L  
L T T G F V P M Y V G E V S P T A L R G A L G T L H Q L G  I W G  I L I  A Q V F G L  -  D S I M — G N E E  L  
L I S G L V P M Y I G E I A P T A L R G A L G T F H Q L A I V T G I L I S Q I I G L - E F I L - - G N Y D  L -------
L I S G L V P M Y I G E I A P T T L R G A L G T L H Q L A L V T G I L I S Q I A G L - S F I L - - G N Q D  Y -------
L I S G L V P M Y I G E I A P T T L R G A L G T L H Q L A L V T G I L I S Q I A G L - S F I L - - G N Q D  H  
L C T G F V P M Y I G E I S P T A L R G A F G T L N Q L G I W G I L V A Q I F G L - E F I L - - G S E E  L -------
L T S G L V P M Y V G E I A P T H L R G A L G T L N Q L A I V I G I L I A Q V L G L - E S L L - - G T A S  L -------
L T S G L V P M Y V G E I A P T H L R G A L G T L N Q L A I V I G I L V A Q V L G L - E S M L - - G T A T  L -------
L T S G L V P M Y V G E I A P T H L R G A L G T L N R L A I V I G I L V A Q V L G L - E S M L - - G T A T  L --------
V S S N W P M Y L G E L A P K N L R G A L G W P Q L F I T V G I L V A Q I F G L - R N L L — A N V D  G  
F A N Q A V P L Y L S E M A P Y K Y R G A L N I G F Q L S I T I G I L V A E V L N Y - F F A K - - I K G G  W -------
L G S Q W P Q Y L S E V A P F S H R G M L N I G Y Q L F V T I G I L I A G L V N Y A V R D W E N G ----------------------------
A A S V I A P A Y I A E V S P A H L R G R L G S L Q Q L A I V S G I F I A L L S N W F I A L M A G G S A Q N P W L F G A
A I S A W P L Y Q A E A T H K S L R G A I I S T Y Q W A I T W G L L V S S A V S Q G T H A R N D A S S ----------------------
W S T L T P T Y I A E I R P P D K R G Q M V S G Q Q M A I V T G A L T G Y I F T W L L A H F G S I D W V  N A
I A S Y T A P L Y L S E M A S E N V R G K M I S M Y Q L M V T L G I V L A F L S D T A F S Y S - - G N -------------------------
L A S M L S P M Y I A E L A P A H I R G K L V S F N Q F A I I F G Q L L V Y C V N Y F I A R S - - G D A S  W L N T
G I A V L C P M L I S E I A P K H L R G T L V S C Y Q L M I T A G I F L G Y C T N Y G T K S Y S N S V Q ----------------------
G I T V L S P M L I S E T A P K H L R G T L V S C Y Q L M I T F G I F L G Y C T N Y G T K N Y S N S V Q ----------------------
I A N A A A P T Y C A E V A P A H L R G K V A G L Y N T L W S V G S I V A A F S T Y G T N K N F P N S S K -------------------
V I C V A C P V Y T D Q N A H P K W K R T I G V M F Q V F T T L G I F V A A L M G L A L G Q S I R F D H D G D Q K V M A
G A S N M V P I Y I S E L A P P A V R G R L V G I Y E L G W Q I G G L V G F W I N Y G V N T T M A P T R S -------------------
A G S N I C P I Y I S E M A P S A I R G R L V G V Y E L G W Q I G G W G F W I N Y G V D E T L A P S H K -------------------
3 6 1
H U M G L U T l
R A T G L U T l
M U S G L U T l
R A B G L U T 1
P I G G L U T l
H U M G L U T 2
R A T G L U T 2
M U S G L U T 2
H U M G L U T 3
H U M G L U T 4
R A T G L U T 4
M U S G L U T 4
H U M G L U T 5
A _ T H A L I A N A
C K E S S _ G L U T
SYNECHOCYS
S C E R E _ S N F 3
Z _ M O B _ G L U T
E C O A R A B / H +
ECOXYLO/H+
S C E R E _ G A L 2
K L A C T _ R A G 1
K L A C T _ L A C P
L E N R I _ G L U T
N _ C R A S S Q T R
A _ N I G Q P E R M
- - W P L L L S I I F I P A L L Q C I V L P F C P E S P R F L L - I N R N E E N R A K S V - - L K K L R G T A D - V T H  
- - W P L L L S V I F I P A L L Q C I L L P F C P E S P R F L L - I N R N E E N R A K S V - - L K K L R G T A D - V T R  
- - W P L L L S V I F I P A L L Q C I L L P F C P E S P R F L L - I N R N E E N R A K S V — L K K L R G T A D - V T R  
— W P L L L S V I F V P A L L Q C I V L P L C P E S P R F L L - I N R N E E N R A K S V — L K K L R G N A D - V T R  
- - W P L L L S V I F I P A L L Q C V L L P F C P E S P R F L L - I N R N E E N R A K S V - - L K K L R G T A D - V T R  
- - W H I L L G L S G V R A I L Q S L L L F F C P E S P R Y L Y - I K L D E E V K A K Q S - - L K R L R G Y D D - V T K  
- - W H I L L G L S A V P A L L Q C L L L L F C P E S P R Y L Y - L N L E E E V R A K K S - - L K R L R G T E D - I T K  
- - W H I L L G L S A V P A L L Q C L L L L F C P E S P R Y L Y - I K L E E E V R A K K S - - L K R L R G T E D - V T K  
— W P L L L G F T I L P A I L Q S A A L P F C P E S P R F L L - I N R K E E E N A K Q I — L Q R L W G T Q D - V S Q  
- - W P L L L G L T V L P A L L Q L V L L P F C P E S P R Y L Y - I I Q N L E G P A R K S - - L K R L T G W A D - V S G  
— W P L L L A I T V L P A L L Q L L L L P F C P E S P R Y L Y - I I R N L E G P A R K S — L K R L T G W A D - V S D  
- - W P L L L A L T V L P A L L Q L I L L P F C P E S P R Y L Y - I I R N L E G P A R K S - - L K P L T G W A D - V S D  
- - W P I L L G L T G V P A A L Q L L L L P F F P E S P R Y L L - I Q K K D E A A A K K A - - L Q T L R G W D S - V D R  
- G W R L S L G G A W P A L I I T I G S L V L P D T P N S M -  -  I E R G Q H E E A K T K -  - L R R I R G V D D - V S Q  
- - W R L S L G L A A A P G A I L F L G S L V L P E S P N F L - - V E K G K T E K G R E V - - L Q K L R G T S E V D A E  
A A W R W M F W T E L I P A L L Y G V C A F L I P E S P R Y L - - V A Q G Q G E K A A A I - - L W K V E G - G D - V P S  
- - Y R I P I G L Q Y V W S S F L A I G M F F L P E S P R Y Y V - L K D K L D E A A K S L S F L R G V P V H D S G L L E  
S G W C W S P A S E G L I G I A F L L L L L T A P D T P H W L - - V M K G R H S E A S K I - - L A R L E P Q A D - P N L  
-  -  W R A M L G V L A L P A V L L I I L W F L P N S P R W L - - A E K G R H I E A E E V — L R M L R D T S E - K A R  
D G W R Y M F A S E C I P A L L F L M L L Y T V P E S P R W L - - M S R G K Q E Q A E G I — L R K I M G N T L - A T Q  
- - W R V P L G L C F A W S L F M I G A L T L V P E S P R Y L C - E V N K V E D A K R S I A K S N K V S P E D P A V Q A  
- - W R V P L G L C F A W A I F M V L G M M F V P E S A R F L V - E T D Q I E E A R K S L A K T N K V S I D D P W K Y  
- A F K I P L Y L Q M M F P G L V C I F G W L I P E S P R W L V G V G R E E E A R E F I I K Y H L N G D R T H P L L D M
R M Q G L C V F S T L F S L L T W L G I V T - R E S R A K F D G G E E G R A E L N P S E Y G Y V E M I P R ----------------
- Q W L I P F A V Q L I P A G L L F L G S F W I P E S P R W L Y - A N G K R E E A M K V L C W I R N L E P T D R Y I V Q
- Q W I I P F A V Q L I P A G L L I I G A L L I R E S P R W L F - L R G N R E K G I E T L A W I R N L P A D H I Y M V E
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Appendixl. Glucose Transporter Alignment
/ / / / / / / / / / M 7 / / / / / / / / /
421
H U M G L U T l  : D L Q E M K E E S R Q M M R E K K V T I L E L F -----------R S P A Y R Q P I L I A W L Q L S Q Q L S G I N A V F Y Y S T
R A T G L U T l  : D L Q E M K E E G R Q M M R E K K V T I L E L F -----------R S P A Y R Q P I L I A W L Q L S Q Q L S G I N A V F Y Y S T
M U S G L U T l  : D L Q E M K E E G R Q M M R E K K V T I L E L F -----------R S P A Y R Q P I L I A W L Q L S Q Q L S G I N A V F Y Y S T
R A B G L U T l  : D L Q E M K E E S R Q M M R E K K V T I L E L F -----------R S P A Y R Q P I L S A W L Q L S Q Q L S G I N A V F Y Y S T
P I G G L U T l  : D L Q E M K E E S R Q M M R E K K V T I L E L F -----------R S A A Y R Q P I L I A W L Q L S Q Q L S G I N A V F Y Y S T
H U M G L U T 2  : D I N E M R K E R E E A S S E Q K V S I I Q L F -----------T N S S Y R Q P I L V A L M L H V A Q Q F S G I N G I F Y Y S T
R A T G L U T 2  : D I N E M R K E K E E A S T E Q K V S V I Q L F -----------T D P N Y R Q P I W A L M L H L A Q Q F S G I N G I F Y Y S T
M U S G L U T 2  : D I N E M K K E K E E A S T E Q K V S V I Q L F -----------T D A N Y R Q P I L V A L M L H M A Q Q F S G I N G I F Y Y S T
H U M G L U T 3  : D I Q E M K D E S A R M S Q E K Q V T V L E L F -----------R V S S Y R Q P I I I S I V L Q L S Q Q L S G I N A V F Y Y S T
H U M G L U T 4  : V L A E L K D E K R K L E R E R P L S L L Q L L -----------G S R T H R Q P L I I A W L Q L S Q Q L S G I N A V F Y Y S T
R A T G L U T 4  : A L A E L K D E K R K L E R E R P L S L L Q L L -----------G S R T H R Q P L I I A W L Q L S Q Q L S G I N A V F Y Y S T
M U S G L U T 4  : A L A E L K D E K R K L E R E R P M S L L Q L L -----------G S R T H R Q P L I I A W L Q L S Q Q L S G I N A V F Y Y S T
H U M G L U T 5  : E V A E I R Q E D E A E K A A G F I S V L K L F -----------R M R S L R W Q L L S I I V L M G G Q Q L S G V N A I Y Y Y A D
A _ T H A L I A N A : E F D D L V A A S K E S Q S I E H - P W R N L L  R - R K Y R P H L T M A V M I P F F Q Q L T G I N V I M F Y A P
C K E S S _ G L U T : F A D I V A A V E I A R P I T M R Q S W A S L F  T R R Y M P Q L L T S F V I Q F F Q Q F T G I N A I I F Y V P
S Y N E C H O C Y S : R I E E I - Q A T V S L D H K P R F S D L - L S  R R G G L L P I V W I G M G L S A L Q Q F V G I N V I F Y Y S S
S C E R E _ S N F 3 : E L V E I K A T Y D Y E A S F G S S N F I D C F I S S K S R P K Q T L R M F T G I A L Q A F Q Q F S G I N F I F Y Y G V
Z _ M O B _ G L U T : T I Q K I K A G F D K A M D K S S A G L F A F ---------------------------G I T W F A G V S V A A F Q Q L V G I N A V L Y Y A P
E C O A R A B / H + : E - - E L N E I R E S L K L K Q G G W A L - F K  I N R N V R R A V F L G M L L Q A M Q Q F T G M N I I M Y Y A P
E C O X Y L O / H +  : A V Q E I K H S L D H G R - - K T G G R L L M F -----------G V G V  1 V I G  V M L S I F Q Q F V G I N W L  Y Y A P
S C E R E _ G A L 2 : E L D L I M A G I E A E K L A G N A S W G E L F  S T K T K V F Q R L L M G V F V Q M F Q Q L T G N N Y F F Y Y G T
K L A C T _ R A G l : E L L K I Q S S I E L E K A A G N A S W G E L I  T G K P S M F R R T L M G I M I Q S L Q Q L T G D N Y F F Y Y G T
K L A C T _ L A C P : E M A E I I E S F H G T D L S N P L E M L D V R - S L F R T R S D R Y R A M L V I L M A W F G Q F S G N N V C S Y Y L P
L E N R I _ G L U T : -------------------------------------------------------------------------------------------------------- L L M G C  V M A G T L Q L T G I N A V M N Y A P
N _ C R A S S Q T R : E V S F I D A D L E R Y T R Q V G N G F W K P F - L S L K Q R K V Q W R F F L G G M L F F W Q N G S G I N A I N Y Y S P
A _ N I G Q P E R M : E I N M I E Q S L E Q Q R V K I G L G F W K P F K A A W T N K R I L Y R L F L G S M L F L W Q N G S G I N A I N Y Y S P
/ / / / / / / / / M 8 / / / / / / / / / / / / / / / / / / M 9 / / / /
4 8 1
H U M G L U T l  : S I F E K A G V  Q Q P V Y A T I G S G I V N T A F T W S L F V - V E R A G R R T L H L I G L A G M A G C A I L M
R A T G L U T l  : S I F E K A G V  Q Q P V Y A T I G S G I V N T A F T W S L F V - V E R A G R R T L H L I G L A G M A G C A V L M
M U S G L U T l  : S I F E K A G V  Q Q P V Y A T I G S G I V N T A F T W S L F V - V E R A G R R T L H L I G L A G M A G C A V L M
R A B G L U T l  : S I F E K A G V  Q Q P V Y A T I G S G I V N T A F T W S L F V - V E R A G R R T L H L I G L A G M A A C A V L M
P I G G L U T l  : S I F E K A G V  Q Q P V Y A T I G S G I V N T A F T W S L F V - V E R A G R R T L H L I G L A G M A G C A V L M
H U M G L U T 2  : S I F Q T A G I  S K P V Y A T I G V G A V N M V F T A V S V F L - V E K A G R R S L F L I G M S G M F V C A I F M
R A T G L U T 2  : S I F Q T A G I  S Q P V Y A T I G V G A I N M I F T A V S V L L - V E K A G R R T L F L A G M I G M F F C A V F M
M U S G L U T 2  : T I F Q T A G I  S Q P V Y A T I G V G A I N M I F T A V S V L L - V E K A G R R T L F L T G M I G M F F C T I F M
H U M G L U T 3  : G I F K D A G V  Q E P I Y A T I G A G W N T I F T W S L F L - V E R A G R R T L H M I G L G G M A F C S T L M
H U M G L U T 4  : S I F E T A G V  G Q P A Y A T I G A G W N T V F T L V S V L L - V E R A G R R T L H L L G L A G M C G C A I L M
R A T G L U T 4  : S I F E L A G V  E Q P A Y A T I G A G W N T V F T L V S V L L - V E R A G R R T L H L L G L A G M C G C A I L M
M U S G L U T 4  : S I F E S A G V  G Q P A Y A T I G A G W N T V F T L V S V L L - V E R A G R R T L H L L G L A G M C G C A I L M
H U M G L U T 5  : Q I Y L S A G V P E - E H V Q Y V T A G T G A V N W M T F C A V F V - V E L L G R R L L L L L G F S I C L I A C C V L
A _ T H A L  I  A N A : V L F N T I G F T T - D A S L M S A W T G S V N V G A T L V S I Y G - V D R W G R R F L F L E G G T Q M L I C Q A W
C K E S S _ G L U T : V L F S S L G S A N - S A A L L N T V W G A V N V G S T L I A V M F - S D K F G R R F L L I E G G I Q C C L A M L T T
S Y N E C H O C Y S : V L W R S V G F T E - E K S L L I T V I T G F I N I L T T I V A I A F - V D K F G R K P L L L M G S I G M T I T L G I L
S C E R E _ S N F 3  : N F F N K T G V  S N S Y L V S F I T Y A V N W F N V P G L F F - V E F F G R R K V L W G G V I M T I A N F I V
Z _ M O B _ G  L U T : Q M F Q N L G F G A - D T A L L Q T I S I G W N F I F T M I A S R V - V D R F G R K P L L I W G A L G M A A M M A V L
E C O A R A B / H + : R I F K M A G F T T T E Q Q M I A T L W G L T F M F A T F I A V F T - V D K A G R K P A L K I G F S V M A L G T L V L
E C O X Y L O / H + : E V F K T L G A S T - D I A L L Q T I I V G V I N L T F T V L A I M T - V D K F G R K P L Q I I G A L G M A I G M F S L
S C E R E _ G A L 2 : V I F K S V G L  D D S F E T S I V I G W N F A S T F F S L W T - V E N L G R R K C L L L G A A T M M A C M V I Y
K L A C T _ R A G l : T I F Q S V G M  D D S F E T S I V L G I V N F A S T F F A L Y T - V D H F G R R N C L L Y G C V G M V A C Y W Y
K L A C T _ L A C P : T M L R N V G M K S V S L N V L M N G V Y S I V T W I S S I C G A F F - I D K I G R R E G F L G S I S G A A L A L T G L
L E N R I _ G L U T : T I M G S L G L  A P L V G N F W M L W N F V T T L A S I P L S Y V F T M R H V F L F G S I F T S C M C L F M C
N _ C R A S S Q T R :  T V F R S I G I T G T D T G F L T T G I F G W K M V L T I I W L L W L V D L V G R R R I L F I G A A G G S L C M W F I
A _ N I G Q P E R M : R V F K S I G V S G G N T S L L T T G I F G W T A V I T F V W L L Y L I D H F G R R N L L L V G A A G G S V C L W I V
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Appendixl. Glucose Transporter Alignment
H U M G L U T l
R A T G L U T l
M U S G L U T l
R A B G L U T l
P I G G L U T l
H U M G L U T 2
R A T G L U T 2
M U S G L U T 2
H U M G L U T 3
H U M G L U T 4
R A T G L U T 4
M U S G L U T 4
H U M G L U T 5
A _ T H A L I A N A
C K E S S _ G L U T
S Y N E C H O C Y S
S C E R E _ S N F 3
Z _ M O B _ G L U T
E C O A R A B / H +
E C O X Y L O / H +
S C E R E _ G A L 2
K L A C T _ R A G 1
K L A C T _ L A C  P
L E N R I _ G L U T
N _ C R A S S Q T R
A _ N I G Q P E R M
6 0 1
H U M G L U T l  : A A I A V A G F S N W T S N F I V G M C F Q ---------- ------- Y V E Q L -------- ------- C G P Y V F I I F T V L L V L F F I F T
R A T G L U T l  : A A V A V A G F S N W T S N F I V G M C F Q ---------- ------- Y V E Q L -------- ------- C G P Y V F I I F T V L L V L F F I F T
M U S G L U T l  : A A I A V A G F S N W T S N F I V G M C F Q ---------- ------- Y V E Q L -------- ------- C G P Y V F I I F T V L L V L F F I F T
R A B G L U T l  : A A V A V A G F S N W T S N F I V G M C F Q ---------- ------- Y V E Q L -------- ------- C G P Y V F I I F T V L L V L F F I F T
P I G G L U T l  : A A I A V A G F S N W T S N F I V G M C F Q ---------- ------- Y V E Q L -------- ------- C G P Y V F I I F T V L L V L F F I F T
H U M G L U T 2  : A A L A I A A F S N W T C N F I V A L C F Q ---------- ------- Y I A D F -------- ------- C G P Y V F F L F A G V L L A F T L F T
R A T G L U T 2  : T A L A L A A F S N W V C N F I I A L C F Q ---------- ------- Y I A D F -------- ------- L G P Y V F F L F A G W L V F T L F T
M U S G L U T 2  : T A L A L A A F S N W V C N F V I A L C F Q ---------- ------- Y I A D F -------- ------- L G P Y V F F L F A G W L V F T L F T
H U M G L U T 3  : A A M A V A G C  S N W T S N F  L V G  L  L F  P ---------- ------- S A A H Y -------- ------- L G A Y V F I I F T G F L I T F L A F T
H U M G L U T 4  : A A M A V A G F S N W T S N F I I G M G F Q ---------- ------- Y V A E A -------- ------- M G P Y V F L L F A V L L L G F F I F T
R A T G L U T 4  : A A M A V A G F S N W T C N F I V G M G F Q ---------- ------- Y V A D A -------- ------- M G P Y V F L L F A V L L L G F F I F T
M U S G L U T 4  : A A M A V A G F S N W T C N F I V G M G F Q ---------- ------- Y V A D R -------- ------- M G P Y V F L L F A V L L L G F F I F T
H U M G L U T 5  : S A F M V G G S V H W L S N F T V G L I F P ---------- ------- F I Q E G -------- ------- L G P Y S F I V F A V I C L L T T I Y I
A _ T H A L I A N A : A A Q S I T V S V N M I F T F I I A Q I F L ---------- ------- T M L C H -------- ------- L K F G L F L V F A F F V W M S I F V
C K E S S _ G L U T : A G T A V A W G N F L F S F V I G Q A F V ---------- ------- S M L C A -------- ------- M E Y G V F L F F A G W L V I M V L C A
S Y N E C H O C Y S : A A L S V A A G V Q W I A N F I I S T T F P P ------- ------- L L D T V -------- ------- G L G P A Y G L Y A T S A A I S I F F I
S C E R E _ S N F 3 : K C T A I C A A A N W L V N F I C A L I T P ---------- ------- Y I V D T G S H T S S L G A K I F F I W G S L N A M G V I W
Z _ M O B _ G L U T : A A M P I A V T G Q W L A N I L V N F L F K V A D G S P A L N Q T F ------- ------- N H G F S Y L V F A A L S I L G G L I V
E C O A R A B / H + : F G I T C S T T T N W V S N M I I G A T F L T ------- ------- L L D S I -------- ------- G A A G T F W L Y T A L N I A F V G I T
E C O X Y L O / H + : K A L A I A V A A Q W L A N Y F V S W T F  P M M D K N S W L V A H F ------- ------- H N G F S Y W I Y G C M G V L A A L F M
S C E R E _ G A L 2 : K C M A L A S A S N W V W G F L I A F F T P ---------- ------- F I T S A -------- ------- IN F Y Y A Y V F M G C L V A M F F Y V
K L A C T _ R A G 1 : K A M A I A S A S N W I W G F L I G F F T P ---------- ------- F I T S A -------- ------- I H F Y Y G Y V F M G C M V F A F F Y V
K L A C T _ L A C P : K A Q L L N F W S G V A Q F V N Q F A T P ---------- ------- K A M K N -------- ------- I K Y W F Y V F Y V F F D I F E F I V I
L E N R I _ G L U T : R G A S F T Q V A Q F I F N L I I N V C Y P ---------- - I A T E S I S G G P S G N Q D K G Q A V A F I F F G G L G L I C F
N _ C R A S S Q T R : L G Q A S A A A N N W F W N F I I S R F T P ---------- ------- Q M F I K -------- ------- M E Y G V Y F F F A S L M L L S I V F I
A _ N I G Q P E R M : L A Q A C A A A S N W L W N F L I S R F T P ---------- ------- Q M F T S -------- ------- M G Y G V Y F F F A S L M I L S I V F V
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/ / M 9 / / /  1 1 1 1 1 1 1 1 / M 1 0 / / / / / / / / /
5 4 1  . . . . . .
T I A L A L L --------------------E - Q L P - - W M S Y L S I V A I F G F V A F F E V G P G P I P W F I V A E L F S Q G P R P
T I A L A L L --------------------E - Q L P - - W M S Y L S I V A I F G F V A F F E V G P G P I P W F I V A E L F S Q G P R P
T I A L A L L --------------------E - R L P - - W M S Y L S I V A I F G F V A F F E V G P G P I P W F I V A E L F S Q G P R P
T I A L A L L --------------------E - Q L P - - W M S Y L S I V A I F G F V A F F E V G P G P I P W F I V A E L F S Q G P R P
T I A L A L L --------------------E - Q L P — W M S Y L S I V A I F G F V A F F E V G P G P I P W F I V A E L F S Q G P R P
S V G L V L L ------------------- N - K F S — W M S Y V S M I A I F L F V S F F E I G P G P I P W F M V A E F F S Q G P R P
S L G L V L L --------------------D - K F T - - W M S Y V S M T A I F L F V S F F E I G P G P I P W F M V A E F F S Q G P R P
S V G L V L L --------------------D - K F A — W M S Y V S M T A I F L F V S F F E I G P G P I P W F M V A E F F S Q G P R P
T V S L L L K --------------------D - N Y N — G M S F V C I G A I L V F V A F F E I G P G P I P W F I V A E L F S Q G P R P
T V A L L L L --------------------E - R V P - - A M S Y V S I V A I F G F V A F F E I G P G P I P W F I V A E L F S Q G P R P
T V A L L L L --------------------E - R V P - - S M S Y V S I V A I F G F V A F F E I G P G P I P W F I V A E L F S Q G P R P
T V A L L L L --------------------E - R V P - - A M S Y V S I V A I F G F V A F F E I G P G P I P W F - V A E L F S Q G P R P
T A A L A L Q --------------------D - T V S - - W M P Y I S I V C V I S Y V I G H A L G P S P I P A L L I T E I F L Q S S R P
A A C I G A K F G V D G T P G - E L P - K W Y A I V W T F I C I Y V A G F A W S W G P L G W L V P S E I F P L E I R S
G W L A I E F --------A K Y G T D P L P K A V A S G I L A V I C I F I S G F A W S W G P M G W L I P S E I F T L E T R P
S W F G G A T W N G - Q P - T L T - G A A G I I A L V T A N L Y V F S F G F S W G P I V W V L L G E M F N N K I R A
A I V G C S L ------------------- K - T V A --------A A K V M I A F I C L F I A A F S A T W G G W W V I S A E L Y P L G V R S
G C C F W F K ----------------------------------------V G G V L P L A S V L L Y I A V F G M S W G P V C W W L S E M F P S S I K G
G Y C L M Q F D --------------N G - T A S - S G L S W L S V G M T M M C I A G Y A M S A A P W W I L C S E I Q P L K C R D
G T A F Y T Q ----------------------------------------A P G I V A L L S M L F Y V A A F A M S W G P V C W V L L S E I F P N A I R G
A S V G V T R L Y P H G K S Q - P S S - K G A G N C M I V F T C F Y I F C Y A T T W A P V A W V I T A E S F P L R V K S
A S V G V T R L W P D G P D H P D I S S K G A G N C M I V F A C F Y I F C F A T T W A P I A Y W I S E S Y P L R V K G
S I C T A R Y --------------------E - K T K K K S A S N G A L V F I Y L F G G I F S F A F T P M Q S M Y S T E V S T N L T R S
G I P V Y P G ---------------------- V S K K L E A K N G V A I T G I L L F I L G F E V C V G P C Y Y V L T Q D M F P P S F R P
G A Y I K I A D P G S N K A E - D A K L T S G G I A A I F F F Y L W T A F Y T P S W N G T P W V I N S E M F D Q N T R S
G G Y I K I A K P E N N - P E - G T Q L D S G G I A A I F F F Y L W T A F Y T P S W N G T P W V I N S E M F D P T V R S
/ / / / / / / / M i l / / / / / / / / / /  / / / / / / / / M 1 2 / / / / / / / /
Appendixl. Glucose Transporter Alignment
II
661
H U M G L U T l  : Y F K V P E T K G R T F D E I A S G F - - R - - - Q G G A S ---------------------- - Q S D K T P E E L F H P L G A D S Q V - -
R A T G L U T l  : Y F K V P E T K G R T F D E I A S G F - - R - - - Q G G A S ---------------------- - Q S D K T P E E L F H P L G A D S Q V - -
M U S G L U T l  : Y F K V P E T K G R T F D E I A S G F - - R - - - Q G G A S ---------------------- - Q S D K T P E E L F H P L G A D S Q V - -
R A B G L U T l  : Y F K V P E T K G R T F D E I A S G F - - R - - - Q G G A S ---------------------- - Q S D K T P E E L F H P L G A D S Q V - -
P I G G L U T l  : Y F K V P E T K G R T F D E I A S G F - - R - — Q G G A S ---------------------- - Q S D K T P E E L F H P L G A D S Q V - -
H U M G L U T 2  : F F K V P E T K G K S F E E I A A E F - - Q - — K K S G S ---------------------- - A H R P K A A V E M K F L G A T E T V - -
R A T G L U T 2  : F F K V P E T K G K S F D E I A A E F - - R - - - K K S G S ----------------------- - A P P R K A T V Q M E F L G S S E T V - -
M U S G L U T 2  : F F K V P E T K G K S F E E I A A E F — R - — K K S G S ---------------------- - A P P R K A A V Q M E F L A S S E S V - -
H U M G L U T 3  : F F K V P E T R G R T F E D I T R A F E G Q - - - A H G A D ---------------------- - R S G K D G V M E M N S I E P A K E T T T
H U M G L U T 4  : F L R V P E T R G R T F D Q I S A A F H - R - - - T P S L L ----------------------- - E Q E V K P S T E L E Y L G P D E N D - -
R A T G L U T 4  : F L R V P E T R G R T F D Q I S A T F R - R - - - T P S L L ------------------------- E Q E V K P S T E L E Y L G P D E N D - -
M U S G L U T 4  : F L K V P E T R G R T F D Q I S A A F R - R - - - T P S L L ------------------------- E Q E V K P S T E L E Y L G P D E N D - -
H U M G L U T 5  : F L I V P E T K A K T F I E I N Q I F - - T - - - K M N K V -------------------------  S E V Y P E K E E L K E L P P V T S E Q -
A _ T H A L  I  A N A : Y I F L P E T K G I P I E E M G Q V W R S H W Y W S R F V E ----------------------- - D G E Y G N A L E M G K N S N Q A G T K H
C K E S S _ G L U T : I F L L P E T K G V P I E R V Q A L Y A R H W F W N R V M G P A A A E V I A E D E K R V A A A S A I I K E E E L S K A M
S Y N E C H O C Y S :
S C E R E _ S N F 3 : Y L T V Y E T K G L T L E E I D E L Y ---------- -  I K S S T G W S P K F N K D I R -------
Z _ M O B _ G L U T : A R F V P E T K G R S L D E I E E M W R S K -
E C O A R A B / H + :
E C O X Y L O / H + :
S C E R E _ G A L 2 : F F F V P E T K G L S L E E I Q E L W E E G V L P W K S E G W I P --------------- S S R R G N N Y D L E D L Q H D D K P W Y
K L A C T _ R A G 1 : Y F F V P E T K G L T L E E V N E M Y S E G V L P W K S S S W V P --------------- S S R R G A E Y D V D A L Q H D D K P W Y
K L A C T _ L A C P : Y F F F V E T K G R S L E E L E W F E A P N P R K A S V D Q A F L A Q V R A T L V Q R N D V R V A N A Q N L K E Q E P
L E N R I _ G L U T : V I Q V F F L H P W D E E R D G K K W A P A I G K K E L S E E S I G N R A E ------------------------------------------------------------
N _ C R A S S Q T R : Y F F L P V T K S I P L E A M D R L F E I K P V Q N A N K N L M A E L N F D R N P E R E E S S S L D D K D R V T Q T E N
A _ N I G Q P E R M : F F L I P E T K G V P L E S M E T L F D K K P V W H A H S Q L I R E L R E N E E A F R A D M G A S G K G G V T K E Y V E
H U M G L U T l
R A T G L U T l
M U S G L U T l
R A B G L U T l
P I G G L U T l
H U M G L U T 2
R A T G L U T 2
M U S G L U T 2
H U M G L U T 3
H U M G L U T 4
R A T G L U T 4
M U S G L U T 4
H U M G L U T 5
A _ T H A L I A N A
C K E S S _ G L U T
S Y N E C H O C Y S
S C E R E _ S N F 3
Z _ M O B _ G L U T
E C O A R A B / H +
E C O X Y L O / H +
S C E R E _ G A L 2
K L A C T _ R A G 1
K L A C T _ L A C  P
L E N R I _ G L U T
N _ C R A S S Q T R





K A M L E ----------------------------------
K A M L -------------------------------------




Appendix 2. Sequences o f cloned PCR products
Appendix 2. Sequences of Cloned PCR Products
Sequence of Product A.
F r o n t  o f  g e n e
P V G H L L T N T S A N H S  
E S P R Y F Q * A I F * Q T P Q P T I Q  
OLIGONUCLEOTIDE S S R P S F D K H L S Q P F K  
TGAAAGTCCTAGATATTTCCAGTAGGCCATCTTTTGACAAACACCTCAGCCAACCATTCA 
10 20 30 40 50 60
N K L L F * H L F * L C E L P Y * T * N  
T N F C F D T F F N Y A S F R I K P R I  
Q T F V L T P F L T M R A S V L N L E S  
AACAAAC TTTTGTTTTGACAC C TTTTTTAAC TATGCGAGC TTC CGTATTAAAC C TAGAAT 
70 80 90 100 110 120
L Y S E D P C Q * T Q P A L V L C F L P  
S T Q R T H V N K L S L L * S Y V S F H  
L L R G P M S  I N S A C S S L M F P S T  
CTCTACTCAGAGGACCCATGTCAATAAACTCAGCCTGCTCTAGTCTTATGTTTCCTTCCA 
130 140 150 160 170 180
P L S H T L K I H S H T Y  
P Y P T P L K S I P T H I  
L I  P H P * N P F P H I F  
CCCTTATCCCACACCCTTAAAATCCATTCCCACACATATT 
190 200 210
B a c k  o f  g e n e
H H F H P P H L V E S F V H *  I T * F I 
I T F I L P I L * K A L C T E S P N S L  
S L S S S P S C R K L C A L N H L I H *  
CATCACTTTCATCCTCCCCATCTTGTAGAAAGCTTTGTGCACTGAATCACCTAATTCATT 
10 20 30 40 50 60
K K I K G I S F F K F G I  * F Q P W V F  
R K S R A L A S L S S E Y S F N H G S S  
E N Q G H * L L * V R N I V S T M G L Q  
AAGAAAATCAAGGGCATTAGCTTCTTTAAGTTCGGAATATAGTTTCAACCATGGGTCTTC 
70 80 90 100 110 120
K I L * A P R R E R I W R G F N S  OLIGONUC 
K F S E L P G G R E S G E V S I V E R A  
N S L S S Q E G E N L E R F Q *
AAAATTC TC TGAGC TC C CAGGAGGGAGAGAATC TGGAGAGGTTTCAATAGTAGAAAGAGC 
130 140 150 160 170 180
-- MULTIPLE CLONING SITE-- 
R R T Smal Xbal
BamHI
TC GAAGAAC AACGGGGATC C TC TAGAGTCGAC C TGCAGGCA 
190 200 210 220
184
Appendix 2. Sequences o f cloned PCR products
Sequence of Product B
C o m p l e t e  S e q u e n c e .
H W T W I Q S M R Y  
Multiple OLIGONUCLEOTIDE I G H G S N L * D I
Cloning SiteE R A R R R T L D M D P I Y E I F  
AG AGGAGC C C CGAAAGAGC TCGAAGAAGAACATTGGACATGGATC CAATC TATGAGATAT 
10 20 30 40 50 60
S E Y H * E S F W R V C L H V H H V * F  
Q N I I R N H F G G C V C M S I M F S S  
R I  S L G I  I L E G V F A C P S C L V L  
TCAGAATATCATTAGGAATCATTTTGGAGGGTGTGTTTGCATGTCCATCATGTTTAGTTC 
75 90 105 120
Y I Q V P G H P N F S S W Q L C I V S L  
T S R S L D I Q I S V P G S C A L S V L  
H P G P W T S K F Q F L A A V H C Q S W  
TACATCCAGGTCCCTGGACATCCAAATTTCAGTTCCTGGCAGCTGTGCATTGTCAGTCTT 
135 150 165 180
G L L  * C L Q S Q V H H T L V D H S N  K 
G Y  S S V F N L K Y T T H W L T T P T S  
V T L V S S I S S T P H I G * P L Q Q A  
GGGTTACTCTAGTGTCTTCAATCTCAAGTACACCACACATTGGTTGACCACTCCAACAAG 
195 210 225 240
L * A N I A P A H L A D R L * V K G F V  
S E P T L P Q H I L Q T G C E * K V L C  
L S Q H C P S T S C R Q V V S K R F C V  
CTCTGAGCCAACATTGCCCCAGCACATCTTGCAGACAGGTTGTGAGTAAAAGGTTTTGTG 
255 270 285 300
S G F M S V P P M E V P Y L P L L A V L  
L G S C Q S H Q W K F L I F H Y * Q S S  
W V H V S P T N G S S L S S I T S S P H  
TCTGGGTTCATGTCAGTCCCACCAATGGAAGTTCCTTATCTTCCATTACTAGCAGTCCTC 
315 330 345 360
T R Y R A 
L G T E 




Appendix 2. Sequences o f cloned PCR products
Sequence of Product C.
F r o n t  o f  s e q u e n c e
BamHI E R A R R R T L Q A H T H K E S  
Smal C K H T H T K N H
 M C S   OLIGONUCLEOTIDE  A S T H T Q R I T
AGAGGATCCCCAGAAAGAGCACGAAGAAGAACATTGCAAGCACACACACACAAAGAATCA 
15 30 45 60
H Y N I L I S H I N * F C D G Q * N * Y  
T I I F *  * A T * I N S V M D N E T N I  
L * Y F D K P H K L I L * W T M K L I S  
CACTATAATATTTTGATAAGCCACATAAATTAATTCTGTGATGGACAATGAAACTAATAT 
75 90 105 120
H N H I  S * Y D S D V L  
I I T S V N M T A M F  
* S H Q L I  * Q R C S  
CATAATCACATCAGTTAATATGACAGCGATGTTCTT 
135 150
B a c k  o f  s e q u e n c e .
D * R V G Q E  P L G N K T T W Y L L H R  
T R E L D K S H L G T R P H G I C Y I G  
L E  S W T R A T W E Q D H M V F V T  * V 
GACTAGAGAGTTGGACAAGAGCCACTTGGGAACAAGACCACATGGTATTTGTTACATAGG 
15 30 45 60
F C  P R L R T P V I T V A E G S W L N I  
S V L D * E H Q L S Q W Q K A H G S T L  
L S  * T K N T S Y H S G R R L M A Q H C  
TTCTGTCCTAGACTAAGAACACCAGTTATCACAGTGGCAGAAGGCTCATGGCTCAACATT 
75 90 105 120
V L D R K H A V G A L L  
S L I E N M Q L E H C C  




Appendix 2. Sequences o f cloned PCR products
Sequence of Product D.
F r o n t  o f  g e n e
A R R R T F A I T R C G R L P Q C L M P
P S Q D A A G F R S A L C H  
OLIGONUCLEOTIDE H H K M R P A S A V P Y A T
GCACGTAGAAGAACATTTGCCATCACAAGATGCGGCCGGCTTCCGCAGTGCCTTATGCCA 
10 20 30 40 50 60
P K Q R T S C V Q E * C A P S H K P T L  
L N K E Q A V C K S N A R Q V I  S P P W  
* T K N K L C A R V M R A K S  * A H P G 
CCTAAACAAAGAACAAGCTGTGTGCAAGAGTAATGCGCGCCAAGTCATAAGCCCACCCTG 
70 80 90 100 110 120
G V S M R S W V S D Q S G V D T D A G V  
A C L  * D L G * A T S Q A W T P T R V Y  
R V Y E  I L G K R P V R R G H R R G C  I 
GGCGTGTCTATGAGATCTTGGGTAAGCGACCAGTCAGGCGTGGACACCGACGCGGGTGTA 
130 140 150 160 170 180
Y K Q R L  S E A L V F L  I N M Q  * R L A  
I S S A F L R H L S S S S I C N K D W L  
* A A P F * G T C L P H Q Y A I K I G C  
TATAAGCAGCGCCTTTCTGAGGCACTTGTCTTCCTCATCAATATGCAATAAAGATTGGCT 
190 200 210 220 230 240
A E D C V V C F C R R K R T D V T H T  
Q K T V S C A S A A G N A R T * H T L  
R R L C R V L L P Q E T H G R N T H -  
GCAGAAGACTGTGTCGTGTGCTTCTGCCGCAGGAAACGCACGGACGTAACACACACTG 
250 260 270 280 290
B a c k  o f  P r o d u c t
T S S F L S S D * R Q M S L C S H G C P  
H P L S C L L I R D R C H C V A M A V L  
I L F L V F * L E T D V T V *  P W L S  *
ACATC C TC TTTC TTGTC TTC TGATTAGAGACAGATGTCAC TGTGTAGC CATGGC TGTCC T 
10 20 30 40 50 60
R T C Y V D Q T S L E L T E I  S C L Y F  
E L A M *  I R L V L N S Q R S P A S T S  
N L L C R S D * S * T H R D L L P L L P  
AGAACTTGCTATGTAGATCAGACTAGTCTTGAACTCACAGAGATCTCCTGCCTCTACTTC 
70 80 90 100 110 120
P S N R V D N I Y Y H  I W L F P L F L F  
Q V I G L T I Y T T T Y G F F P S S S S  
K *  * G * Q Y  I L P H M A F  S P L  P L R  
C C AAGTAATAGGGTTGACAATATATAC TAC CACATATGGC TTTTTC C C C TC TTC C TC TTC 
130 140 150 160 170 180
A L L S L L S S S W Q T  
L S S P S F L L L G K H  --Multiple Cloning site--
187
Appendix 2. Sequences o f cloned PCR products
S P L P P F F F L A N M  
GC TC TC C TC TC C C TC C TTTC TTC TTC TTGGCAAACATGGGGATC CTC TAGAGTCGAC C TG 
190 200 210 220 230 240
188
Appendix 2. Sequences o f cloned PCR products
Sequence of Product E.
C o m p l e t e  s e q u e n c e
 Multiple cloning s i t e   V G R D L K * V G
W A G I * S R W V  
G Q G F E V G G  * 
TGC ATGC C TGC AGGTCGAC TC TAGAGGATC C C CGTGGGCAGGGATTTGAAGTAGGTGGGT 
15 30 45 60
E G G R V V I Q E T N P Y C H S E S Q M  
K E A E *  * Y R K L T H I A T V S L K W  
R R Q S S N T G N * P I L P Q * V S N G  
G AAGG AGGC AG AGTAGTAATAC AGG AAAC T AACC C AT ATTGC C AC AGTG AGTC TC AAATG 
75 90 105 120
D G W  S S D G K V W G P L L A F  I Q C  I 
M G G V A M E R C G G L S W L S S S A F  
W V E  * R W K G V G A S P G F H P V H L  
GATGGGTGGAGTAGCGATGGAAAGGTGTGGGGGCCTCTCCTGGCTTTCATCCAGTGCATT 
135 150 165 180
* R K E  * L K L T A C H A S  L C V L H L  
E G R S D * N S L H A M L H S V C C T W  
K E G V I E T H C M P C F T L C A A P G  
TGAAGGAAGGAGTGATTGAAACTCACTGCATGCCATGCTTCACTCTGTGTGCTGCACCTG 
195 210 225 240
A F P P M P V S P V S M L P C T I C K S  
P S H P C P Y H P F P C F H A R S A R V  
L P T H A R I T R F H A S M H D L Q E S  
GCCTTCCCACCCATGCCCGTATCACCCGTTTCCATGCTTCCATGCACGATCTGCAAGAGT 
255 270 285 300
L S F G L P T G P Q D P C A R Y S T K Q  
S P L G Y P Q A L R I  P V L D I  P Q N K  
L L W V T H R P S G S L C  * I F H K T S  
C TC TC C TTTGGGTTAC C C AC AGGC C C TCAGGATC C C TGTGC TAGATATTC CACAAAACAA 
315 330 345 360
A F P L S C M C L V * Y L C H L P C P W  
R S L F H A C A * F S I C V I C L A P G  
V P S F M H V P S L V S V S F A L P L A  
GCGTTC C C TC TTTCATGCATGTGC C TAGTTTAGTATC TGTGTCATTTGC C TTGC C C C TGG 
375 390 405 420
L * E P Q A H K E * F F F E S I R V T E  
F E S P R H I K N S S S S S L F G * P R  
L R A P G T * R I V L L R V Y S G N R  
CTTTGAGAGCCCCAGGCACATAAAGAATAGTTCTTCTTCGAGTCTATTCGGGTAACCGAG 
435 450 465 480
189
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Sequence of Product H - Human GLUT4
F r o n t  o f  s e q u e n c e
A S S R Q Q G * A S L P M P  
M. C. S. Q H L R D S R G R P A C L C H  
T S I F E T A G V G Q P A Y A T
TAGAGGATCCCCCGACCAGCATCTTCGAGACAGCAGGGGTAGGCCAGCCTGCCTATGCCA 
15 30 45 60
P * E L V W S T Q S S P W S R C C W W S
H R S W C G Q H S L H L G L G V V G G A
I G A G V V N T V F T L V S V L L V E R
CCATAGGAGCTGGTGTGGTCAACACAGTCTTCACCTTGGTCTCGGTGTTGTTGGTGGAGC 
75 90 105 120
G R G A D C H S W A W R A C V A
G G A R T V T P G P G G H V W L
A G R G L S L L G L A G M C G C
GGGCGGGGCGCGGACTGTCACTCCTGGGCCTGGCGGGCATGTGTGGCTGT 
135 150 165
B a c k  o f  S e q u e n c e
P D P Q P W L W L V S P I D E Q T S S L  
P T R S H G C G W F L Q S T S K L H H W  
R P A A M A V A G F S N R R A N F I  I G
CCCGACCCGCAGCCATGGCTGTGGCTGGTTTCTCCAATCGACGAGCAAACTTCATCATTG 
15 30 45 60
A W V  S S M L Q E L W A L L F L L F A V  
H G F P V C C R S Y G P Y S S F Y L R S  
M G F Q Y V A G A M G P T L P S  I C G P  
GCATGGGTTTCCAGTATGTTGCAGGAGCTATGGGCCCTACTCTTCCTTCTATTTGCGGTC 
75 90 105 120
L L L G F F I F T F L
S C W A S S S S P S *  OLIGO —
P A G L L H L H L L R V P E  
C TC C TGC TGGGC TTC TTCATC TTCAC C TTC TTAGAGTAC C TGAAAC 
135 150 165
190
Appendix 2. Sequences o f cloned PCR products
Sequence of Product I.
G R D L K * V G E G G R V V I Q E T N P  
A G I * S R W V K E A E  * * Y R K L T H 
Q G F E V G G * R R Q S S N T G N *  P I  
GGC AGGGATTTGAAGTAGGTGGGTGAAGGAGGCAGAGTAGTAATACAGGAAAC TAAC CCA 
15 30 45 60
Y C H S E L * M D G W R C D G K V W G L  
I A T V  S S K W M G G D A M E R C G A S  
L P Q  * A L N G W V E M R W K G V G P L  
TATTGC CACAGTGAGC TC TAAATGGATGGGTGGAGATGCGATGGAAAGGTGTGGGGC C TC 
75 90 105 120
S M L S S V H * R R S D * T H C M P C S  
P C F H Q C  I E G G V I E L T A C H A H  
H A F I S A L K E E * L N S L H A M L I  
TCCATGCTTTCATCAGTGCATTGAAGGAGGAGTGATTGAACTCACTGCATGCCATGCTCA 
135 150 165 180
S R V L H L P P T H A R P H Y G L P D F  
L V C C T C L P P M P V L T T D S L T S  
S C A A P A S H P C P S S L R T P * L P  
TCTCGTGTGCTGCACCTGCCTCCCACCCATGCCCGTCCTCACTACGGACTCCCTGACTTC 
195 210 225 240
P D S  I C K M S L L W V T H R P S G S L  
L T A S A R C L S F G L P T G P Q D P C  
* Q H L Q D V S P L G Y P Q A L R I P V  
CCTGACAGCATCTGCAAGATGTCTCTCCTTTGGGTTACCCACAGGCCCTCAGGATCCCTG 
255 270 285 300
C * I F H K T S V P S F M H V P V C  I C  
A R Y S T K Q A F P L S C M C L F V S V  
L D I P Q N K R S L F H A C A C L Y L C  
TGCTAGATATTCCACAAAACAAGCGTTCCCTCTTTCATGCATGTGCCTGTTTGTATCTGT 
315 330 345 360
V I C L A P G F E S P G  
* F A L P L A L R A Q A  
D L P C P W L * E P R  
GTGATTTGC C TTGC C C C TGGCTTTGAGAGC C CAGGC C 
375 390
G L G S Q S Q G Q G K S H R Y K Q A H A  
A W A L K A R G K A N H T D T N R H M H  
P G L S K P G A R Q I T Q I Q T G T C M  
GGCCTGGGCTCTCAAAGCCAGGGGCAAGGCAAATCACACAGATACAAACAGGCACATGCA 
15 30 45 60
* K R E R L F C G I S S T G I L R A C G  
E R G N A C F V E Y L A Q G S  * G P V G 
K E G T L V L W N I  * H R D P E G L W V  
TGAAAGAGGGAACGCTTGTTTTGTGGAATATCTAGCACAGGGATCCTGAGGGCCTGTGGG 
75 90 105 120
191
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* P K G E T S C R C C Q G S Q G V R S E  
N P K E R H L A D A V R E V R E S V V R  
T Q R R D I L Q M L S G K S G S P *  * G 
T AAC C C AAAGGAGAGACATC TTGCAGATGC TGTCAGGGAAGTCAGGGAGTCCGTAGTGAG 
135 150 165 180
D G H G W E A G A A H E M S M A C  S E F  
T G M G G R Q V Q H T R  * A W H A V  S S 
R A W V G G R C  S T R D E H G M Q  * V Q 
GACGGGCATGGGTGGGAGGCAGGTGCAGCACACGAGATGAGCATGGCATGCAGTGAGTTC 
195 210 225 240
N H S S F N A L M K A W R G P T P F H R  
I T P P S M H *  * K H G E A P H L S  I A  
S L L L Q C T D E S M E R P H T F P S H  
AATCACTCCTCCTTCAATGCACTGATGAAAGCATGGAGAGGCCCCACACCTTTCCATCGC 
255 270 285 300
I S T H P F R A H C G N M G * F P V L L  
S P P I H L E L T V A I W V S F L Y Y Y  
L H P S I * S S L W Q Y G L V S C I T T  
ATCTCCACCCATCCATTTAGAGCTCACTGTGGCAATATGGGTTAGTTTCCTGTATTACTA 
315 330 345 360
L C L L H P P T S N P C  
S A S F T H L L Q I P A  




Appendix 2. Sequences o f cloned PCR products
Sequence of Product J.
F r o n t  o f  c l o n e
* R G S V W A W E G S G L * C L H K H M  
D E A A C G R G R G V G C D A C T S  I C  
T R Q R V G V G G E W A V M L A Q A Y V  
TGACGAGGCAGCGTGTGGGCGTGGGAGGGGAGTGGGCTGTGATGCTTGCACAAGCATATG 
15 30 45 60
Y M Y V Y D W T H H Q R L E L D C  * A S  
T C M Y M T G H I  I R D * N W I A R L L  
H V C  I * L D T S S E T R I G L L G F L  
TACATGTATGTATATGACTGGACACATCATCAGAGACTAGAATTGGATTGCTAGGCTTCT 
75 90 105 120
TAG
*
B a c k  o f  c l o n e
A G T E T H S N S G D R D T Q I L R A H  
Q A R R P I A I Q G T E I R R S  * G L T  
R H G D P * Q F R G Q R Y A D P E G S L  
GCAGGCACGGAGACCCATAGCAATTCAGGGGACAGAGATACGCAGATCCTGAGGGCTCAC 
15 30 45 60
W L T A * P E T V S F Y S S W R P C I K  
G * Q P S Q K Q * V S I P V G D P V S R  
A D S L A R N S E F L F Q L E T L Y Q G  
TGGC TGACAGC C TAGC CAGAAACAGTGAGTTTC TATTC CAGTTGGAGAC C C TGTATCAAG 






Appendix 2. Sequences o f cloned PCR products
RACE gene product.
S e q u e n c e  f r o m  R e g io n  S e n s e  O l ig o n u c l e o t id e .
G N R A I E I G F G * N T  
OLIGONUCLEOTIDE G I G Q * K S A S G K I P  
A V E R A R R E  * G N R N R L R V K Y P  
C TGC AGTTGAAAGAGC TC GAAGGGAATAGGGC AATAGAAATC GGC TTCGGGTAAAATAC C 
15 30 45 60
R A R Q Q R D I  * L F T C V I A V K N D  
V R D N N V I F S F S L A L S R * K T T  
C A T T T * Y L A F H L R Y R G E K R R  
CGTGCGCGACAACAACGTGATATTTAGCTTTTCACTTGCGTTATCGCGGTGAAAAACGAC 
75 90 105 120
V L F I  I F N E R T M L N S H C H C R I  
C C L S S S M N E P C *  I A T A I A A S  
V V Y H L Q * T N H A E * P L P L P H P  
GTGTTGTTTATCATCTTCAATGAACGAACCATGCTGAATAGCCACTGCCATTGCCGCATC 
135 150 165 180
Q S A Q G C S H N T H V T R I D L C F H  
S P L K D V P I  I P T L H A S T F A S I  
V R S R M F P  * Y P R Y T H R P L L P S  
CAGTCCGCTCAAGGATGTTCCCATAATACCCACGTTACACGCATCGACCTTTGCTTCCAT 
195 210 225 240
Q A *  P R A G K I R S G C F F F Y R P D  
R P D H G L G K Y V R V A S S S T G Q T  
G L T T G W E N T F G L L L L L Q A R R  
CAGGCCTGACCACGGGCTGGGAAAATACGTTCGGGTTGCTTCTTCTTCTACAGGCCAGAC 
255 270 285 300
V T R G V H R Q I K R S A G *  I L I C A  
* P V A Y T V K S N A L L G K S  * F V Q 
D P W R T P S N Q T L C W V N P D L C R  
GTGACCCGTGGCGTACACCGTCAAATCAAACGCTCTGCTGGGTAAATCCTGATTTGTGCA 
315 330 345 360
G M T P A P V I C D T E T W H D S  * T A 
A * R Q H P * F A I R K P G M I H K Q P  
H D A S T R N L R Y G N L A * F I N S H  
GGCATGACGCCAGCACCCGTAATTTGCGATACGGAAACCTGGCATGATTCATAAACAGCC 
375 390 405 420
T A N F C C R A W S T S R K N *  S R  
L Q  I F A V V P G L L V V K  I D R  
C K F L L S C L V Y * S * K L I A  
AC TGCAAATTTTTGC TGTCGTGC C TGGTC TAC TAGTCGTAAAAATTGATCGCGG 
435 450 465
194
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Sequence of Product L.
F r o n t  o f  P r o d u c t
F F E L F Q L E Y Y L G P N I  I I A C L  
S S S S F N * N I I * G Q I L S * L V *  
L R A L S T R I L S R A K Y Y H S L S E  
TTC TTCGAGC TC TTTCAAC TAGAATATTATC TAGGGC CAAATATTATCATAGCTTGTC TG 
15 30 45 60
K K C T F P S S M Q * N K L L G T G T G  
R S V P F L V V C S E I S C * A L G Q D  
E V Y L S  * * Y A V K * A A R H W D R M  
AAGAAGTGTAC C TTTC C TAGTAGTATGCAGTGAAATAAGC TGCTAGGCAC TGGGACAGGA 
75 90 105 120
C L E L T S E 
A * N * L V N 
P R T D * * I 
TGC C TAGAAC TGAC TAGTGAATT 
135
B a c k  o f  g e n e
Q E H T R I D S S T L G C H H Q H A I  S 
K S  I Q E L T A A L W V V I  I S T P Y R  
R A Y K N * Q Q H F G L S S S A R H I V  
CAAGAGCATACAAGAATTGACAGCAGCACTTTGGGTTGTCATCATCAGCACGCCATATCG 
15 30 45 60
* L S N C K W S S  OLIGONUCLEOTIDE
S * V T V S G H Q V E R A R R T T  




Appendix 2. Sequences o f cloned PCR products
Sequence of Product P2
F r o n t  o f  G e n e
F Y I D Q S S M A V I  * N E S I C N G I  
S T L T R V P W Q S F E M S Q Y V M E S  
L H *  P E F H G S H L K * V N M * W N Q  
TTCTACATTGACCAGAGTTCCATGGCAGTCATTTGAAATGAGTCAATATGTAATGGAATC 
10 20 30 40 50 60
S S S * K - - E V I Q L Q A * F K T R N  
V L P E K  - - K * F N C K P N L R L E I
F F L K K  - * S N S T A S L I  * D * K S  
AGTTC TTC C TGAAAAAGNNNTGAAGTAATTCAAC TGCAAGC C TAATTTAAGAC TAGAAAT 
70 80 90 100 110 120
R I R K T R C K G H Q *  * K - L  
A L G K Q D A R V I  S N K  - - F
H * E N K M Q G S S V I K - T S  
CGCATTAGGAAAACAAGATGCAAGGGTCATCAGTAATAAAAANNACTTCA 
130 140 150 160
B a c k  o f  g e n e
F R E N S L S Q R Q N G E T E H N E F R  
S E K I A * V K D R M V R Q S  I M N L G  
Q R K  * P E S K T E W * D R A *  * I * G 
TTCAGAGAAAATAGCCTGAGTCAAAGACAGAATGGTGAGACAGAGCATAATGAATTTAGG 
10 20 30 40 50 60
D R N F R Y R W H C V E R A R R T T  
T G I L G I G G I V  OLIGONUCLEOTIDE
P E F  * V * V A L C  
GACCGGAATTTTAGGTATAGGTGGCATTGTGTTGAAAGAGCACGTAGAACAACA 
70 80 90 100 110
196
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Sequence of clone P4
F r o n t  o f  c l o n e
P Q - L T - - L L D S N L C F * F L P F  
H N  - * - P - Y *  I L T C A S S S Y P F
T M - D - L - T R F * L V L L V L T L S  
CCACAATGNCTGACANCCTTNCTACTAGATTCTAACTTGTGCTTCTAGTTCTTACCCTTT 
10 20 30 40 50 60
H * R Y V H L L * Q S L S K K T D  - - R
I K D T S  I C S D S H C L R R L I  - - V
L K I R P F A L T V I V * E D * * - T Y  
C ATT AAAG AT ACGTC C ATTTGC TC TG AC AGTC ATTGTC TAAG AAG AC TG AT AGNNNACGT 









B a c k  o f  c l o n e
F L A V H A Q N *  P K A P L V P R Q L Y  
F L L F M L R T D L K H L * F H G N F I  
S C C S C S E L T * S T S S S T A T L *  
TTTCTTGCTGTTCATGCTCAGAACTGACCTAAAGCACCTCTAGTTCCACGGCAACTTTAT
72
K H L P Q T P H R S L F V L A C S  I S R  
N T C P K P L I G V Y L C L P A V * V E  
T P A P N P S  * E F I C A C L Q Y K * K  
AAACAC C TGC C C CAAAC C C C TCATAGGAGTTTATTTGTGC TTGC C TGCAGTATAAGTAGA
12
K S S 
R A R 
E L E 
AAGAGCTCGAA
197
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S e q u e n c e  o f  C l o n e  Q  
F r o n t  o f  g e n e
OLIGO T P F F S S R L N I K Q E R K R N H  
R G P L F F P P D *  I * N K R G K E T T  
P F F F L P I K Y K T R E E K K P Q  
TAGAGGACCCCTTTTTTTTCCTCCCGATTAAATATAAAACAAGAGAGGAAAAGAAACCAC 





B a c k  o f  G e n e
K I  * K K Y R I K * K M L S K I V V P N  
K Y K R N I G * N K K C Y R K * W F Q T  
N I K E I S D K I K N V I E N S G S K P  
AAAATATAAAAGAAATATCGGATAAAATAAAAAATGTTATCGAAAATAGTGGTTCCAAAC 
10 20 30 40 50 60
L V T K N V K N G G M K I E N I  S G M E  
* * R K T * R M V G * K S K I Y L E W N  
S D E K R K E W W D E N R K Y I W N G M  
CTAGTGACGAAAAACGTAAAGAATGGTGGGATGAAAATCGAAAATATATCTGGAATGGAA 
70 80 90 100 110 120
* Y V H  * H I K K V V R P L  
D M C T D I  * R K W S G R S  
I C A L T Y K E S G Q A A H  
TGATATGTGCACTGACATATAAAGAAAGTGGTCAGGCCGCTCA 
130 140 150 160
198
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Sequence of Clone R2
f r o n t  o f  C l o n e
L R * K V N I F P * N E T E G F * E T S  
Y G E K *  I S S H K T R Q K D S E K Q V  
T V K S K Y L P I K R D R R I L R N K F  
C T ACGGTG AAAAGTAAATATC TTC C C ATAAAACG AG AC AG AAGG ATTC TG AGAAAC AAGT 
10 20 30 40 50 60
L * C V Y  S A N R V E P L F  * C 
C D V C T Q L T E W N L S F D A  OLIGONUCLEOTIDE 
V M C V L S  * Q S G T S L L M Q Q F S G  
TTGTGATGTGTGTACTCAGCTAACAGAGTGGAACCTCTCTTTTGATGCAACAATTTTCCG 






Appendix 2. Sequences o f cloned PCR products
Sequence of clone R6
F r o n t  o f  G e n e
OLIGONUCLEOTIDE R M T E V * L * F L Y T K C
G * L K C N Y N S F I P N V  
P M Y V G E D D  * S V I  I I P L Y Q M C  
TTC C TATGTATGTTGGAGAGGATGAC TGAAGTGTAATTATAATTC C TTTATAC CAAATGT
60
V C  I L Q H L M G F L Q N F H L K I S P  
Y A F S S I  * W D S S K I S I S K S A H  
M H S  P A F D G I  P P K F P S Q N Q P I  
GTATGCATTCTCCAGCATTTGATGGGATTCCTCCAAAATTTCCATCTCAAAATCAGCCCA
120
S V E Q S H A A S  * L Y G M * W F V A V  
Q * N S H M L P V N Y M E C D G L W L Y  
S R T V T C C Q L I I W N V M V C G C I  
TCAGTAGAACAGTCACATGCTGCCAGTTAATTATATGGAATGTGATGGTTTGTGGCTGTA
180
F Q Q S T M T 
S N R A P * H 
P T E H H D 
TTCCAACAGAGCACCATGACAC
200
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Sequence of Clone R7 - Putative P. falciparum enolase.
60
TTC C TATGTATGTAGGTGATGAAGGTGGATTTGC TC CAAATATATTAAACGCTAATGAAG
K V D L L Q I Y * T L M K  
OLIGONUCLEOTIDE R W I C S K Y I K R *  * S
P M Y V G D E G G F A P N I L N A N E A
120
C TC TTGATTTATTAGTAAC TGC C ATTAAATCAGC TGGTTATGAAGGAAAGGTTAAAATTG 
L L I Y *  * L P L N Q L V M K E R L K L  
S * F I S N C H * I S W L * R K G * N C  
L D L L V T A I K S A G Y E G K V K I A
180
CTATGGATGTTGCCAGCTCTGAATTTCGACAAGTGAACAAAACATACGATTTAGATTTCA 
L W M L P A L N F D K * T K H T I  * I S  
Y G C C Q L *  I S T S E Q N I R F R F Q  
M D V A S S E F R Q V N K T Y D L D F K
240
AAACTCCAAATAATGACAAATCATTAGTTAAGACTGGAGCTCAATTAGTTGACTTATACA
K L Q I M T N H * L R L E L N * L T Y T
N S K * * Q I I S * D W S S I S * L I H
T P N N D K S L V K T G A Q L V D L Y I
TTGATTTAGTAAAGAAATATC CAATTGTTTC TATT 
L I  * * R N I Q L F L  
* F S K E I S N C F Y  
D L V K K Y P I V S I
201
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Sequence of clone RIO - Rat GLUT2
F r o n t  o f  g e n e
R L L Q P H S G V P W A L F T N  
OLIGO D C S N H T Q G C P G H S S P T  
Y V G E  I A P T T L R G A L G T L H Q L
TGTACGTTGGAGAGATTGCTCCAACCACACTCAGGGGTGCCCTGGGCACTCTTCACCAAC
60
W L L Y R H S Y *  S D C W L S S F W A I  
G S C T G I P I S Q I A G S V H S G Q S  
A L V Q A F L L V R L L A Q F I L G N Q  
TGGCTCTTGTACAGGCATTCCTATTAGTCAGATTGCTGGCTCAGTTCATTCTGGGCAATC
120
B a c k  o f  c l o n e
V G K K A * R L G P E T S P K I L M S E  
S A R K L E D * G L R R H Q R Y *  * V R  
R Q E S L K T R A * D V T K D I N E * G
GTCGGCAAGAAAGC TTGAAGAC TAGGGC C TGAGACGTCAC CAAAGATATTAATGAGTGAG 
10 20 30 40 50 60
E R K G R G V D  * A E G L R D P A L  
K E K E E A S T E Q K V S V I Q L L
K K R K R R R L S R R S P * S S S *
GAAAGAAAAGGAAGAGGCGTCGAC TGAGCAGAAGGTC TCCGTGATCCAGC TC TT 
70 80 90 100 110
202
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Sequence of Clone R14
F r o n t  o f  c l o n e
R P R R  * G E M K W P T Y V T K N Y I T  
D R E D E G K * N G L H M * Q K T T *  P 
T E K M R G N E M A Y I C N K K L H N Q  
AGACCGAGAAGATGAGGGGAAATGAAATGGCCTACATATGTAACAAAAAACTACATAACC
60
N I F C  * S I F G I F T * G E K Q T N K  
T F F V S P S L A Y L H K E K N K Q I K  
H F L L V H L W H I Y I R R K T N K *  
AACATTTTTTGTTAGTCCATCTTTGGCATATTTACATAAGGAGAAAAACAAACAAATAAA
120
B a c k  o f  C l o n e
P N V Y A F S S I * W D S S K I - - S K  
Q M C M H S P A F D G I  P P K  - - S Q - 
K C V C  I L Q H L M G F L Q N  - - L K -
CCAAATGTGTATGCATTCTCCAGCATTTGATGGGATTCCTCCAAAATTXXCXTCTCAAAA 
10 20 30 40 50 60
GGTTTAC ACATACGTAAGAGGTCGTAAAC TAC C C TAAGGAGGTTTTAA--G-AGAGTTTT 
W I H I C E  G A N S P I G G F N  - - * F
L H T H M R W C K I  P N R W F  - R L -
F T Y A N E L M Q H S E E L I  - - E F -
203
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Sequence of Clone SI
V P M Y V G E K E M I S L F Y I A E L *  
OLIGONUCLEOTIDE K K K * Y H Y F I * L N Y S
K R N D I I I L Y S *  I I V  
GTAC C TATGTATGTTGGAGAAAAAG AAATG AT ATC ATTATTTTATATAGC TG AATTATAG
60
S I V Y N T T F L L S F H P L M D T * V  
P L Y I  I P H F Y Y L F I L * W T L R L  
H C I * Y H I F I I F S S F D G H L G *  
TCCATTGTATATAATACCACATTTTTATTATCTTTTCATCCTTTGATGGACACTTAGGTT
120
D Y M S L L L *  I L L *  * T Y N A S I F  
I T C L C Y C E Y C C D K H T M Q V S F  
L H V F V I V N T A V I N I Q C K Y L F  
GATTACATGTCTTTGTTATTGTGAATACTGCTGTGATAAACATACAATGCAAGTATCTTT
180
L L Q  * L F P W * M H S  S G I D G W N V  
Y Y  S D Y F L G R C  I V V G L M D G M L  
I T V I  I S L V D A *  * W D * W M E C  * 
TTATTACAGTGATTATTTCCTTGGTAGATGCATAGTAGTGGGATTGATGGATGGAATGTT
240
S S V F S P * E I S I L F P * R L Y * F  
V L F L V L E K S P Y C F H R G C I N L  
F C F *  S L R N L H I V S I E V V L I  * 
AGTTC TGTTTTT AGTC C TTGAG AAATC TC C ATATTGTTTC C AT AGAGGTTGT ATTAATTT
300
N F T P T V Y K H F H F S V S S P  
T S H Q Q Y I S I S I S L Y P H L  
L H T N S I  * A F P F L C I L T  
AACTTCACACCAACAGTATATAAGCATTTCCATTTCTCTGTATCCTCACCTA
204
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Sequence of Clone S3
F r o n t  o f  G e n e
OLIGONUCLEOTIDE P R R * G E M K C L H M  
F V P M Y V G D R E D E G K * N A Y I C
T E K M R G N E M P T Y V
TTTTGTTCCTATGTATGTTGGAGACCGAGAAGATGAGGGGAAATGAAATGCCTACATATG
10 20 30 40 50 60
* Q K L H N Q H F C * S I F  
N K N Y I T N I F V S P S L  
T K T T *  P T F L L V H L Y  
TAACAAAAACTACATAACCAACATTTTTGTTAGTCCATCTTT 
70 80 90 100
B a c k  o f  G e n e
K P S H S  I I I N W A A C D C S T D -  
N H H I  P L * L T G Q H V T V L L -  
T I T F H Y N * L G S M * L F Y *  - - L
AAACCATCACATTCCATTATAATTAACTGGGCAGCATGTGACTGTTCTACTGATKKKKKT 
10 20 30 40 50 60
* F * D G N F G G I  P S N A G E C  I H I  
D F E M E  I L E E S H Q M L E N A Y T F  
I L R W K F W R N P  I K C W R M H T H L  
TGATTTTGAGATGGAAATTTTGGAGGAATCCCATCAAATGCTGGAGAATGCATACACATT 
70 80 90 100 110 120
W Y K G T Y N L H F S  
G I K E L I T Y T S V  




Appendix 2. Sequences o f cloned PCR products
Sequence of Clone S6
F r o n t  o f  C l o n e
M R Y I R A K R H S Y F F  
OLIGONUCLEOTIDE * G T S E L K D T V I S S  
V P M Y V G D E V H Q S  * K T Q L F L Q  
TTGTAC C TATGTACGTTGGAGATGAGGTACATCAGAGC TAAAAGACACAGTTATTTC TTC 
10 20 30 40 50 60
K R V C E L V V * R L T * T V L W L T C  
K E F V N L W Y K D * H R Q C Y G L H V  
K S L  * T C G I K I D I D S V M A Y M *  
AAAAGAGTTTGTGAACTTGTGGTATAAAGATTGACATAGACAGTGTTATGGCTTACATGT 
70 80 90 100 110 120
E L Y V H V H *
N Y M Y M Y I S  
I I C T C T L A  
GAATTATATGTACATGTACATTAG 
130 140
B a c k  o f  c l o n e
V L Y T * F G D G N * K Y Q T V *  * T V 
F Y T R N L G T V I K N T K Q Y N E Q S  
S I H V I W G R * L K I  P N S  I M N S H  
GTTCTATACACGTAATTTGGGGACGGTAATTAAAAATACCAAACAGTATAATGAACAGTC 
10 20 30 40 50 60
I Y S R H K Q M C I I I * F C P C K N I  
Y I P D T S R C A L L S N F V L A K I L  
I F Q T Q A D V H Y Y L I L S L Q K Y Y  
ATATATTC C AGACACAAGCAGATGTGCATTATTATC TAATTTTGTC C TTGCAAAAATATT 
70 80 90 100 110 120
T I E V L C P F Y K * E N G G S  
R * K C Y A L S I N E K M E A H  
D R S V M P F L  * M R K W R L T  
ACG ATAG AAGTGTTATGC CC TTTC TATAAATG AGAAAATGGAGGC TC AC 
130 140 150 160
206
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Sequence of Clone S8
F o r w a r d  s e q u e n c e
G P M Y V G E Y I Y I Y I A F F W H C S  
OLIGONUCLEOTIDE N I Y I F I  * H F S G T V H
I Y I Y L Y S  I F L A L F T  
GGTCCTATGTATGTTGGAGAATATATATATATTTATATAGCATTTTTCTGGCACTGTTCA 
10 20 30 40 50 60
L F I H I Y V C V Y I Y I T L I - - I Y  
S L Y I Y M C V C I Y I * L * - - - Y I  
L Y T Y I C V C V Y I Y N F D  - - - I F
C TC TTT AT AC ATATATATGTGTGTGTGTAT ATATATATAAC TTTGATTNNNNNNATATAT 
70 80 90 100 110 120
F H R S 
S I G H  
P S V I 
TTC CATCGGTCATT 
130
R e v e r s e  s e q u e n c e
R E D F I S H L E D M * N S K T  
OLIGO G R T L F L I W K T C E T A K P  
Y V G E G G L Y F S S G R H V K Q Q N P  
TGTATGTTGGAGAGGGAGGACTTTATTTCTCATCTGGAAGACATGTGAAACAGCAAAACC 
10 20 30 40 50 60
L L V L Y M G R R * E A H T V S W S F S  
F W F C  I W A D V E K P I R S H G P F P  
S G F V Y G Q T L R S  P Y G L M V L F L  
C TTC TGGTTTTGTATATGGGCAGACGTTGAGAAGC C CATACGGTC TCATGGTC C TTTTC C 
70 80 90 100 110 120
GAAGACCAAAACATATACCCGTCTGCAACTCTTCGGGTATGCCAGAGTACCAGGAAAAGG
L Y A G S * G D D S * G I Q E I K S S N  
C M L A P E G M I P K E F K R * N Q A I  
V C W L L R G * F L R N S R D K I K Q  * 
TTGTATGC TGGC TC C TGAGGGGATGATTC C TAAGGAATTCAAGAGATAAAATC AAGCAAT 
130 140 150 160 170
207
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Sequence of clone S ll
FRONT OF CLONE
P M Y V G E G G L Y F S S G R H V K Q Q  
OLIGONUCLEOTIDE R E D F I S H L E D M * N S K  
G R T L F L I W K T C E T A K  
C C T ATGTACGTTGGAG AGGG AGG AC TTTATTTC TC ATC TGGAAGACATGTG AAAC AGC AA 
10 20 30 40 50 60
N P S G K V Y G Q T L R S P Y C L M V L  
T L L E K Y M G R R * E A H T V S W S F  
P F W K S  I W A D V E K P  I L S H G P F  
AAC C C TTC TGGAAAAGTAT ATGGGC AG ACGTTGAG AAGC CC ATACTGTC TC ATGGTC C TT 
70 80 90 100 110 120
F L V C W L L R G S Y P R K F K R * K S  
S L Y A G S  * G V V I Q G N S R D K N Q  
P C M L A P E G * L S K E I Q E I K I K  
TTC C TTGT ATGC TGGC TC C TGAGGGGTAGTTATC C AAGG AAATTC AAG AGATAAAAATC A 
130 140 150 160 170 180
S K * L 
A N N Y 




K T L L E K Y M G S V E K P S V S R S F  
K P F W K S  I W A A L R S H R S L G P F  
N P S G K V Y G Q R * E A I G L * V L F  
AAAAC C C TTC TGGAAAAGTATATGGGCAGCGTTGAGAAGC CATCGGTCTC TAGGTCC TTT 
10 20 30 40 50 60
S L Y A G L L R G * F L R K F K R * K S  
P C M L A S  * G D D S  * G N S R D K N Q  
L V C W P P E G M I P K E I Q E I K I K  
TC C TTGTATGC TGGC C TC C TGAGGGGATGATTC C TAAGGAAATTCAAGAGATAAAAATCA 
70 80 90 100 110 120
S K * Y * E * P S A V Q  
A N N I K N D H Q Q Y K  




Appendix 2. Sequences o f cloned PCR products
Sequence of Clone T3
F o r w a r d  s e q u e n c e
N I Y I F I  * H F S G T V H  
OLIGONUCLEOTIDE I Y I Y L Y S I F L A L F T  
P M Y V G E Y I Y I Y I A F F W H C S L  
TTCCTATGTACGTTGGAGAATATATATATATTTATATAGCATTTTTCTGGCACTGTTCAC
60
S L Y I Y M C V C I Y I * L D *
L Y T Y I C V C V Y I Y N L I
F I H I Y V C V Y I Y I T * L
TCTTTATACATATATATGTGTGTGTGTATATATATATAACTTGATTAA
209
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Sequence of Clone T8
F r o n t  o f  c l o n e
P L V L S T S W S R W Y S E S N L W S I  
L * C S Q P A G V V G I L N P I F G L F  
F S A L N Q L E S L V F  * I Q S L V Y S  
C C TTTAGTGC TC TCAAC CAGC TGGAGTCGTTGGTATTC TGAATC CAATC TTTGGTC TATT
H L G S K S Y T Q L I H C S Q S F  
I L G L R A I  P N L Y I V A S P L  
S W V *  E L Y P T Y T L  * P V L Y  
CATC TTGGGTC TAAGAGC TATAC C CAACTTATACATTGTAGC CAGTC CTTT 
70 80 90 100 110
BACK OF CLONE
G - R L E Y P A V L T T H C H F H H A P  
- - V * S T Q L Y * Q P T V I S I M L Q  
- A F R V P S C  I N N P L S F P S C S S  
GGXGXGCGTTTAGAGTAC C CAGC TGTATTAACAAC C CAC TGTCATTTC CATCATGCTC CA
A L S V A L W I N V V F Y Y S M R I V Q  
L S Q * L S G S M L S S I T Q * E S F K  
S L S S S L D Q C C L L L L N E N R S R  
GCTCTCTCAGTAGCTCTCTGGATCAATGTTGTCTTCTATTACTCAATGAGAATCGTTCAA 
70 80 90 100 110 120
G C R W L E K -  - I L *  I S A G  - - G *
D A G G L R  - - - S Y R L V Q  - - - V N
M Q V A * E - - N P I D * C R - - - L I  
GGATGCAGGTGGCTTGAGAAGKKKKKAATCCTATAGATTAGTGCAGGAKKKKKKGGTTAA 
130 140 150 160 170 180
Y Y L L D C S L S V C G  OLIGONUCLEOTIDE 
I I F L T V V S L F V V E R A R R R T  
L S S * L * S L C L W *  
TATTATCTTCTTGACTGTAGTCTCTCTGTTTGTGGTAGAAAGAGCTCGAAGAAGAACA 
190 200 210 220 230
210
